---
document_datetime: 2024-03-13 12:28:40
document_pages: 128
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/blenrep-epar-public-assessment-report_en.pdf
document_name: blenrep-epar-public-assessment-report_en.pdf
version: success
processing_time: 177.1906298
conversion_datetime: 2025-12-17 08:24:32.948364
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

23 July 2020 EMA/CHMP/414341/2020 Corr.* Committee for Medicinal Products for Human Use (CHMP) Assessment report BLENREP International non-proprietary name: belantamab mafodotin Procedure No. EMEA/H/C/004935/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

<!-- image -->

Official address

Domenico Scarlattilaan 6

Address for visits and deliveries

●

1083 HS Amsterdam

●

The Netherlands

Refer to www.ema.europa.eu/how-to-find-us

Send us a question

An agency of the European Union

Go to www.ema.europa.eu/contact

Telephone

+31 (0)88 781 6000

© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged.

* Data in table 30 corrected in line with SmPC

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

<!-- image -->

Name of the medicinal product:

BLENREP

Applicant: Active substance: International Non-proprietary Name/Common Name: Pharmaco-therapeutic group (ATC Code): L01XC39 Therapeutic indication: BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Pharmaceutical form: Powder for concentrate for solution for infusion Strength: 100 mg Route of administration: Intravenous use Packaging: vial (glass) Package size: 1 vial Medicinal product no longer authorised

GlaxoSmithKline (Ireland) Limited

12 Riverwalk

Citywest Business Campus

Dublin 24

IRELAND

Belantamab mafotdotin

belantamab mafodotin

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                 | ..............................................8                                                          |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................8      |                                                                                                          |
| 1.2. Steps taken for the assessment of the                                                                                 | product.......................................................11                                         |
| 2. Scientific discussion                                                                                                   | ..............................................................................12 authorised              |
| 2.1. Problem statement                                                                                                     | .............................................................................................12          |
| 2.1.1. Disease or condition.........................................................................................12     |                                                                                                          |
| 2.1.2. Epidemiology                                                                                                        | ..................................................................................................12     |
| 2.1.3. Biologic features..............................................................................................13   |                                                                                                          |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                | ............................................13                                                           |
| 2.1.1. Management...................................................................................................13     |                                                                                                          |
| 2.2. Quality aspects                                                                                                       | ..................................................................................................15     |
| 2.2.1. Introduction....................................................................................................15  |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................16     |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                          | ................................................................................24                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................28 longer                |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ......................28                                                                                 |
| 2.2.6. Recommendations for future quality development................................................28                    |                                                                                                          |
| 2.3. Non-clinical aspects ............................................................................................28   |                                                                                                          |
| 2.3.1. Introduction....................................................................................................28  |                                                                                                          |
| 2.3.2. Pharmacology .................................................................................................29 no |                                                                                                          |
| 2.3.3. Pharmacokinetics.............................................................................................33     |                                                                                                          |
| 2.3.4. Toxicology                                                                                                          | ......................................................................................................36 |
| 2.3.5. Ecotoxicity/environmental risk assessment product                                                                   | .........................................................41                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................41          |                                                                                                          |
| 2.3.1. Conclusion on the non-clinical aspects................................................................45            |                                                                                                          |
| 2.4. Clinical aspects                                                                                                      | ..................................................................................................46     |
| 2.4.1. Introduction....................................................................................................46  |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................46     |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................53        |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................56            |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................59 Medicinal   |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                     | ..................................................................................................59     |
| 2.5.1. Dose response study........................................................................................59       |                                                                                                          |
| 2.5.2. Main study......................................................................................................60  |                                                                                                          |
| 2.5.3. Discussion on clinical efficacy............................................................................84       |                                                                                                          |
| 2.5.4. Conclusions on the clinical efficacy.....................................................................87         |                                                                                                          |
| 2.6. Clinical safety                                                                                                       | ....................................................................................................88   |
| 2.6.1. Discussion on clinical safety ............................................................................          | 106                                                                                                      |
| 2.6.2. Conclusions on the clinical safety.....................................................................             | 110                                                                                                      |
| 2.7. Risk Management Plan                                                                                                  | ...................................................................................... 111               |
| 2.8. Pharmacovigilance............................................................................................         | 115                                                                                                      |
| 2.9. New Active Substance.......................................................................................           | 115                                                                                                      |
| 2.10. Product information                                                                                                  | ........................................................................................ 116             |

<div style=\"page-break-after: always\"></div>

2.10.1. User consultation  .........................................................................................  116

2.10.2. Additional monitoring ...................................................................................  116

3. Benefit-Risk Balance............................................................................  116

3.1. Therapeutic Context .........................................................................................  116

3.1.1. Disease or condition  .......................................................................................  116

3.1.2. Available therapies and unmet medical need  ..................................................... 116

3.1.3. Main clinical studies .......................................................................................  117

3.2. Favourable effects ............................................................................................  117

3.3. Uncertainties and limitations about favourable effects  ........................................... 117

3.4. Unfavourable effects  .........................................................................................  117

3.5. Uncertainties and limitations about unfavourable effects ....................................... 118

3.6. Effects Table  ....................................................................................................  119

3.7. Benefit-risk assessment and discussion  ............................................................... 119

3.7.1. Importance of favourable and unfavourable effects  ............................................ 119

3.7.2. Balance of benefits and risks  ...........................................................................  120

3.7.3. Additional considerations on the benefit-risk balance ......................................... 120

4. Recommendations ...............................................................................  122

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

Anti-Drug Antibody

ADC

Antibody-Drug Conjugate

ADCC Antibody-Dependent Cellular Cytotoxicity ADCP Antibody-Dependent Cellular Phagocytosis AE Adverse Event AESI Adverse Event of Special Interest AUC Area Under Concentration Curve BCMA B Cell Maturation Antigen BM Bone Marrow CBR Clinical Benefit Ratio CI Confidence Interval CL Clearance CMA Conditional Marketing Authorisation CMAA Conditional Marketing Authorisation Application CMC Chemistry, Manufacturing, and Controls CoA Certificate of Analysis CPP Critical Process Parameter CPV Continuous Process Verification CQA Critical Quality Attribute CTD Common Technical Doxument DAR Drug-Antibody Ratio DL Drug Load DLT Dose Limiting Toxicity DOR Duration of Response DP Drug Product DS Drug Substance DSC Differential Scanning Calorimetry exempli gratia (for example) eGFR Estimated Glomerular Filtration Ratio ELISA Enzymo-Linked Immunosorbent Assay ER Exposure/Response EU European Union Fc Fragment chrysallizable FIHT First In Human Trial FTIR Fourier Transform Infrared GC Gas Chromatography GCP Good Clinical Practice HPLC High Pressure Liquid Chromatography Hazard Ratio i.e. id est (that is) Medicinal product no longer authorised

e.g.

HR

IC

Ion Chromatography

ICD

Immunogenic Cell Death

Ig

Immunoglobulin

<!-- image -->

IMWG

International Myeloma Working Group

INN

Interanational Non-proprietary Name

IPC

In Process Control

IRC

Independent Review Committee

IRR Infusion Related Reaction ITT Intention To Treat IV Intravenous(ly) LC-MS/MS Liquid Chromatography with tandem Mass Spectrometry LMW Low Molecular Weight mAb Monoclonal Antibody mc maleimidocaproyl mec microcyst-like epithelial changes MedDRA Medical Dictionary for Regulatory Activities MM Multiple Myeloma MMAF Monomethyl Auristatin F MoA Mechanism of Action MRD Minimal Residual Disease MRP Multi-Drug Resistance associated protein MTD Maximum Tolerated Dose NEI VFQ-25 National Eye Institute Visual Function Questionnaire -25 NHL Non-Hodgkin's Lymphoma NK Natural Killer (cell) OATP Organi Anion Transporting Polypeptide ORR Overall Response Rate OS Overall Survival PC Plasma Cell PD PharmacoDynamic(s) PFS Progression Free Survival P-gp P-glycoprotein PI Proteasome Inhibitor PI Product Information PK Pharmakokinetic(s) PR Partial Response PT Preferred Term Q3W Every Three Weeks Quality Target Product Profile Revised International Staging System for Multiple Myeloma Relapsed and/or Refractory Multiple Myeloma RS Reference Standard Serious Adverse Event soluble form of B-Cell Maturation Antigen stringent Complete Response Medicinal product no longer authorised

QTPP

R-ISS

RRMM

SAE

sBCMA

sCR

SOB

Specific Obligation

SOC

System Organ Class

SPE

Solid Phase Extraction

SW-AUC

Sedimentation-Velocity Analytilcal UltraCentrifugation

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

<!-- image -->

EMA/CHMP/414341/2020

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

- The applicant GlaxoSmithKline (Ireland) Limited submitted, on 18 December 2019, an application for marketing authorisation to the European Medicines Agency (EMA) for BLENREP, through the centralised procedure falling within the Article 3(1) and point 4 of Annex I of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 12 October 2017. BLENREP was designated as an orphan medicinal product EU/3/17/1925 on 16 October 2017 in the following condition: Treatment of multiple myeloma. BLENREP was granted eligibility to PRIME on 12 October 2017 in the following indication:  Treatment of relapsed or refractory multiple myeloma patients whose prior therapy included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. Eligibility to PRIME was granted at the time in view of the following: · Despite available treatments, there is still a need for new options in the intended initial indication for the treatment of relapsed and refractory multiple myeloma patients whose prior therapy included a proteasome inhibitor (PI), an immunomodulatory agent and an anti-CD38 antibody. The unmet medical need was agreed. · The mechanism of action (MoA) is plausible and nonclinical data were supportive of the proof of principle. · Preliminary results from the Phase I open-label, dose escalation and expansion study BMA117159 in subjects with relapsed/refractory multiple myeloma were presented. The baseline characteristics showed that the patients were heavily pre-treated, with 94% of treated RRMM subjects in Study BMA117159 had received three or more lines of prior therapy. Further, 89% of patients enrolled in Part 2 were considered double refractory to both immunomodulatory drug and PIs, and 40% had previously received daratumumab. The ORR was of 60% in the overall population and the ORR in patients (n=14) that had received prior daratumumab treatment and in patients that were double refractory to an immunomodulatory agent and PI (n=31) were 43% and 58%, respectively. Most responses (51%) were deep (VGPR or better) and seem to be durable (the 25th percentile for Duration of Response (DoR) is 6.7 months and the median Progression Free Survival (PFS) was 7.9 months). · Overall, these results appeared promising and supported the product's potential to bring a major therapeutic advantage to relapsed/refractory MM patients that have received prior lines of therapies included immunomodulatory agent, PI and daratumumab. The applicant applied for the following indication: BLENREP is indicated as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received three prior lines of therapy including an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent. Medicinal product no longer authorised

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of BLENREP as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the Orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep

<div style=\"page-break-after: always\"></div>

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain tests or studies. Information on Paediatric requirements Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0347/2019 on the granting of a product-specific waiver. Information relating to orphan market exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products. Applicant's requests for consideration Conditional marketing authorisation The applicant requested consideration of its application for a Conditional marketing authorisation (CMA) in accordance with Article 14-a of the above-mentioned Regulation. Accelerated assessment The applicant requested accelerated assessment in accordance to Article 14 (9) of Regulation (EC) No 726/2004. New active Substance status The applicant requested the active substance belantamab mafodotin contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union. PRIME support Upon granting of eligibility to PRIME, Tuomo Lapveteläinen was appointed by the CHMP as rapporteur. Medicinal product no longer authorised

A kick-off meeting was held on 23 March 2018. The objective of the meeting was to discuss the development programme and regulatory strategy for the product. The applicant was recommended to address the following key issues through relevant regulatory procedures: proposed scientific advice on comparability and proposed quality data package, recommendation to seek scientific advice on the quality data to be included in MAA for the intermediate chemical substance of the Antibody-Drug

<div style=\"page-break-after: always\"></div>

Conjugate (ADC), overview of nonclinical data package for MAA, proposed scientific advice on longterm toxicity studies, clarification on antibody half-life, immunogenicity assessments, overview of clinical pharmacology studies and proposed future scientific advice on clinical pharmacology, overview of clinical development and proposed scientific advice on phase II and III studies, statistical analysis plan and rationale for phase II and phase III studies, MRD endpoint and draft guideline, ocular adverse reactions risk management, orphan designation and maintenance of orphan designation at approval, plans for CMA and  PIP strategy.

| Date              | Reference                                        | SAWP co-ordinators                               |
|-------------------|--------------------------------------------------|--------------------------------------------------|
| 18 May 2017       | EMEA/H/SA/3559/1/2017/I                          | Dr David Brown, Dr Odoardo Olimpieri             |
| 28 June 2018      | EMEA/H/SA/3559/2/2018/PA/PR/III                  | Prof. Dieter Deforce, Dr Olli Tenhunen           |
| 20 September 2018 | EMEA/H/SA/3559/3/2018/PR/PA/II                   | Dr Rune Kjeken, Dr Olli Tenhunen                 |
| 15 November 2018  | EMEA/H/SA/3559/2/FU/1/2018/PA/PR/II              | Dr Jens Reinhardt, Dr Olli Tenhunen              |
| 31 January 2019   | EMEA/H/SA/3559/2/FU/2/2018/PA/HTA/ PR/III longer | Dr Olli Tenhunen, Ms Blanca García- Ochoa Martín |
| 17 October 2019   | EMEA/H/SA/3559/2/FU/3/2019/PA/PR/III no          | Dr Olli Tenhunen, Ms Blanca García- Ochoa Martín |

Protocol assistance The applicant received the following Protocol assistance on the development relevant for the indication subject to the present application: The Protocol assistance pertained to the following quality, non-clinical, and clinical aspects: Quality development: · Cell line control strategy. · Demonstration of analytical comparability and, provided comparability can be demonstrated at quality level, that no additional non-clinical or clinical tests will be needed to qualify the proposed process changes, comparability acceptance criteria, list of potentially critical quality attributes. · Acceptability of the validation approach for mAb, ADC DS and DP as well as stability. · Proposed activity and potency assays and their categorization as release and stability or characterization assays for commercialisation. · API starting materials, agreement that the drug-linker component of the product is a nonbiologically derived drug substance. Advice was also sought regarding the tests and acceptance criteria to control the quality of the linker component. Non-clinical development: Medicinal product no longer authorised

- Acceptability of the overall non-clinical data package for MAA.
- Environmental risk assessment.

<div style=\"page-break-after: always\"></div>

- Acceptability of the nonclinical toxicology package to support a MAA and that no additional genotoxicity or embryo-fetal developmental toxicity studies are needed.

## Clinical development:

| The application was received by the EMA on                                               | 18 December 2019   |
|------------------------------------------------------------------------------------------|--------------------|
| Accelerated Assessment procedure was agreed-upon by CHMP on                              | 14 November 2019   |
| The procedure started on                                                                 | 30 January 2020    |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on Medicinal | 31 March 2020      |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on        | 10 April 2020      |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on      | 7 April 2020       |
| The PRAC agreed on the PRAC Assessment Overview and Advice to                            | 17 April 2020      |

· Corneal event mitigation strategy. · Adequacy of the study DREAMM-2 design to support a CMA application, including dosing, primary and key secondary endpoints, proposed statistical analysis plan and immunogenicity analysis plan. · Adequacy of the phase III monotherapy trial 207495 (DREAMM-3) to convert the CMA to a full approval, in particular regarding the comparator and the statistical analysis plan of the primary and secondary endpoints. · Agreement of the overall clinical development plan to support a CMA for the proposed indication. · Acceptability of the proposed specific obligations (SOB) to convert the initial CMA into a full MAA. · Adequacy of the proposed pharmacokinetic assessments. · Acceptability of the overall clinical pharmacology package to support the registration of Belantamab mafodotin lyophilized configuration as monotherapy, appropriateness of the pharmacokinetic data analysis approach proposed for the lyophilized configuration and that the clinical data can be submitted during review. · Acceptability of the risk management plan (RMP) for the initial CMA. 1.2. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Tuomo Lapveteläinen Co-Rapporteur:  Blanca Garcia-Ochoa The co-rapporteur was only appointed to the application at a very late stage replacing the previous corapporteur from the same national competent authority. The appointed co-rapporteur was considered exceptionally justified because the individual had previously been acting as coordinator for Protocol assistance on the development relevant for the indication subject to the present application. The appointed rapporteur had no such prominent role in protocol assistance relevant for the indication subject to the present application. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| CHMP during the meeting on                                                                                                                                                                     |                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                        | 28 April 2020           |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                            | 20 May 2020             |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                        | 11 June 2020 authorised |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                        | 23 June 2020            |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                | 30 June 2020            |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                               | 9 July 2020             |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to BLENREP on longer | 23 July 2020            |
| The CHMP adopted a report on similarity of BLENREP with Darzalex, Farydak, Imnovid, Kyprolis, and Ninlaro of the authorised orphan medicinal products on                                       | 23 July 2020            |

Multiple myeloma (MM) is a rare and incurable disease of the plasma cells which typically affects adults who are more than 60 years of age (median age is at diagnosis is ~ 70 years). It is the second most common haematological malignancy (after non-Hodgkin's lymphoma [NHL]), representing 1% of all cancers and 2% of all cancer deaths. In 2018, the estimated annual, age-standardised, MM incidence rate worldwide was 1.7 per 100,000 (Ferlay, 2019). Progress has been made over the last 15 years in the treatment of multiple myeloma, such that survival of patients with newly diagnosed multiple myeloma has increased from approximately 3 years in the years 1985 to 1998 (Kyle 2003) to 6 to 10 years (Moreau 2015).

2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition BLENREP was proposed to be indicated as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received three prior lines of therapy including an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent. 2.1.2. Epidemiology Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.1.3. Biologic features

Multiple myeloma is characterized by marrow plasmacytomas (plasma cell tumours) and overproduction of monoclonal immunoglobulins (IgG, IgA, IgD or IgE) or Bence-Jones protein (monoclonal K or h light chains), while the production of normal immunoglobulin is impaired.

Current treatment of MM includes glucocorticoids (dexamethasone, prednisolone, methylprednisolone), chemotherapy, primarily alkylating agents, including high dose chemotherapy followed by autologous stem cell transplantation (ASCT), proteasome inhibitors (PIs, such as bortezomib, carfilzomib and ixazomib), immunomodulatory agents (such as thalidomide, lenalidomide and pomalidomide), monoclonal antibodies (mAbs, such as daratumumab, isatuximab and elotuzumab) and the histone deacetylase inhibitor panobinostat.

Based on karyotype, MM is classified as nonhyperdiploid and hyperdiploid, with the latter accounting for 50% to 60% of cases and characterized by trisomies in odd-numbered chromosomes. MM has a heterogeneous progression pathway, whereby several MM cell subclones coexist at baseline and compete for dominance over time, leading to the evolution of drug-resistance clones [Laubach, 2014]. Thus, drug resistance to prior regimens in patients with relapsed/refractory (RR) MM is due to continuous changes in the disease biology, in which a higher proportion of malignant cells are expressing a more aggressive, highly proliferative phenotype over time (Anderson, 2008). Therapies with a multi-modal MoA, that both target MM cells and elicit an immunogenic response are expected to minimise development of drug resistance in MM. 2.1.4. Clinical presentation, diagnosis and stage/prognosis The clinical features of MM are varied and can arise from the effects of the tumour itself, or the toxicity of the tumour products, or the host's own immune response. The most common symptoms include persistent skeletal pain (especially pain in the back or thorax), pathological fractures and vertebral collapse, anaemia, renal impairment, hypercalcaemia and recurrent or persistent bacterial infections. Approximately 20% of patients are asymptomatic at the time of diagnosis. The most common criteria used in diagnosis of symptomatic MM is the presence of neoplastic plasma cells comprising greater than 10% of BM cells or presence of a plasmacytoma; paraprotein (M-protein) in the serum and/or urine; and evidence of related organ or tissue impairment due to plasma cell disorder. The International Staging System (ISS) is used for prognosis and it was revised by The International Myeloma Working Group (IMWG) including cytogenetics by fluorescence in situ hybridization (FISH) and lactate dehydrogenase (LDH, Revised International Staging System for Multiple Myeloma, R-ISS), and is now widely accepted (Palumbo, 2015). At the time of diagnosis, patients are typically categorized according to R-ISS, their age, comorbidity and their suitability for intensive treatment. Despite advance in therapy, MM remains incurable. All patients eventually relapse and with each successive relapse, the chance of response and duration of response typically decreases and ultimately the disease becomes refractory and results in cumulative end organ damage (e.g., renal, cytopenia's, infections and bone complications). 2.1.1. Management Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

After the approval of daratumumab and its wide use in combinations in earlier lines of treatment, a new population of patients has emerged, referred to as triple-class refractory, encompassing those patients with disease refractory to at least 1 PI, 1 immunomodulatory agent and an anti-CD38 mAb. These patients have generally been exposed to all 5 drugs that have demonstrated single-agent effect (with or without glucocorticoids), including bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab. Most of these patients have already received alkylating agent therapy, other anti-MM drugs, as well as multiple courses of glucocorticoids, they also have numerous comorbidities and receive multiple concomitant medications. There is a clear unmet medical need for new therapies because the treatment options are very limited and their median overall survival is around 3-5 months (Usmani, 2016; Gandhi, 2019; Mikhael, 2020).

About the product Belantamab mafodotin is a humanised IgG1κ mAb conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF). Belantamab mafodotin binds to cell surface B Cell Maturation Antigen (BCMA) and is rapidly internalised. Once inside the tumour cell, the cytotoxic agent is released disrupting the microtubule network, leading to cell cycle arrest and apoptosis. The antibody enhances recruitment and activation of immune effector cells, killing tumour cells by antibody-dependent cellular cytotoxicity and phagocytosis. Apoptosis induced by belantamab mafodotin is accompanied by markers of immunogenic cell death, which may contribute to an adaptive immune response to tumour cells (SmPC, section 5.1). The applicant initially requested  approval for the following indication: BLENREP is indicated as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received three prior lines of therapy including an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent. The final indication applied for by the applicant following CHMP review of this application is: BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 antibody, and who have demonstrated disease progression on the last therapy. The recommended dose is 2.5 mg/kg of belantamab mafodotin administered as an intravenous infusion once every 3 weeks (SmPC, section 4.2). It is recommended that treatment should be continued until disease progression (SmPC, section 4.2). Type of Application and aspects on development The CHMP agreed to the applicant's request for an accelerated assessment as the product was considered of  major  public  health  interest.  This  was  based  on  the  clinical  studies  submitted  for  belantamab mafodotin.  The  product  had  shown  promising  treatment  effect  in  196  multiple  myeloma  patients (DREAMM-2) previously treated with a proteasome inhibitor, an immunomodulatory agent and an antiCD38 mAb ; ORR assessed by an independent review committee was 31% for 2.5 mg/kg dose cohort and 34% for the 3.4 mg/kg dose cohort. The intended patient population does not have specifically approved treatment options available, and the expected PFS and OS are dismal. Medicinal product no longer authorised

The applicant requested consideration of its application for a CMA in accordance with Article 14-a of the above-mentioned Regulation, based on the following criteria:

- The benefit-risk balance is positive.

<div style=\"page-break-after: always\"></div>

- It is likely that the applicant will be able to provide comprehensive data. The Applicant confirmed its intention to provide the following data as specific obligation covert the initial CMAA to a full approval:

1. Provision of the end of study report for DREAMM-2 (Study 205678): This will provide longterm safety and efficacy data in the indicated patient population. 2. Provision  of  randomised  data  from  DREAMM-3 (Study 207495): This will include mature safety and efficacy data (PFS) of belantamab mafodotin monotherapy in a third line plus RRMM patient population. · Unmet medical needs will be addressed, as there is currently no EU approved treatment for patients with RRMM double refractory to a PI and an immunomodulatory agent and are failing on  an  anti-CD38  therapy.  Belantamab  mafodotin  has  shown  significant  benefit  in  terms  of improved clinical efficacy (ORR) and addresses the unmet medical need in terms of deep and durable clinical responses compared to historical data and an improvement in patient-reported disease-related symptom as reported in DREAMM-2. · The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. Belantamab mafodotin is indicated for a subset of MM patients with a dismal prognosis and limited approved treatment options. Based on the positive benefit: risk demonstrated in DREAMM-2, immediate availability of belantamab mafodotin would provide these patients with an important and novel therapeutic option whist additional data are being generated to confirm safety and efficacy of belantamab mafodotin in a randomised Phase III study (DREAMM-3). 2.2. Quality aspects 2.2.1. Introduction The active substance (INN: belantamab mafodotin) is an antibody-drug conjugate (ADC) composed of a recombinant, human (IgG1) afucosylated mAb (belantamab) conjugated to cytotoxic microtubuledisrupting agent, monomethyl auristatin F (MMAF). Belantamab is partially reduced and conjugated with SGD-1269 active substance intermediate at the interchain cysteine residues, resulting into belantamab mafodotin active substance, which has a target drug-antibody ratio (DAR) of four (4). Belantamab mafodotin binds specifically to the anti-B-cell maturation antigen (BCMA) and kills multiple myeloma (MM) cells expressing BCMA via a multi-modal mechanism including delivery of cytotoxic MMAF inducing apoptosis, enhancing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, and inducing immunogenic cell death. The finished product is presented as powder for concentrate for solution for infusion containing 100 mg of belantamab mafodotin as active substance. Other ingredients are: sodium citrate, citric acid, trehalose dihydrate, disodium edetate and polysorbate 80. Belantamab mafodotin is reconstituted in sterile water (2 mL) to provide a concentration of 50 mg / mL. Medicinal product no longer authorised

The product is available in Type 1 glass vials sealed with bromobutyl rubber stopper and aluminium overseal with a plastic removable cap containing 100 mg powder, as described in section 6.5 of the SmPC.

<div style=\"page-break-after: always\"></div>

Although this dossier is not considered a Quality by Design application, certain elements of an enhanced approached were applied.

## 2.2.2. Active Substance

<!-- image -->

<!-- image -->

## Manufacture, process controls and characterisation (belantamab antibody intermediate)

2.2.2.1. Belantamab antibody intermediate General Information (belantamab antibody intermediate) Belantamab (Figure 1) is a recombinant afucosylated humanized IgG1 κ mAb specific for B-cell maturation antigen (BCMA).  The functional protein consists of two kappa light chains (LC) and two IgG1 heavy chains (HC) with a total of 1330 amino acids. There are 451 amino acids in each heavy chain and 214 amino acids in each light chain. The heavy chains are connected to each other by two interchain disulfide bonds and a light chain is attached to a heavy chain by a single interchain disulfide bond. The light chain has two intrachain disulfide bonds and the heavy chain has four intrachain disulfide bonds. The antibody is  N-linked glycosylated on each heavy chain at asparagine (Asn) N301 with afucosylated structures composed  of  N-acetyl-glucosamine, mannose,  and  galactose. The major glycans present are afucosylated bi-antennary structures with varying amounts of terminal galactose and low levels of sialic acids. The polypeptide molecular mass is 146 kDa and the carbohydrate molecular mass is approximately 3 kDa resulting in a total estimated molecular mass of 149 kDa for belantamab. Figure 1: Schematic representation of belantamab Medicinal product no longer authorised

Description of manufacturing process and process controls

<div style=\"page-break-after: always\"></div>

The commercial belantamab Process 3 is a conventional mAb production process that starts by thawing of one WCB vial followed by a serial of cell culture expansion steps in shake flasks and two seed bioreactors until the production bioreactor step is reached. Belantamab is purified from the harvest through centrifugation followed by depth filtration and membrane filtration, Protein A chromatography, low pH virus inactivation, flow-through ion exchange chromatography, and virus filtration as well as an ultrafiltration/diafiltration steps. The applicant has described the batch manufacturing system, including reprocessing or manufacturing multiple batches from a single working cell bank vial. The batch size is the mass of the mAb produced from a single scale bioreactor.

Information on the structural, biochemical, and biological characteristics of belantamab was obtained through characterization tests performed on the primary reference standard (PRS) lot 172405900, manufactured by Process 2.

Four processes have been used for belantamab manufacture: 1 process for non-clinical studies, 2 processes for clinical studies and 1 process for clinical and commercial studies. The applicant has sufficiently described the process changes made during development of belantamab manufacturing process. These include increase of the process scale, implementation of working cell bank (WCB), change of the media supplement, virus filter and ultrafiltration/diafiltration membrane change and manufacturing site change. The intended commercial process material is manufactured using Process 3. QP declarations for the manufacturing sites have been provided. Valid GMP certificates have been provided for the mAb intermediate manufacturing sites. To support the process changes extensive comparability assessments have been performed to demonstrate comparable process performances and analytical comparability for belantamab. These studies have included process comparability, extended characterization, forced degradation studies, comparability of stability results and batch analyses. The process control strategy for belantamab manufacturing process has been described in detail. Manufacturing process hold times are indicated in the process flow diagrams. Reprocessing is allowed for virus filtration and final filtration step in case of filter integrity test failure or other operational deviation not associated with excursions from microbiological control action limits, studies supporting the reprocessing have been provided. In process hold times for Clarified Unprocessed Bulk (CUB) and purification intermediates have been validated by studying the biochemical and microbiological stability. Raw materials are presented in tables for cell culture and for purification processes. Most of the raw materials are of compendial grade referred to USP, EP, NF or JP. In addition, specifications for all noncompendial raw materials are provided. No raw materials of animal or human origin have been used in the manufacture of belantamab cell banks or during belantamab manufacture. Sufficient information on the raw materials used in the cell culture and purification process are presented. Control of critical steps and process intermediates As part of the development of the control strategy, a series of risks assessment have been performed on each stage of the process to identify the process parameters (PPs) that impact on critical quality attributes (CQAs). The acceptable ranges for the process parameters were established in characterization studies using qualified small-scale models. Characterisation Medicinal product no longer authorised

The characterisation studies included physicochemical characterisation to address primary structure (amino-acid sequence of H- and L-chain) by peptide mapping, liquid chromatography-mass

<div style=\"page-break-after: always\"></div>

spectroscopy/mass spectroscopy (LC-MS/MS) analysis, intact and reduced mass analysis (LC-MS: masses of the intact molecule and H- and L- chains), disulfide-bond pattern and free sulfhydryls (LCMS/MS), secondary structure (fourier transform infrared, FTIR), tertiary structure (near ultraviolet circular dichroism, near-UV-CD), temperature-induced unfolding (differential scanning calorimetry, DSC), glycosylation on both HCs at N301 (ultra-high pressure liquid chromatography (UPLC), capillary gel electrophoresis (CGE), LC-MS/MS). In addition, belantamab specific binding activity to antigen, FcgRIIIa, FcRn was determined by surface plasmon resonance (SPR). Data of binding to FcγRI, FcγRIIa, and FcγRIIb by SPR were also include in the characterization exercise. Potency determination by an ADCC reporter bioassay was carried out. CDC activity is not considered to be a significant MoA.

Process related impurities remain at acceptable levels for daily exposure based on risk assessment and ability of the manufacturing process to reduce process-related impurities. Clearance of host cell protein (HCP), host cell DNA and Protein A by the belantamab manufacturing process to acceptable levels has been shown through successful manufacture. Product-related impurities and substances include charge variants, aggregates, and fragments. Purity profiles were generated using Capillary Isoelectric Focusing (cIEF) for charge variants, CGE for fragments, and Size Exclusion Chromatography (SEC) for fragments and aggregates.  Belantamab exists primarily in its monomeric form with low levels of dimeric aggregates. The levels of aggregates are controlled at release and stability. Fragmentation studies showed that belantamab size variants result from various combinations of the heavy chain and light chain subunits, i.e., fragments of belantamab HC and LC species, disulfide and non-disulfide linked covalent variants, and truncated HC and LC. These variants are considered in the control strategy. Process validation Appropriate validation studies have been performed for belantamab manufacturing Process 3. The Applicant has applied a three-staged approach: Process Design, Process Performance Qualification (PPQ) and Continued Process Verification (CPV). Ongoing/ Continued process verification is covered by EU GMP. Five consecutive commercial scale PPQ batches have been manufactured. All batches were successfully processed through upstream process and downstream process steps. The release specification criteria were met for the five belantamab batches. Data from PPQ campaign shows that the manufacturing process can consistently produce belantamab that meets its predefined acceptance criteria. Based on the provided results the process is able to remove impurities to acceptable low levels for HCP, hcDNA, bioburden, endotoxins, retroviruses and other putative viruses and media components. A risk assessment concluded that the risk of extractables and leachables is low in the belantamab manufacturing process as there are effective purge point for any potential leachable and extractables in the manufacturing of belantamab mafodotin process. Resin lifetimes have been validated using small scale models of Protein A and Ion Exchange chromatography. The established resin lifetimes will be verified at full scale during commercial manufacturing. Cleaning validation employed for the chromatography resins has been performed. Commercial scale results of the resin cleaning validation studies showed no carry-over of protein. Shipping validation reports have been provided, showing that belantamab packaging and shipping process is reliable, repeatable and robust. Medicinal product no longer authorised

## Generation of cell substrate and Cell banking system

The applicant described in detail the origin of the gene sequences encoding the two chains of belantamab. Also, a detailed description and rationale is provided of the gene constructs and the two expression plasmids. Appropriate information on the gene construct, producer cell line, and establishment of cell

<div style=\"page-break-after: always\"></div>

banks is provided. A conventional two-tiered cell banking system has been established and tested for adventitious agents, cell viability, identity, integrity of expression construct, and gene copy number. Genetic stability of the producer cells was demonstrated using cells at the limit of in  vitro cell  age. Specification and qualification are presented for manufacture and testing of new WCB. Cell banks (MCB, WCB and EPCB) have been sufficiently characterised and shown to be free from non-viral and viral adventitious agents.

Specification, analytical procedures, reference standards, batch analysis, and container closure (belantamab antibody intermediate) The specification for belantamab follows the requirements of present guidelines and Ph. Eur. 'monoclonal antibodies for human use' monograph (01/2012:2031). For the non-compendial methods the principles of the analytical procedures have been described. Specifications are based on processand product understanding, including batch release results from Process 1, Process 2, Process 3, including clinical lots, PPQ lots and post-PPQ lots. The agreed belantamab specification is considered suitable. Appropriate method descriptions and method validations have been provided for all analytical methods. During the procedure cIEF has been added to the belantamab release and shelf life specification. The Applicant has agreed to tighten the belantamab release and shelf life specification acceptance limits for % Main and %Acidic by cIEF. Reference standards The applicant has adequately described the reference standards (RS). Four RS have been manufactured during the development of belantamab using material from GSK development process, non-clinical Process 1, clinical Process 2 and clinical Process 3. A two-tiered system consisting of primary RS (PRS) and working RS (WRS) is used. The PRS is representative of the material used in clinical studies. The PRS and WRS have been appropriately qualified through release testing and additional characterisation. For future WRS, qualification protocol consisting of release testing, additional characterisation and acceptance criteria is presented.  Stability of the reference standards is monitored in the ongoing stability program. Belantamab batch analytical data Batch analytical data of 29 belantamab batches manufactured by processes 1, 2 and 3 is presented. Stability (belantamab antibody intermediate) The design of the stability studies follows the ICH Q5C guideline. Stability data are presented for nine belantamab batches, these include process registration batches (3), clinical batches (3), and Process Performance Qualification batches (3). No  trends  were  observed  in  any  of  the  parameters  tested  for  the  duration  of  the  study  of  frozen belantamab. Process 2, Process 3 and PPQ batches stored at the long-term storage conditions show consistent results. Medicinal product no longer authorised

Based on the stability results under long term storage condition, results from accelerated and stress studies the proposed shelf-life for belantamab antibody intermediate is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.2.2.2. Drug substance intermediate SGD-1269 (linker-drug intermediate)

## General Information (linker-drug intermediate)

<!-- image -->

SGD-1269 is composed of monomethyl auristatin F and maleimide functionality linked by caproic acid. The maleimide moiety reacts with the antibody in the conjugation reaction to belantamab mafodotin. SGD-1269 contains 9 stereogenic centres. General information was provided for solid state form, melting point, moisture sorption, solubility, optical rotation and UV-visible absorption. Full information for the active substance intermediate SGD-1269 was provided in the dossier. No INN has been assigned, other common names are maleimidocaproyl monomethylauristatin F and mcMMAF. Figure 2: SGD-1269 linker-drug intermediate structural formula Manufacture, process controls and characterisation (linker-drug intermediate) The manufacturing process of SGD-1269 is a six-stage convergent synthesis. The synthesis includes starting materials and isolated intermediates. The manufacturing process of SGD-1269 was described in sufficient detail, including all reagents, reaction temperatures and solvents. The overall control strategy is based on specifications of the starting materials, intermediates and after purification steps. No routine reworking or reprocessing is included in the process. The starting materials for the synthesis of SGD-1269 were agreed in the EMA Scientific Advice (Procedure No: EMEA/H/SA/3559/2/FU/1/2018/PA/PR/II). All starting materials have defined chemical properties and structure and are incorporated as significant structural fragments into the structure of the active substance.  All  starting  materials  undergo  several  chemical  transformations  and  purifications.  The synthetic routes of the starting materials were described, and typical impurities were determined using validated analytical methods. Appropriate specifications were set for the starting materials and batch data from each supplier complied with the specifications. The criticality of the process parameters was evaluated on the basis of stretching the parameters and examining the effect on SGD-1269 purity and yield. The intermediates are controlled by specifications that include tests for identification and assay. These intermediates do not contain impurities that could be carried on to SGD-1269. The specifications of intermediates also include tests for related impurities. Appropriate validated methods were used. Medicinal product no longer authorised

The pharmaceutical development followed Quality by Design principles outlined in ICH Q8, Q9, Q10 and Q11 using a risk management approach.

<div style=\"page-break-after: always\"></div>

Identity, assay and purity were identified as critical quality attributes. The overall control strategy was based on setting appropriate specification limits for all starting materials and intermediates. The origin and fate of each observed and potential related impurity was discussed thoroughly and examined by stretching studies of the manufacturing process, spiking experiments and determining the purge factors of the impurities.

The cytotoxic moiety of belantamab mafodotin, is expected to be genotoxic in mammalian systems given it  is  a  microtubule disrupting agent. The SGD-1269 related impurities sharing a similar structure are expected  to  have  similar  toxicity  as  the  SGD-1269  molecule.  The  known  and  reasonably  predicted impurities present in SGD-1269 have been assessed to be non-mutagenic. The structure of SGD-1269 was characterized by 1H and 13C NMR, MS of the protonated molecule and fragment ions and IR. The used methods are appropriate for structure elucidation of SGD-1269. An exhaustive list of observed and potential impurities was provided. The origin and fate of the related impurities was thoroughly discussed. Specification, analytical procedures, reference standards, batch analysis, and container closure (linker-drug intermediate) The specification of SGD-1269 includes tests for description, identification by IR, assay, purity and related impurities by HPLC, [solvent] content by ion chromatography (IC), water content by KarlFischer -titration (KF) and residual solvents by gas chromatography (GC). Validated analytical methods were used. The HPLC method for assay, purity and related impurities is considered appropriate. Different analytical methods were used at different stages of development for the determination of related impurities. All batches complied with the specification at the time of analysis. The proposed specification limit for assay was justified. As outlined in the guidance 'Information on nitrosamines for marketing authorisation holders' (EMA/189634/ 2019) and Questions and answers on 'Information on nitrosamines for marketing authorisation holders' (EMA/CHMP/428592/2019 Rev. 2), Marketing Authorisation Holders of products on the European market need to perform a risk assessment with respect to potential formation of nitrosamine impurities and the potential for cross-contamination for all their medicinal products. Following this assessment, it was concluded that there is no risk identified for the presence of nitrosamines. Stability (linker-drug intermediate) The stability studies were conducted according to ICH guidance. No significant changes or trends were observed in stability indicating parameters. Based on the stability results under long term storage condition, results from accelerated and stress studies the proposed retest period for SGD-1269 linker-drug intermediate is acceptable. 2.2.2.3. Belantamab mafodotin active substance Medicinal product no longer authorised

## General information

Belantamab mafodotin is an antibody-drug conjugate that includes belantamab (IgG1) monoclonal antibody which has 16 disulfide bonds, including four 4 interchains. Belantamab is partially reduced

<div style=\"page-break-after: always\"></div>

and conjugated with SGD-1269 at the interchain cysteine residues, resulting into belantamab mafodotin active substance, which has a target drug-antibody ratio (DAR) of four (4).

## Manufacture, process controls and characterisation

<!-- image -->

Extensive studies have been performed to support the comparability of belantamab mafodotin active substance manufactured by Process 1 and Process 2 using belantamab batches from Process 1, 2 and 3. These studies have included extended characterization, forced degradation, stability comparability and comparison of batch analytical results. The provided results support the comparability of the belantamab mafodotin manufactured by Process 1 and Process 2.

<!-- image -->

The sites involved in the manufacture, packaging, testing, and release of belantamab mafodotin active substance are found acceptable. Description of manufacturing process and process controls The belantamab mafodotin manufacturing process is composed of five steps. The process starts with (1) thawing of the belantamab and solution preparation for reduction, (2) partial reduction of disulfide bonds for conjugation of belantamab with SGD-1269 and quenching of the process, (3) concentration of the belantamab-SGD-1269 conjugate and removal small molecular weight impurities by bufferchange step, (4) formulation and final filtration, (5) filling of active substance in containers and freezing. The manufacture is designed to be operated sequentially, without hold points or critical processing times. A risk assessment was performed on each process step to identify process parameters with impact on CQAs. Acceptable ranges, and associated CQAs for the manufacturing process are provided with rationale, justifications and supportive data for all relevant manufacturing steps. The process control strategy includes in-process controls (IPCs), Process Parameters (PPs) and Critical Process Parameters (CPPs) with acceptable ranges. Raw Materials Adequate information on the raw materials used in the belantamab mafodotin active substance manufacturing process is presented. Most of the materials are of compendial grade referred to in Ph.Eur, USP-NF or JP. Specifications for non-compendial raw materials used in the manufacturing processes are given. The non-compendial raw materials are tested per local specification and they are required and verified to meet the specifications reported by the vendor on the Certificate of Analysis (CoA). No raw materials of animal or human origin are used. Manufacturing Process Development The history, development and control strategy of the belantamab mafodotin manufacturing process has been sufficiently described. Belantamab mafodotin has been manufactured by process1 and 2 using belantamab antibody from Process-1, -2 and -3. Initial belantamab mafodotin manufactured by Process 1 active substance was used in non-clinical and clinical studies. Modifications were made to Process 2 to accommodate the finished product change of frozen solution presentation to lyophilized powder and increase of active substance concentration. Further changes were introduced to optimize the process and scale-up to commercial scale manufacturing. The number of process stages (5) has remained the same for belantamab mafodotin Processes 1 and 2. No changes were made to the conjugation stage between Process 1 and Process 2. Comparability Assessment of belantamab mafodotin DS Process 1 and Process 2 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Characterisation

Extensive characterisation studies of belantamab mafodotin have been conducted.

## Process-related impurities

The applicant has evaluated the clearance of process-related impurities that result from the coupling of belantamab with SGD-1269. The Applicant has performed a risk assessment showing that the maximum expected levels of the process-related impurities remain below the permitted daily exposure supporting the safety conclusion. Product related impurities The Applicant has identified product-related impurities of belantamab mafodotin, these include acidicand basic-charge variants, aggregates, fragments, and drug load (DL) variants. Process validation The manufacturing process for belantamab mafodotin was validated using a three step approach. In stage1 small-scale studies were performed to determine acceptable ranges for parameters and to establish attributes for PPQ studies. In stage2, three Process Performance Qualification batches were manufactured to demonstrate consistency in process performance and production of the active substance meeting established quality criteria. For stage3, the Applicant has planned ongoing/continued process verification (CPV) to monitor performance attributes and process parameters, and to accumulate trend data to provide assurance that the process remains in a state of control during routine commercial manufacturing. Three commercial scale batches of belantamab mafodotin were manufactured during the PPQ studies. The provided data show that the manufacturing process can consistently produce the active substance fulfilling the pre-defined quality criteria. Clearance of process-related residuals and impurities has also been validated demonstrating consistent clearance of both impurities. The information provided concerning the process validation is found acceptable. Container Closure System The chosen container closure system is adequate, complies with relevant standards and has been described in sufficient detail . Specification The agreed belantamab mafodotin active substance specification is considered suitable. For establishing acceptance criteria, clinical ranges, risk to overall product efficacy and safety, historical ranges, process capability and expected method variability, assurance of stability have been taken into consideration. At the request of CHMP the Applicant has reviewed and revised the active substance release and shelflife acceptance criteria. Analytical methods Medicinal product no longer authorised

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with ICH guidelines.

## Batch analysis

<div style=\"page-break-after: always\"></div>

Batch analysis data on 21 belantamab mafodotin active substance batches manufactured by Process 1 and Process 2 were provided. The results are within the specifications and confirm consistency of the manufacturing process.

Reference materials A two-tiered reference standard (RS) system is used. Primary RS is representative of the material used in clinical studies and will be used for the qualification of new working RS. Working RS will be used as a reference for the release of DS and during stability testing. The primary and working RS have been appropriately qualified and characterised. A protocol describing the qualification of future reference standards is included. Stability Stability  data  have  also  been  presented on accelerated and stressed storage conditions. All batches included in the stability studies are representative of the commercial manufacturing process. No trends were observed in any of the parameters tested for the duration of the study of frozen belantamab mafodotin active substance. Based on the stability results under long term storage conditions, results from accelerated and stress studies the proposed shelf-life for belantamab mafodotin is acceptable. Photostability study showed that belantamab mafodotin is light sensitive and should therefore be protected from light. Based on results from freeze/thaw studies, the active substance can tolerate up to five cycles of freezing and thawing with no changes in quality. 2.2.3. Finished Medicinal Product Description of the product and pharmaceutical development Belantamab mafodotin for injection, 100 mg finished product is a powder for concentrate for solution for infusion. It is supplied as a sterile, preservative-free, white to yellow lyophilized powder in a single dose vial, manufactured from a bulk drug product (BDP) solution containing 50 mg/mL belantamab mafodotin. Other ingredients include sodium citrate/citric acid, trehalose, disodium edetate and polysorbate 80. Belantamab mafodotin finished product is filled and lyophilized in Type 1 untreated clear glass vials. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards. There are no novel excipients used in the finished product formulation. Belantamab mafodotin finished product is reconstituted with 2.0 mL of sterile water for injection (WFI). The lyophilized powder after reconstitution forms a clear to opalescent and colourless to yellow to brown solution that is essentially free from visible particulates. The sterile WFI used for reconstitution of belantamab mafodotin finished product is not supplied by the Applicant. Pharmaceutical development Medicinal product no longer authorised

The main objective of the formulation development was to achieve long-term stability of critical quality attributes and to find a finished product presentation to meet the quality target product profile (QTPP).

Two different finished product presentations of belantamab mafodotin were used in clinical studies: a 20 mg/mL solution for infusion and a 100 mg powder for solution for infusion. Only the powder for

<div style=\"page-break-after: always\"></div>

solution for infusion is proposed for commercialization and therefore it is emphasized that the liquid presentation is not assessed or approved within this submission.

The Applicant has conducted comparability assessments to evaluate the impact of manufacturing process changes between the liquid and lyophilized finished product processes. Pre-determined acceptance criteria were used to determine comparability. Detailed description on setting the acceptance criteria was not provided and no justification for the set criteria was located. However, as the analytical test results were provided the data can be evaluated regardless of the comparability acceptance criteria. Based on the provided results, it can be agreed with the Applicant's overall conclusion that manufacturing process changes have not impacted the quality or biological activity of belantamab mafodotin. The formulation and manufacturing process were developed to minimize product degradation as a result of exposure to stresses such as freeze-thaw/temperature cycling, exposure to light, time out of cold storage, and shear stresses and to produce a product that meets the product quality attributes. Process characterization studies were performed on each unit operation of the process to mitigate the identified risks, evaluate process parameter impact on product quality, understand the risk and criticality of process parameters, to define proven acceptable ranges, and set in-process controls. The commercial manufacturing controls were established using the process understanding attained from lab-scale process, characterization studies, the production-scale process capability, and finished product quality data obtained from the engineering batch and clinical manufacturing. No significant changes were made to the manufacturing process after establishing process conditions with an engineering batch, with the exception of the removable cap colour and the primary drying time during lyophilization. The selected manufacturing process consists mainly of active substance thaw, pooling, dilution and mixing of the active substance, sterile filtration and aseptic filling into vials, partial stoppering, lyophilization and stoppering followed by capping. The primary packaging is Type 1 glass vials sealed with bromobutyl rubber stopper and aluminium overseal with a plastic removable cap. The material complies with Ph. Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product. Manufacture of the product and process controls Description of manufacturing process and process controls The sites involved in the manufacture, packaging, testing, and release of belantamab mafodotin finished product are appropriately provided. Valid GMP certificates have been provided for all listed finished product manufacturers. The Applicant has provided a batch formula representing the intended batch size range. Medicinal product no longer authorised

A clear step-by-step description and a flow chart of the belantamab mafodotin finished product manufacturing process including CPPs and IPCs were provided. The process starts with thawing of active substance and involves preparation of diluent solution, pooling the active substance and compounding of the BDP, sterile filtration, filling and partial stoppering, and lyophilization followed by capping. After capping, the vials are externally washed, inspected, packaged in bulk, and stored at 28°C at the manufacturing site. There are no re-processing steps. The manufacturing process has been sufficiently described.

The critical process parameters (CPPs) and in-process tests (IPTs) with their associated acceptance criteria or limit or acceptable ranges have been presented for all relevant manufacturing steps.

<div style=\"page-break-after: always\"></div>

Rationale and justification for the classification of process controls applied in finished product manufacture was provided. Overall, the presented process controls are appropriate and the proposed control strategy for the finished product manufacturing process is acceptable.

Process validation The belantamab mafodotin finished product manufacturing process was validated at the proposed commercial manufacturing site through controlled process parameters and performance parameters with predetermined acceptance criteria. Three consecutive commercial scale PPQ batches were produced for the studies. The validation studies included: Process performance qualification, Validation of the sterilization processes, Media fill trials, and Shipping validation. In addition, a verification of the total BDP solution hold time was conducted during the PPQ batches. Overall, all PPQ batches satisfactorily met the pre-determined acceptance criteria for all controlled process parameters, in-process tests and release tests. The Applicant has confirmed that the media fills and SIP process meet GMP requirements as defined in EudraLex Vol 4 Annex 1. Product specification The agreed finished product specification is considered suitable for control of the finished product. A difference in acceptance criteria between release and shelf life specifications is proposed for residual moisture. Overall, the test parameters proposed to be included in the specification are considered relevant and in line with current guidance. The specification includes tests for appearance, identity, purity, potency, quantity and general tests. The majority of methods are used to control both the active substance and finished product and have been discussed in the active substance part of the report. The potential presence of elemental impurities in the finished product has been assessed on a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on three batches using a validated Inductively coupled plasma-mass spectroscopy (ICP-MS) method was provided. The information on the control of elemental impurities is satisfactory. Analytical methods The analytical methods used have been adequately described and (non-compendial methods) appropriately validated in accordance with ICH guidelines. Batch analysis Batch analysis data on 20 batches of different scales of the finished product were provided. The results are within the specifications and confirm consistency of the manufacturing process. Reference materials The same product-specific reference standard is used for release and stability testing of belantamab mafodotin bulk active substance and belantamab mafodotin finished product. Refer to the relevant part of the report for details. Stability of the product Medicinal product no longer authorised

The Applicant has provided data on stability studies performed at the long-term storage condition at the accelerated storage condition and at the stress storage conditions. All evaluated long-term stability parameters met the acceptance criteria.

<div style=\"page-break-after: always\"></div>

The proposed shelf-life specification differs from release specification for residual moisture, and for stability studies container closure integrity is tested instead of sterility.

Based on the provided data, the proposed shelf-life of 18 months, when stored at 2 - 8°C, for belantamab mafodotin finished product is acceptable.

In-use microbiological study, and in-use stability study for reconstituted and diluted finished product support the in-use storage conditions proposed in the SmPC: i.e ., reconstituted solution can be stored for up to 4 hours at room temperature or stored in a refrigerator (2°C to 8°C) for up to 4 hours, and the diluted solution can be stored in a refrigerator (2ºC to 8ºC) prior to administration for up to 24 hours. In the SmPC it also stated that 'Filtration of the diluted solution is not required. However, if the diluted solution is filtered, polyethersulfone (PES) based filter is recommended'. Data to support the use of the PES based filter has been provided. Adventitious agents The Applicant has addressed both non-viral and viral contaminants. In the manufacturing process of belantamab mafodotin no material from animal or human origin is used and therefore the risk of TSE contamination from the raw materials used is considered negligible. The Applicant has also provided a risk assessment for all raw and starting materials. In-process testing is in place to ensure safety from bioburden and mycoplasma and cell banks have been tested to be free from non-viral (sterility and mycoplasma) and viral adventitious agents. Release of belantamab production batches requires testing of unprocessed bulk for the presence of adventitious viruses. A tabulated summary of the analytical qualification/validation results of these analytical procedures should be provided. The viral clearance validation (VCV) studies were performed in accordance with requirements in ICH Q5A(R1) to demonstrate the capacity of belantamab Process 3 to remove and/or inactivate viruses. The Applicant has provided appropriate details on the methods and method qualification/validation. The manufacturing process for belantamab includes steps specifically designed to remove viruses (virus filtration) and inactivate viruses (low pH viral inactivation) and additionally the chromatography steps contribute to the overall virus clearance. Overall, the inactivation/removal of different types of viruses is considered to be sufficiently demonstrated. GMO Not relevant. Post-approval change management protocol (PACMP) Belantamab mafodotin finished product The PACMP for belantamab mafodotin finished product describes the transfer of the finished product manufacturing process and vial inspection. Medicinal product no longer authorised

Overall the proposed analytical testing program is considered sufficient and acceptable for comparability evaluation for the proposed technology transfer. The Applicant has justified the statistical approach used to determine the acceptance criteria and committed to follow possible trends in the analytical test results. The Applicant's proposal to submit the data report upon completion of the

<div style=\"page-break-after: always\"></div>

technology transfer activities as a Type IB variation, if all specified criteria are met, is considered acceptable. In case significant changes are planned to the PACMP described here, the Applicant commits to submit the changes to EMA for review and approval before implementation.

2.2.4. Discussion on chemical, pharmaceutical and biological aspects Quality Development Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product, which pertain to suggested studies and review of documentation once more manufacturing experience is obtained. These points are put forward and agreed as recommendations for future quality development. 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety. 2.2.6. Recommendations for future quality development In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation: · The Applicant is recommended to review, and if found appropriate, to revise the acceptance limits for cIEF, Binding by SPR and cell growth inhibition assay. · The Applicant is recommended to carry out additional studies on the MCB and WCB as part of the qualification of the new WCBs which is expected to be completed in 3-7 years. 2.3. Non-clinical aspects 2.3.1. Introduction Medicinal product no longer authorised

Primary and secondary pharmacology studies described in this section were conducted in accordance with  accepted  practice  for  these  study  types  and  in  general  agreement  with  the  principles  of  Good Laboratory Practice (GLP). The single in vitro safety pharmacology study was conducted according to GLP regulations, furthermore safety pharmacology evaluations [cardiovascular and/or respiratory] were incorporated into the GLP repeat dose toxicology studies in rats and monkeys. All GLP studies were carried out in an Economic Co-Operation and Development (OECD) member country in accordance with the OECD Test Guidelines.

<div style=\"page-break-after: always\"></div>

Selected evaluations were conducted with cys-mcMMAF, the active cytotoxic moiety, and GSK2857914, the parent, unconjugated afucosylated anti-BCMA antibody, to further characterize the overall nonclinical profile of belantamab mafodotin.

Two different DS presentations have been used during nonclinical development: solution and powder for solution (which is proposed for commercialization). All definitive toxicology studies supporting the development of belantamab mafodotin were conducted in full compliance with Good Laboratory Practice (GLP) regulations and were conducted in an Organisation of Economic Cooperation and Development (OECD) member country in accordance with the OECD Test Guidelines. Other studies were performed in accordance with accepted scientific practice and in general agreement with the principles of GLP. 2.3.2. Pharmacology Primary pharmacodynamic studies · In vitro studies BCMA binding and internalisation, fragment chrysallizable (Fc-R) binding Belantamab mafodotin binds with high nanomolar affinity to human rBCMA (Kd 1.1 - 1.6 nM at 25°C and 3.1  nM  at  37°C).  Supporting  the  selection  of  cynomolgus  monkey  as  a  species  for  toxicological evaluation, comparable affinity to monkey BCMA (Kd 0.7 nM at 25°C and 8.4 nM at 37°C) was shown, and no binding to mouse or rat BCMA. Conjugation  or  afucosylation  did  not  affect  the  binding  affinity  of  belantamab  mafodotin  to  hBCMA. Afucosylation  improved  binding  to  FcγRIIIa (human  and  monkey  of  origin)  by  10-  to  20-fold.  The afucosylation or conjugation did not affect the binding affinity for the other Fc-receptors (human or monkey of origin), including the FcRn. Unconjugated parent anti-BCMA Mab (GSK2857914) neutralised binding of BCMA ligands BAFF and APRIL to BCMA in a cell-free plate assay with IC50 values of 749 ng/mL and 617 ng/mL, respectively, and inhibited BAFF- and APRILinduced NFκB signalling in NCI -H929 cells with IC50 values of 1.84 µg/mL and 1.56 µg/mL, respectively. Binding and internalisation of belantamab mafodotin and unconjugated GSK2857914 to the BCMA on cell surface was shown with flow cytometry and confocal microscopy on human MM NCI-H929 cells. Upon binding BCMA on MM cells, belantamab mafodotin was internalised within 1 hour out to 7 hours and active cytotoxic drug (cys-mcMMAF) was released via lysosome mediated degradation of the ADC. ADC-mediated Cytotoxicity G2/M arrest and apoptosis induced by belantamab mafodotin was shown in a concentration and time dependent manner in MM cell lines using cell viability assays and flow cytometry assays for cell cycle analysis and cleaved caspase 3/7 expression. Belantamab mafodotin at 0.01 to 10 µg/mL concentration had cytotoxicity potency against MM cells with IC50 values ranging from 6 to 70 ng/mL. Belantamab mafodotin decreased viability of patient-derived primary CD138+ MM cells of the whole bone marrow mononuclear cells together with MM patient plasma mimicking the tumour microenvironment. Medicinal product no longer authorised

The kinetics of belantamab mafodotin -induced cell death was directly affected by number of BCMA receptors. The growth inhibitory activity was achieved even in the presence of physiologically relevant concentrations of soluble BCMA or the BCMA ligand APRIL.

<div style=\"page-break-after: always\"></div>

Belantamab mafodotin did not have by-stander killing effect on BCMA-negative bone marrow stromal cells and various effector cells.

## Antibody-Dependent Cellular  Cytotoxicity  (ADCC)/ Antibody-Dependent Cellular  Phagocytosis  (ADCP) activity

In  xenograft  mice  bearing  NCI-H929  human  multiple  myeloma  cell  tumours,  a  complete  tumour regression that was maintained for the whole 60 days, was achieved with 4 mg/kg dose of belantamab mafodotin administered twice weekly for 4 weeks. At this dose varying the drug-antibody ratios (DAR) from 3.5 to 4.6 had no effect on anti-tumour activity. For clinical batches the DAR was 4. Anti-tumour activity (decreased necrosis, increased infiltration of leucocytes into the tumour, decreased markers for cell proliferation and apoptosis) was confirmed in histology.

Afucosylation of the antibody moiety of belantamab mafodotin was shown to enhance the interaction with Fc gamma receptors (Fc γ Rs) present on primary immune cells (e.g. natural killer [NK] cells and macrophages), and lead to ADCC- and ADCP -mediated killing of MM cells. Belantamab mafodotin (and unconjugated afucosylated GSK2857914) had ADCC activity with an IC50 value of 1.8 ng/mL and a maximal cytotoxicity of 70% at 100 ng/mL when assessed on human PBMNC effector cells (E) and BCMApositive ARH77-10B5 leukaemia target cells (T) at an E:T ratio of 50:1. Both donor and cell line variability was noted, with the EC50 ranging from 0.57 ng/mL to 111 ng/mL. Belantamab mafodotin induced ADCC in primary BM derived CD138+ cells from MM subjects. Belantamab mafodotin was active in both the allogeneic setting (using healthy donor PBMCs) and in autologous setting (using PBMCs derived from the same patient as the CD138+ MM cells). EC50 values were estimated to be approximately 100 ng/mL. Belantamab mafodotin was active against the plasmablasts with the mean EC50 value was 98 ng/mL. Belantamab mafodotin at 2 and 10 µg/mL promoted ADCP in human macrophages derived from M-CSFstimulated monocytes and MM cell lines at an E:T ratio of 4:1. Induction of immunogenic cell death Belantamab mafodotin induced a wide range of immunogenic cell death markers (incl. ATP, HMGB1, CRT) indicative of early phase (ER stress), mid-phase (modulation of immune response) and initiation of the  inflammatory  reaction  as  well  as  late  phase  (apoptosis  and  necrosis)  in  NCI-H929  MM  cells. Dolastatins (a family of natural toxins from which MMAF is derived from), have been shown to induce immunogenic cell death (ICD), leading to an enhancement of dendritic cell maturation and T cell priming. Immune-modulatory effects Belantamab  mafodotin  had  minimal  immunomodulatory  effects  on  human  PBMC-derived  CD4+  and CD8+ T cell activation and no significant effect on IFNγ and IL -4 production in both CD4+ and CD8+ T cells. The study in immature dendritic cells showed that belantamab mafodotin may have an effect on activation/maturation of immature DCs. In vitro activity in combination with other agents used in MM therapies The apoptotic and ADC-mediated cytotoxicity (ADCC) activity of belantamab mafodotin in vitro in MM cell  lines  and  MM  patient  samples  was  enhanced  when  combined  with  a  proteasome  inhibitor  (i.e. bortezomib),  immunomodulatory  agents  (i.e.  lenalidomide  and  pomalidomide),  as  well  as  gamma secretase inhibitors. · In vivo studies Anti-tumour activity in mouse xenograft, orthotopic and immune competent syngeneic models Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

In  xenograft  mice  bearing  OPM-2  tumours  with  two  total  doses  of  100  µg  (4  mg/kg)  belantamab mafodotin dosed twice weekly resulted in near complete tumour eradication out to 36 days in 3 of 5 mice.

In  mouse  orthotopic  MM1Sluc  tumour  graft  model  and  in  EL4-hBCMA  syngeneic  model  (expressing human BCMA), belantamab mafodotin significantly reduced tumour growth and increased survival. Full tumour regression was obtained with 30 mg/kg. The results showed that belantamab mafodotin toxininduced ICD can result in an adaptive immune response resulting in complete tumour regression. CD4+ and CD8+ T cells had significant impact in the anti-tumour activity of belantamab mafodotin in EL4hBCMA syngeneic tumour model. Anti-tumour activity, such as increased tumour necrosis and presence of tumour infiltrating lymphocytes, was confirmed by immunohistochemistry. PD study in cynomolgus monkey Reduction of BCMA expressing plasma cells in blood and bone marrow were observed in cynomolgus monkeys after treatment with a 1 mg/kg IV-dose of belantamab mafodotin or GSK2857914. Treatment with belantamab mafodotin had no effects in absolute counts of CD4+ T cells, CD8+ T cells, CD14+ monocytes, granulocytes or NK-like cells (CD3-/CD4-/CD8+). There was an initial drop in the level of free  soluble  BMCA  which  then  increased,  whereas  the  level  of  complexed  sBCMA  increased  initially increased and then started to decrease at 4 days until undetectable when the drug level had reduced below the detection level. The impact on the IgE levels was the highest while IgG, IgA and IgM levels were reduced. Levels of IL10, IL-12, IL1β and IL -8 were variable between the animals but trended to small increase towards the end of the study. IL-6 levels showed a small peak 6 hours post dosing in all animals in both treatment groups. The effects on Ig levels and cytokines were in general comparable for belantamab mafodotin and GSK2857914. In vivo activity in combination with other agents used in MM therapies Belantamab mafodotin enhanced anti-tumour activity  and/or prolonged  survival  in  combination  with agents such as lenalidomide and bortezomib, but not with pomalidomide, dexamethasone. Secondary pharmacodynamic studies GSK2857914 neutralization of BAFF and APRIL ligand binding to BCMA (Report 2011N125952) GSK2857914 completely neutralized both BAFF and APRIL ligand binding to BCMA in a plate-based assay while the control mAb palivizumab was inactive. The antibody potency was compared in a cell-based assay to evaluate the effects on cell signalling. GSK2857914 was found to completely neutralize BAFF induced NFκB cell signalling. In addition, GSK2857914 completely neutralized APRIL induced NFκB cell signalling in the absence of soluble BCMA. BAFF induced cell signalling was reduced in the absence or presence of soluble BCMA. Isotype control antibodies were inactive in the assay. GSK2857914-induced agonism (Report 2013N175851) Medicinal product no longer authorised

No agonism was observed with GSK2857914 at ≥100 µg/mL in NCI -H929, OPM-2 or JJN3 cells. However, GSK2857914 cross-linked with an anti-human IgG significantly increased NFκB cell signaling greater than GSK2857914 antibody alone by approximately 2 and 5-fold in NCI-H929 and OPM-2 cells with EC50 values of approximately 1.2 and 1.13 µg/mL, respectively, but no change was noted in JJN3 cells. There were  small  (&lt;1.1-fold)  but  significant  differences  in  NFκB  induction  in  NCI -H929  cells  when  plate immobilized GSK2857914 is compared to control IgG.

Selective in vitro cytotoxicity of belantamab mafodotin (Reports 2013N176111 and 2014N224675)

<div style=\"page-break-after: always\"></div>

Belantamab mafodotin did not affect viability of isolated PBMCs, NK cells, CD14+ monocytes, or BMSCs. Belantamab mafodotin at 500 ng/mL or 5000 ng/mL had no significant effect on normal human bone marrow derived myeloid progenitor or on patient bone marrow derived MM progenitors cell numbers, respectively. Plasmacytoid dendritic cells from healthy donors and myeloma subjects were also shown to express low levels of BCMA. However, limited cell killing activity was observed in these cells relative to killing levels observed in MM cells.

The  effect  of  belantamab  mafodotin  on  various  CD4+  and  CD8+  T  cell  functions  was  evaluated  by measuring T cell proliferation (Report 2014N224675). Following treatment with belantamab mafodotin there  were  no  negative  effects  on  the  function  of  activated  CD4+  or  CD8+  T  cells  (proliferation, activation, and cytokine production) based on multiple blood donors. Safety pharmacology programme Standalone safety pharmacology studies were not conducted with belantamab mafodotin, instead the cardiovascular and/or respiratory function endpoints were included in the repeat dose toxicity studies in rats  and  monkeys.  Additionally,  a  single in  vitro hERG  assay  assessing  the  potential  for  delayed ventricular repolarization  was  conducted  with the active cytotoxic  drug,  cys-mcMMAF.  Safety pharmacology evaluations (cardiovascular and/or respiratory) were incorporated into the GLP repeat dose toxicology studies in rats and monkeys. Belantamab mafodotin In the 3 week repeat dose toxicity study with belantamab mafodotin in the cynomolgus monkey (Report 2013N158643), ECGs from the females in each group were collected continuously for approximately 1 minute at baseline, prior to the second weekly dose on Day 8, and at approximately 30 minutes after dosing on Day 8. ECGs from the males in each group were collected continuously for approximately 1 minute at baseline, for approximately 24 hours on Day -7 or -4 and again on Day 8, after dosing. Quantitative assessments conducted on ECGs from males following the second weekly dose (Day 8) showed no apparent belantamab mafodotin-related effects on heart rate or RR, PR, QRS, QT or QTc interval  durations.  All  ECGs  evaluated  in  this  study  were  qualitatively  considered  normal  for  the cynomolgus monkey and, based on their sporadic occurrence and/or low frequency, none of the findings were considered to be related to belantamab mafodotin. There were no abnormal ECG findings detected from the administration of belantamab mafodotin. In the 13 weeks repeat dose toxicity study with belantamab mafodotin in the cynomolgus monkey ECG recordings were performed using a non-invasive telemetry system (Report 2018N375127]. Recordings were performed once prior to the start of dosing for all animals at baseline for approximately 27 hours. In Week 5 (Day 29) and Week 12 (Day 78) ECGs were collected approximately 3 hours immediately prior to the daily dosing and approximately 24 hours after the daily dosing. ECGs were assessed, and the following parameters reported: Heart rate, PR, QRS and QT intervals, QTc. An increase in heart rate was noted during Week 5 from 4 to 18 hours post dose in males administered 10 mg/kg/week. No effects on heart rate or ECG parameters were observed at the end of the off-dose period in animals previously administered 3 mg/kg/week. Serum cardiac troponin I was measured in the rat and monkey 3 week studies and no treatment-related effects were observed (Reports 2013N174857 and 2013N158643). Medicinal product no longer authorised

Detailed cage-side clinical observations following dosing were performed in the 3 and 13 week IV rat and monkey toxicology studies with belantamab mafodotin, and although no formal assessment of effects on the central nervous system was undertaken no clinical observations indicative of neurobehavioral effects

<div style=\"page-break-after: always\"></div>

were observed in any of the studies (Reports 2013N174857, 2018N374327, 2013N158643, 2018N375127).

## cys-mcMMAF

The potential of cys-mcMMAF to inhibit hERG tail current was measured by whole cell patch clamping in HEK293 cells stably transfected with hERG cDNA (Report 2018N376608). Current arising from hERG channel operation was measured prior to and following exposure to cys-mcMMAF (0, 10 and 100 µM). Cys-mcMMAF inhibited hERG current by (Mean ± SEM) 1.2 ± 0.7% at 10 µM and 3.4 ± 0.4% at 100 µM versus 1.1 ± 0.6% in control. The IC50 for the inhibitory effect of cys-mcMMAF was estimated to be greater than 100 µM. Under identical conditions, the positive control (60 nM terfenadine) inhibited hERG potassium current by (Mean ± SD) 87.5 ± 1.3%. Thus, cys-mcMMAF has no inhibitory effect on hERG channel. Evaluation of ECG, blood pressure, respiratory rate and heart rate was performed in the 5 day repeat dose  toxicity  study  in  the  cynomolgus  monkey  study  with  cys-mcMMAF  (Report  2013N177530).  All animals received an ECG examination prior to dosing, at 1 to 2 hours after dosing Day 1, and on Days 7 and 18. Standard ECGs were recorded, RR, PR, and QT intervals and QRS duration were measured, and heart rate was determined. The systolic, diastolic, and mean arterial pressure, heart rate, and respiratory rate  were  also  measured  at  each  interval.  There  was  no  effect  on  qualitative  or  quantitative  ECG parameters or respiratory rate following IV administration of cys-mcMMAF. There was a dose-related trend towards increased systolic, diastolic and mean blood pressure readings on Day 1 and Day 7 when the pooled data were evaluated. These changes were not statistically significant when the data were assessed by sex. No clinical observations indicative of neurobehavioral effects was observed in the toxicology studies with cys-mcMMAF (Reports 2013N177527 and 2013N177530). GSK2857914 (Mab) ECGs were recorded from each animal once prior to the start of dosing and on Day 15 of the 4 week repeat dose toxicity study in cynomolgus monkey with GSK2857914 (Report 2012N150466). During the treatment period ECG recordings were made prior to dosing and at the approximate Tmax (48 hours after dosing). All ECGs were within normal limits. Pharmacodynamic drug interactions No pharmacodynamic (PD) drug interaction studies with belantamab mafodotin have been submitted (see discussion on non-clinical aspects). 2.3.3. Pharmacokinetics The pharmacokinetics (PK), absorption, distribution and excretion of belantamab mafodotin (ADC), GSK2857914 (the parent, unconjugated anti-BCMA antibody) and cys-mcMMAF (the active cytotoxic moiety released from belantamab mafodotin) have been investigated through a series of in vivo intravenous (IV) studies and a single intraperitoneal (IP) study to mice, rats and cynomolgus monkeys. Additionally, toxicokinetics (TK) of belantamab mafodotin, GSK2857914 and cys-mcMMAF were evaluated in single and repeat dose toxicity studies. Medicinal product no longer authorised

The results of the PK studies of belantamab mafodotin or GSK2857914 following single IV and single IP dose to mice are presented in Table 1 .

Table 1 Absorption after a single intravenous or intraperitoneal dose (Mouse)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| authorised   |
|--------------|

<!-- image -->

a = For bioanalytical purposes, belantamab mafodotin is quantified as belantamab mafodotin (ADC) and belantamab mafodotin (total mAb). belantamab mafodotin (ADC) is defined as GSK2857914 conjugated to one or more mcMMAF groups (DAR &gt;0) and belantamab mafodotin (total mAb) is defined as GSK2857914 with or without conjugated mcMMAF (DAR≥0). AUC = area under the serum or blood concentration time curve; BCMA = B-cell maturation antigen; Cmax = Maximum observed serum or blood drug concentration. Cl = clearance; MRT = Mean residence time; NA = Not available; NC = Not calculated; PK= Pharmacokinetics; SCID = Severe combined immunodeficiency. t½ = Terminal elimination half-life; Tmax = Time at which Cmax occurred; Vss = Volume of distribution at steady-state. The results of the PK studies of belantamab mafodotin or GSK2857914 following single IV dose to rat and monkey are presented in Table 2 . Table 2 Absorption after a single intravenous dose (Rat and Monkey) Medicinal product no longer authorised

| Medicinal   |
|-------------|

a = Due to rapid decline in serum concentrations from 504 hours in two of the animals dosed with GSK2857914 the PK parameters for GSK2857914 are based on the data from only one animal.

b = Data dose normalised as belantamab mafodotin dosed at 0.6 mg/kg.

c = Samples also taken at 4800 hours, but not analysed

d = For bioanalytical purposes, GSK2857916 is quantified as GSK2857916 (ADC) and GSK2857916 (total mAb). GSK2857916 (ADC) is defined as GSK2857914 conjugated to one or more mcMMAF groups (DAR &gt;0) and GSK2857916 (total mAb) is defined as GSK2857914 with or without conjugated mcMMAF (DAR≥0). AUC0-t = Area

<div style=\"page-break-after: always\"></div>

under the serum concentration time curve (from time 0 to last time point); AUCinf = Area under the plasma concentration time curve extrapolated to infinity. Cmax = Maximum observed serum drug concentration; Cl = Clearance; mAb = Monoclonal antibody; MRT = Mean residence time; NC = Not Calculated. t½ = Terminal elimination half-life; Tmax = Time at which Cmax occurred; Vss = Volume of distribution at steady-state.

<!-- image -->

The results of the PK studies of cys-mcMMAF following single IV dose to rat and monkey are presented in Table 3 . Table 3 Absorption after a Single Intravenous Dose (Rat and Monkey) Belantamab mafodotin was stable when incubated in rat, monkey or human plasma at 37ºC, as less than approximately 3% of the total MMAF conjugated to the antibody was released as free cys-mcMMAF over a 96-hour period. In an incubation of belantamab mafodotin with human serum, maleimide exchange was observed; the transfer of mcMMAF from belantamab mafodotin onto human serum albumin (HSA) to form HSA-mcMMAF. Following incubation of belantamab mafodotin with HCEC cells and RPTECs, there was evidence for colocation of drug with lysosomes and catabolism to release cys-mcMMAF. Following a single IV administration of fluorescently labelled belantamab mafodotin or GSK2857914 to rats, the fluorescent signal of both antibodies in liver, kidney and eyes was similar. Both antibodies were associated with connective tissue in the eye and eyelids, extra-orbital lacrimal and harderian glands and liver, as well as muscle in the eyelids but was not observed in the cornea or glands in the eyelids. The fluorescent signal was higher in liver and kidneys compared to the eye. Cys-mcMMAF liberated from belantamab mafodotin was detected at very low levels in liver, bone marrow, kidney, harderian gland and extra-orbital lacrimal gland, but was not detected in the cornea, eyelid or whole eye. Following IV administration of belantamab mafodotin to rabbits, belantamab mafodotin (ADC and total mAb) and cys-mcMMAF were detected in tear fluid, but no effect on tear production was observed in belantamab mafodotin-treated animals when compared to vehicle control. Medicinal product no longer authorised

The binding of cys-mcMMAF to plasma proteins was investigated at 0.5, 5, and 50 ng/mL in human plasma from 3 donors, using equilibrium dialysis. Cys-mcMMAF exhibited low protein binding in human plasma in a concentration-dependent manner. The unbound percentages in the 3 donors ranged from 49.1 to 61.8% at 0.5 ng/mL, from 68.8 to 70.7% at 5 ng/mL, and from 80.9 to 88.7% at 50 ng/mL.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| product   |
|-----------|

Cys-mcMMAF has limited metabolic clearance. In vitro (rat, monkey, human) and in  vivo (rats),  the linear isomer of cys-mcMMAF was predominately chemically hydrolysed and dehydrated to the cyclized isomer of cys-mcMMAF, with a very minor amount of Phase I/II enzymatic biotransformations. It is the sum of the linear and cyclized isomers that are measured in the bioanalytical assay for cys-mcMMAF. Following IV dosing of  3 H-cys-mcMMAF to rats, radioactivity was excreted in faeces (83%) and urine (13%), predominately as either the cyclized or linear or isomers of cys-mcMMAF, respectively. In rat faeces, the cyclized isomer of cys-mcMMAF (SGD-1462) constituted the major component being 13.8% of the total radioactivity. Cys-mcMMAF was not an inducer neither inhibitor of key CYP enzymes in human hepatocytes. In vitro , cys-mcMMAF was not a substrate of transporters OAT1, OAT3, OCT1, OCT2, MATE1 or MATE2-K, but was a substrate of OATP1B1 and OATP1B3. In vitro, cys-mcMMAF was not an inhibitor of  transporters  OATP1B1,  OATP1B3,  OAT1,  OAT3,  OCT1,  OCT2,  MATE1  or  MATE2-K.  A  study  was conducted  to  determine  if  cys-mcMMAF  was  either  a  substrate  or  inhibitor  of  the  following  efflux transporters using vesicular transport assays: P-gp; BCRP; BSEP; MRP1, MRP2, MRP3, MRP4 and MRP5. The studies showed that cys mcMMAF is a substrate of organic anion transporting polypeptide (OATP)1B1 and  OATP1B3,  multidrug  resistance-associated  protein  (MRP)1,  MRP2,  MRP3,  bile  salt  export  pump (BSEP), and a possible substrate of P-glycoprotein (P-gp). 2.3.4. Toxicology Single dose toxicity A summary of the single dose toxicity studies is included in Table 4 . Single dose toxicity studies were conducted in rats and monkeys with belantamab mafodotin (ADC in the table) or the cytotoxic moiety cys-mcMMAF. Table 4 Single dose toxicity studies conducted with belantamab mafodotin or cys-mcMMAF Repeat dose toxicity Medicinal product no longer authorised

Repeat dose toxicity studies ( Table 5 ) were conducted to investigate the effects of repeated administration of belantamab mafodotin (ADC below in the table), cys-mcMMAF and GSK2857914 in rats and monkeys.

<div style=\"page-break-after: always\"></div>

Table 5 Repeat dose toxicity studies conducted with belantamab mafodotin, cys-mcMMAF and GSK2857914

<!-- image -->

| Study ID                              | Species/ Number /Group   | Dose (mg/kg/ week) Route          | Duration    | NOEL/ NOAEL (mg/kg/ week)   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------|--------------------------|-----------------------------------|-------------|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2013N174857 (R30467G) GLP ADC         | Rat 10- 16/sex/gr oup    | 3, 10, 30 mg/kg/wee k IV          | 3 weeks     | 3                           | Findings were observed in testes, lung, teeth (irreversible), kidney, sternum/bone marrow (reversible). Non adverse changes in lymph nodes, eyes, femur, male mammary gland, epididymides, ovaries, spleen, liver, thymus, injection site. authorised                                                                                                                                                                                        |
| 2018N374327 (R32025G) GLP ADC         | Rat 12- 28/sex/gr oup    | 3, 10, 30 (once every 3 weeks) IV | 13 weeks    | <3                          | Lung damage at all doses. Adverse findings in testes, teeth, kidney. Non adverse changes in eye, male mammary gland, spleen, liver.                                                                                                                                                                                                                                                                                                          |
| 2013N158643 (P70260G) GLP ADC         | Monkey 3- 5/sex/gro up   | 1, 3, 10 IV                       | 3 weeks     | 1                           | Systemic inflammatory response: spleen, bone marrow, thymus. ↑ CRP, WBC ↓ albumin, red cell mass, platelets. Glomerulopathy, nephron degeneration. ↓ IgM, IgG, NK cells ↑ AST, GLDH, GGT, ALT, bilirubin, cholesterol, triglyceride.                                                                                                                                                                                                         |
| 2018N375127 (5002582) GLP ADC         | Monkey 3- 5/sex/gro up   | 1, 3, 10 IV                       | 13 weeks no | 1                           | Severe pathological changes at 10 mg/kg/week, 1 death, cessation of dosing after 5 weeks. Likely caused by immune complex disease and ADA. Degeneration and necrosis in kidneys, GI tract, lymph nodes, thymus, spleen, liver, mostly reversible. Reversible increase in macrophages in BM, brain, spleen, thymus. Extramedullary , haematopoiesis in liver and lymph nodes. Systemic inflammation. Seminiferous tubule degeneration. longer |
| 2013N177527 (1019-010) GLP Cys-mcMMAF | Rat 12/sex/gr oup        | 1, 5, 10 mg/kg/day IV             | 5 days      | 10 mg/kg/day                | Corneal opacity. ↑ Lung weight, alveolar histiocytosis, inflammation. ↑ AST, ALT, neutrophils.                                                                                                                                                                                                                                                                                                                                               |
| 2013N177530 (1019-009) GLP Cys-mcMMAF | Monkey 3/sex/gro up      | 0.5, 2, 5 mg/kg/day product       | 5 days      | 5 mg/kg/day                 | ↑ monocytes, lymphocytes.                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2012N150466 (P70204G) GLP GSK2857914  | Monkey 3/sex/gro up      | 10, 30, 100                       | 4 weeks     | > 100                       | Skin reddening, scabs, epidermal degeneration and necrosis, hyperplasia and inflammation. Microscopic changes in spleen, liver, kidney, bone marrow. ↑ inflammatory cytokines and CRP Systemic inflammation.                                                                                                                                                                                                                                 |

| Type of test/study ID/GLP                        | Test system                                                                | Concentrations/ Concentration range/ Metabolising system   | Results   |
|--------------------------------------------------|----------------------------------------------------------------------------|------------------------------------------------------------|-----------|
| Gene mutations in bacteria (Ames) Cys-mcMMAF GLP | Salmonella strains TA98, TA100, TA1535, TA1537, and E coli strain WP2 uvrA | +/- S9 50-5000 µg/plate                                    | Negative  |

<div style=\"page-break-after: always\"></div>

| Gene mutations in mammalian cells Cys-mcMMAF GLP                                         | Mouse lymphoma L5178Y TK +/- locus            | +S9 (4h): 5.34-16.9 µg/mL -S9 (4h): 4-16.9 µg/mL -S9 (24h): 0.475-3 µg/mL   | Negative   |
|------------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------|------------|
| Chromosomal aberrations in vitro - induction of micronuclei Belantamab mafodotin Non-GLP | Human peripheral blood lymphocytes            | -S9 (24h): 577 µg/mL                                                        | Positive   |
| Chromosomal aberrations in vivo Cys-mcMMAF GLP                                           | Rat, micronuclei in bone marrow 5 males/group | 2.5-25 mg/kg IV                                                             | Negative   |

<!-- image -->

Carcinogenicity No carcinogenicity studies with belantamab mafodotin were submitted (see discussion on non-clinical aspects). Reproduction Toxicity No reproduction toxicity studies with belantamab mafodotin were submitted (see discussion on nonclinical aspects). Toxicokinetic data The results of the TK of belantamab mafodotin, GSK2857914 and cys-mcMMAF in repeat dose toxicity studies are presented in Table 7 and Table 8 : Table 7 Overview of Toxicokinetics (AUC) data belantamab mafodotin (adc and total antibody) following weekly or every 3 weeks intravenous administration of belantamab mafodotin Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 8 Overview of Toxicokinetics (AUC) data cys-mcMMAF following weekly or every 3 weeks intravenous administration of belantamab mafodotin

<!-- image -->

To investigate the potential for belantamab mafodotin to cause cytotoxicity in HCECs and to examine the mechanism of uptake that plays a role, simple monolayer models using primary HCECs were established (Report 2019N410330). GSK2857914 was used as a negative control to demonstrate the antibody alone did not induce cytotoxicity. Vinblastine sulphate was used as a comparator tubulin inhibitor. Experiments to  investigate  the  role  of  macropinocytosis  in  belantamab  mafodotin-mediated  cytotoxicity  were conducted  using  EIPA  to  inhibit  the  pathway  of  non-specific  uptake.  Cytotoxicity  was  assessed  by

Local Tolerance No separate local tolerance studies have been conducted with belantamab mafodotin. IV injection sites were inspected in the toxicology studies. Clinical and histopathological analysis of injection sites were performed following IV administration of belantamab mafodotin as liquid and lyophilized formulations to rats and monkeys as part of the repeat dose studies (Reports 2012N134122, 2012N133495 and Reports 2013174857, 2013N158643, 2018N374327, 2018N375127). In the rat 3-week study and the single dose toxicity studies in rat and monkey, injection site changes and inflammatory response indicative of local irritancy were noted at ≥ 3 mg/kg/week (dose concentrations of ≥ 0.3 mg/mL). Findings included localized epidermal hyperplasia, mild perivascular haemorrhage and/or inflammation/inflammatory cell infiltrate and occasional skeletal muscle degeneration/necrosis together with changes in plasma AST, aldolase and creatine kinase. Thirteen weekly doses in the monkey, up to 10 mg/kg (up to a dose concentration of 2.5 mg/mL) and four doses administered 3 weeks apart in the rat, up to 30 mg/kg (up to a dose concentration of 3 mg/mL), did not result in treatment-related changes at the injection site. Other toxicity studies · Mechanistic Ocular Toxicity In vitro studies (Reports 2019N410329, 2019N410330) To investigate the potential for belantamab mafodotin to cause cytotoxicity in human corneal epithelial cells three primary human corneal epithelial cell (HCEC) lines and a primary human renal proximal tubule cells (RPTEC), as a comparator epithelial cell type, were used. All cell lines were confirmed by qPCR to have negligible or no expression of BCMA (Report 2019N410329). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

monitoring Caspase 3/7 markers for apoptosis, the pathway through which MMAF induces cell death, and cell viability in HCECs and RPTECs.

The results indicated that belantamab mafodotin exposure results in significant concentration-dependent increases in apoptosis in vitro . The effects were observed in multiple donors for each cell type and there is  a  trend  for  HCECs  being  slightly  more  sensitive  than  RPTECs  when  assessing  the  lowest  tested concentrations that caused a significant increase in apoptosis.

The potential cross-reactivity of belantamab mafodotin (ADC), prepared as a conjugate of belantamab mafodotin  and  Anti-diotype  mAb  S389105H11,  was  assessed  in  a  definitive  GLP  study  (Report 2013N176627).  The following tissue specimens were evaluated: adrenal, urinary bladder, blood cells, bone  marrow,  breast,  brain  (cerebellum  and  cortex),  endothelium,  eye,  fallopian  tube,  GI  tract (oesophagus, gastric antrum, gastric body, duodenum, ileum, colon), heart, kidney, liver, lung, lymph node, ovary, pancreas, parathyroid, parotid, peripheral nerve, pituitary, placenta, prostate, skin, spinal cord, spleen, striated muscle, testis, thymus, thyroid, tonsil, ureter, uterus (cervix and endometrium).

In the presence of the macropinocytosis inhibitor EIPA pre/co-treatment with EIPA significantly reduced belantamab mafodotin-mediated apoptosis in RPTECs and there was a similar trend in HCECs. Treatment with GSK2857914 showed no significant cytotoxicity, measured as apoptosis or cell viability, for both cell types. Treatment with vinblastine sulphate resulted in no effect on apoptosis, although a trend for decreased cell viability was observed in HCECs. · In vivo rabbit Tolerability and Ocular Toxicity (Report 2018N385412) A study was conducted to determine the tolerability and ocular toxicity of belantamab mafodotin in the New  Zealand  white  rabbit  following  two  or  four  IV  doses  each  given  7  days  apart.  Female  rabbits (n=3/group) were given belantamab mafodotin at 0 [vehicle], 15, or 30 mg/kg/week by IV (bolus) injection for two (0 or 30 mg/kg/week) or four weeks (0, 15 or 30 mg/kg/week). No observations were noted after 2 weekly administrations up to 30 mg/kg/week. After four doses of 30 mg/kg/week,  corneal  epithelial  single  cell  necrosis  (minimal  or  mild)  in  all  3  rabbits,  potentially associated with superficial corneal haze in 1 rabbit on Days 27 and 30, was observed. Increased mitoses (minimal) in the corneal epithelium in 2/3 rabbits given 15 mg/kg/week for four weeks, was also seen. There was no belantamab mafodotin-related effect on tear production when compared to vehicle control. Following  ophthalmologic  examination,  bilateral  striations  observed  in  the  retina  of  a  single  animal, administered 15 mg/kg/week for 4 weeks, were of uncertain relationship to treatment; this observation did not correlate with any microscopic findings in the retina following examination of multiple (n=6) sections containing the retina from this animal. · Tissue cross-reactivity (Report 2013N169796, Report 2013N176627) A non-GLP pilot study was conducted to identify a suitable positive control for use with the belantamab mafodotin and GSK2857914 and to determine the cross-reactivity profile of belantamab mafodotin and GSK2857914 in a limited set of human cell lines and human and cynomolgus monkey tissues by IHC analysis (Report 2013N169796). Mild to moderate specific staining was observed in monkey and human adrenal, heart, kidney, liver, lymph node, spleen and tonsil, in human adipose/skin and in cynomolgus colon. Minimal to mild non-specific staining by the BCMA protein absorption control and no antibody negative control was observed in human and cynomolgus goblet cells in the colon. The level of background staining observed in this study did not prevent evaluation for specific staining. Medicinal product no longer authorised

Under the conditions of this study, antigen-specific binding of belantamab mafodotin was showed in positive control material (human spleen).

<div style=\"page-break-after: always\"></div>

Specific positive staining was observed with belantamab mafodotin conjugate in several tissues examined and this was generally associated with individual or focal groups of cells, blood vessel walls/perivascular tissue  and  connective  tissue.  The  majority  of  specific  positive  staining  observed  with  belantamab mafodotin was cytoplasmic. In all tissues where specific positive staining with belantamab mafodotin was observed, comparable staining was seen with the positive control article but not with the negative control article. All other observed staining was variable and considered to be non-specific.

<!-- image -->

| Substance (international non-proprietary name (INN)/Invented Name): belantamab mafodotin   | Substance (international non-proprietary name (INN)/Invented Name): belantamab mafodotin                                                                                                                                                | Substance (international non-proprietary name (INN)/Invented Name): belantamab mafodotin                                                                                                                                                | Substance (international non-proprietary name (INN)/Invented Name): belantamab mafodotin                                                                                                                                                |
|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CAS-number (if available): n/a                                                             | CAS-number (if available): n/a                                                                                                                                                                                                          | CAS-number (if available): n/a                                                                                                                                                                                                          | CAS-number (if available): n/a                                                                                                                                                                                                          |
| PBT screening                                                                              |                                                                                                                                                                                                                                         | Result                                                                                                                                                                                                                                  | Conclusion                                                                                                                                                                                                                              |
| Bioaccumulation potential- log K ow                                                        | Chemaxon QSAR prediction and published article (Burns et al. Mol Pharm. 2017 p 415 - 42).                                                                                                                                               | log Kow expected be <4.5                                                                                                                                                                                                                | Potential PBT (N)                                                                                                                                                                                                                       |
| PBT-assessment longer                                                                      | PBT-assessment longer                                                                                                                                                                                                                   | PBT-assessment longer                                                                                                                                                                                                                   | PBT-assessment longer                                                                                                                                                                                                                   |
| Parameter                                                                                  | Result relevant for conclusion                                                                                                                                                                                                          |                                                                                                                                                                                                                                         | Conclusion                                                                                                                                                                                                                              |
| Bioaccumulation                                                                            | log K ow                                                                                                                                                                                                                                | No studies conducted                                                                                                                                                                                                                    |                                                                                                                                                                                                                                         |
| Bioaccumulation                                                                            | BCF                                                                                                                                                                                                                                     | No studies conducted                                                                                                                                                                                                                    |                                                                                                                                                                                                                                         |
| Persistence                                                                                | DT50 or ready biodegradability                                                                                                                                                                                                          | No studies conducted                                                                                                                                                                                                                    |                                                                                                                                                                                                                                         |
| Toxicity                                                                                   | NOEC or CMR                                                                                                                                                                                                                             | No studies conducted                                                                                                                                                                                                                    |                                                                                                                                                                                                                                         |
| PBT-statement:                                                                             | For the Cys-mcMMAF moiety of the active ingredient, based on the published data and Chemaxon QSAR prediction, the log Kow is not expected to be >4.5 (Burns et al 2017). Belantamab mafodotin is therefore not PBT nor vPvB. product no | For the Cys-mcMMAF moiety of the active ingredient, based on the published data and Chemaxon QSAR prediction, the log Kow is not expected to be >4.5 (Burns et al 2017). Belantamab mafodotin is therefore not PBT nor vPvB. product no | For the Cys-mcMMAF moiety of the active ingredient, based on the published data and Chemaxon QSAR prediction, the log Kow is not expected to be >4.5 (Burns et al 2017). Belantamab mafodotin is therefore not PBT nor vPvB. product no |
| Phase I                                                                                    | Phase I                                                                                                                                                                                                                                 | Phase I                                                                                                                                                                                                                                 | Phase I                                                                                                                                                                                                                                 |
| Calculation                                                                                | Value                                                                                                                                                                                                                                   | Unit                                                                                                                                                                                                                                    | Conclusion                                                                                                                                                                                                                              |
| PEC surfacewater , default or refined (e.g. prevalence, literature)                        | 0.0025                                                                                                                                                                                                                                  | µ g/L                                                                                                                                                                                                                                   | > 0.01 threshold (N)                                                                                                                                                                                                                    |

Overall, the pharmacodynamics of belantamab mafodotin is adequately characterized. The nonclinical pharmacology data showed the designed mode of action of belantamab mafodotin (anti-tumour activity by ADCC/ADCP activity, ADC-induced apoptosis and cell cycle arrest, ICD) and the selective function targeting both dividing and non-dividing BCMA-expressing tumour cells.

2.3.5. Ecotoxicity/environmental risk assessment Table 9 Summary of main study results Belantamab mafodotin PEC surface water value is below the action limit of 0.01 μ g/L and is not a PBT substance as log Kow does not exceed 4.5. 2.3.6. Discussion on non-clinical aspects Medicinal product no longer authorised

Modifications  to  the  belantamab  mafodotin  manufacturing  process  were  made  during  product development,  and  two  different  DS  presentations  have  been  used  during  nonclinical  development: solution and powder for solution (which is proposed for commercialization). For these, the comparability

<div style=\"page-break-after: always\"></div>

has been demonstrated for the drug substance produced by the earlier manufacturing processes and DS batches used in the nonclinical toxicology studies and in clinical studies, and to commercial DP.

Stability assessments are ongoing for cys-mcMMAF in the presence of belantamab mafodotin at -20°C. Once the stability assessments have been completed, the applicant will make a final assessment of the impact on the cys-mcMMAF dataset. If the maximum storage stability duration is shorter than the time required to support at least 80% of the Study 205678 dataset, the applicant proposes to perform an update of the pharmacokinetic and PK/PD analyses using the data for which storage stability is confirmed and to submit the updated results to the CHMP by 2Q 2021. This was accepted by the CHMP.

Regarding the determination of free soluble BCMA in human serum using ECL the parallelism should be assessed, and the results should be reported. Due to scheduling and staffing complications associated with COVID-19, as well as the lack of suitable incurred samples from study 205678, the assessment has been delayed. The CHMP recommended the applicant to submit the results obtained for the parallelism experiments, when available (Q4 2020). Belantamab mafodotin functionality was shown for large range of BCMA expression levels on MM cells, at concentrations of belantamab mafodotin hypothesized to be achievable in humans, under conditions designed to mimic the human target cells and microenvironment (MM patient plasma) and with the physiological  concentrations  of  BCMA  ligands  and  shedded  BCMA.  Belantamab  mafodotin  induced selective  cell  death  of  BCMA-expressing  MM  cells,  with  minimal  bystander  toxicity  to  non-BCMA expressing cells. Belantamab mafodotin induced durable tumour growth regression in xenograft mice models bearing human multiple myeloma NCI-H929, OPM-2, and MM1Sluc cells, and dependently on the presence  of  CD8+  T-cells  in  immune-competent  syngeneic  mouse  expressing  human  BCMA  (EL4hBCMA).  Furthermore,  in  cynomolgus  monkeys  a  single  dose  of  belantamab  mafodotin  resulted  in reduction in the BCMA-positive plasma cells and IgE levels, and modest reduction in IgG, IgA, and IgM levels. Belantamab mafodotin was taken up into cells throughout the body by a mechanism unrelated to BCMA receptor expression on the cell membrane (SmPC, section 5.3). Limited secondary pharmacodynamic effects are expected, related to low potency to induce cell death, which express low levels of BCMA, such as plasmacytoid dendritic cells, and putative payload of nonspecific uptake (pinocytosis) into non-target cells. Belantamab mafodotin had no significant effects on cardiovascular, respiratory and central nervous systems in rats and monkeys in safety pharmacology evaluations, but potential to cardiotoxicity related to inflammatory response is listed under RMP, Part II nonclinical safety specifications. The Applicant has conducted a comprehensive set of in vitro and in vivo pharmacokinetic studies with each  components  of  the  product.  No  sex  differences  were  observed.  The  serum  t½  of  belantamab mafodotin (ADC) in rats was approximately 11 days, which was slightly longer than in mice. Following IV bolus administration of belantamab mafodotin, Tmax was observed at 0.25 hour in most monkeys; in some animals Tmax was 3, 6 or 24 hours after dosing during Weeks 1 and 3 for belantamab mafodotin (ADC and total mAb). Belantamab mafodotin was shown to be distributed to connective tissue in eyes, eye lids, extra-orbital lacrimal, Harderian glands, liver, and kidney. Cys-mcMMAF was detected only in the bone marrow but not in the cornea, whole eye or eye lids of the rat. Cys-mcMMAF exhibited low protein binding in human plasma in a concentration dependent manner, from 49.1% at 0.5 ng/mL to 88.7% at 50 ng/mL. Binding of cys-mcMMAF to plasma protein was similar in monkeys and humans, but higher in rats. Medicinal product no longer authorised

The metabolism of cys-mcMMAF was shown to be low and was primarily characterized by non-enzymatic transformations and to a minor degree by oxidative and conjugative metabolism. In vitro (rat, monkey, human) and in vivo (rats), the maleimide ring was predominantly chemically hydrolysed and dehydrated

<div style=\"page-break-after: always\"></div>

to  a  cyclized  isomeric  form  of  cys-mcMMAF  with  a  very  minor  amount  of  Phase  I/II  enzymatic biotransformation. It is the sum of the linear and cyclized isomers that are measured in the bioanalytical assay for cys-mcMMAF. Cys-mcMMAF was not a sensitive substrate of cytochrome P450 enzymes in vitro. The metabolic pathways of cys-mcMMAF in rat were hydrolysis, beta-lyse, S-methyltransferase, N-acetylation, reductive C-S-cleavage, amino acid conjugation, oxidation and unknown way. There were some differences in the metabolite profiles between the rat, monkey and human. However, this is not of any concern from clinical point of view since the metabolites accounted for less than 5% of the total radioactivity. Furthermore, metabolites unique to human that might have been missed in the toxicity studies conducted in rats and cynomolgus monkeys, were not identified.

In general, the toxicological data package for belantamab mafodotin is comprehensive. Repeat dose toxicity evaluation was conducted for belantamab mafodotin, cys-mcMMAF and GSK2857914 in rats and cynomolgus  monkeys,  and  in  rabbits  focusing  on  the  ocular  findings.  Of  the  toxicological  species, belantamab mafodotin cross-reacted only with the monkey BCMA target, thus implicating that in rats and rabbits lacking the BCMA binding, not the target specific toxicity, but the off-target or unspecific cytotoxicity via the pinocytosis of the product, has been evaluated. To support the long-term therapeutic use of belantamab mafodotin powder for concentrate for solution for infusion, studies were performed by the IV route of administration for periods of up to 13 weeks in rat ( ≤ 30 mg/kg) and monkey ( ≤ 10

The data showed that cys-mcMMAF is predominantly excreted via the hepato-biliary/faecal pathway (83%), and to a lesser amount via renal clearance (13%). Based on available in vitro and clinical data, there is a low risk of pharmacokinetic or pharmacodynamic drug interactions for belantamab mafodotin (SmPC, section 4.5). Radio-profiles of 0- to 8-hour and 8- to 24-hour pooled urine samples showed that unchanged cysmcMMAF (SGD-1362) was the major component in rat urine, accounting for 9.33% of the radioactive dose (compared to a total of 12.1 % of radioactive dose in the pooled urine samples and 11.6 % of radioactive dose quantitated, 0- to 24-hour post-dose together). Other identified metabolites, including M15, M16, SGD-1462, and M25, each accounted for less than 1% of radioactive dose. Radio-profiles of 0- to 24-hour and 24- to 48-hour pooled faeces samples showed that the unchanged cys-mcMMAF was a minor component recovered in faeces, accounting for 0.748% of the radioactive dose (compared to a total of 81.4% of radioactive dose in the pooled faeces samples and 40.1% of radioactive dose quantitated, 0- to 48-hour post-dose together, due to low extraction recoveries). SGD-1462, an isobaric analogue of SGD-1362, was the only major metabolite, which accounted for 13.8% of radioactive dose. All other identified metabolites, including M25, M31, and M35 through 48, each accounted for less than 5% of radioactive dose. In rats a mass balance study with radiolabelled cys-mcMMAF has been performed. Following IV dosing of 3H-cys-mcMMAF to rats approximately 83 % of the dose was excreted in the faeces. Urinary excretion (approximately  13%)  was  a  minor  route.  Radioactivity  was  excreted  rapidly  and  94  %  of  the administered dose recovered in the first 48 hours after dosing. Total recovery of radioactivity over the 168-hour collection period was 96 %. Radioactivity was excreted predominantly as either the linear or cyclized isomers of cys-mcMMAF. Non-clinical safety studies have shown dose dependent and reversible primary glomerular injury and tubular degeneration (in rat and monkey) directly related to belantamab mafodotin, accompanied by large molecular proteinuria (albuminuria) and enzymuria. Single cell necrosis of the kidney and bladder urothelium was also noted in the 13-week monkey study. Severe tubular degeneration/regeneration and marked  glomerulonephritis  exacerbated  by  immune  complex  disease,  likely  associated  with  ADA, following 5 weekly doses of 10 mg/kg, led to the early euthanasia of one monkey. Glomerulonephritis associated with immune complex formation is not expected to be reversible. Nephrotoxicity has been categorized as an important potential risk (see RMP). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

mg/kg). The toxicology findings with belantamab mafodotin were primarily related to the safety of the cytotoxic drug conjugate, cys-mcMMAF, which follows the reported safety profiles of other auristatins and microtubule disrupting agents. The tubular degeneration/regeneration in the kidneys, seminiferous tubular changes in the testes, luteinized nonovulatory follicles in the ovaries, degeneration of the incisor ameloblast/odontoblast layers (rat), increased liver enzymes with single cell necrosis, lymphocytolytic and/ or cellularity alterations in the bone marrow, spleen and eye (rat) are considered likely to be related to MMAF. Similar effects have been reported with the auristatins or other microtubule disrupting agents such as colchicine and vinblastine.

No carcinogenicity or definitive genotoxicity studies have been conducted with belantamab mafodotin (SmPC, section 5.3). Belantamab mafodotin was genotoxic in an in  vitro screening  assay  in  human lymphocytes,  consistent  with  the  pharmacological  effect  of  cys-mcMMAF-mediated  disruption  of microtubules causing aneuploidy. The absence of carcinogenicity studies is accepted in line with the ICH S9 and S6(R1) guidelines.

Decreases in immunoglobulins were seen in monkeys  at all doses. Decreases in lymphoid cellularity/necrosis (doseresponsive in severity) was noted in the spleen and/or lymph nodes at ≥3 mg/kg/week,  which  was  associated  with  decreases  in  thymic  cellularity  in  rats.  Increased  risk  of infections due to immunosuppression and/or neutropenia has been categorized as an important potential risk (see discussion on clinical safety RMP). Overall, the principal adverse findings (directly related to belantamab mafodotin) in the rat and monkey, at exposures ≥ 1.2 times of the recommended clinical dose of 2.5 mg/kg, were elevated liver enzymes sometimes associated with hepatocellular necrosis at ≥ 10 and ≥ 3 mg/kg, respectively and increases in alveolar macrophages associated with eosinophilic material in the lung at ≥ 3 mg/kg (rat only) (SmPC, section 5.3). Most findings in animals were related to the cytotoxic drug conjugate, the histopathological changes observed in the testes and lung, were not reversible in rats (SmPC, section 5.3). Although ADA formation was evident in monkey studies, the exposures were generally maintained at low and  mid-dose  animals  and  were  approximately  at  the  same  level  in  mid-dose  animals  as  the recommended human dose of 2.5 mg/kg, based on ADC area under concentration curve (AUC). The highest non-severe toxic dose in monkeys was 3 mg/kg and the highest dose tested exceeded the clinical dose by 3.8 and 2.5 -fold (ADC and mAb respectively). Corneal events are one of the most frequently reported AEs associated with belantamab mafodotin in the clinic, and these include keratopathy, blurred vision, dry eyes and photophobia. These corneal events are consistent with those reported in the literature with other MMAF-conjugated ADCs. In nonclinical toxicity studies, corneal effects (bilateral single cell necrosis in the corneal epithelium and/or increased mitoses of corneal epithelial cells) were seen in rats and rabbits, but not in monkeys. Furthermore, in rabbits a finding of bilateral striations in the retina in the 15 mg/kg dose group was reported. Belantamab mafodotin  was  found  in  connective  eye  tissues  but  not  in  cornea  in  rats.  The  data  support  the involvement of non-specific macropinocytosis as a mechanism of cellular uptake to the eye and indicate that the ocular adverse effects observed in rats result from unspecific uptake leading to microtubulin inhibition and apoptosis due to the cys-mcMMAF moiety.  Regarding the retinal finding in rabbit the cause is unknown. It was postulated that it could be a slight alteration in the alignment of retinal ganglion cells. Finding did not correlate with any microscopic alterations. It did not represent a retinal degeneration or adversely affect the surrounding layers. Thus far similar retinal striations have not been reported in patients after treatment with belantamab mafodotin, and it is sufficient, that the eye alterations are and will be followed critically in patients (see discussion on clinical safety and RMP). Medicinal product no longer authorised

No animal studies have been performed to evaluate the potential effects of belantamab mafodotin on reproduction or development. The mechanism of action is to kill rapidly dividing cells which would affect

<div style=\"page-break-after: always\"></div>

a developing embryo which has rapidly dividing cells. There is also a potential risk of heritable changes via aneuploidy in female germ cells (SmPC, section 5.3).

Effects on male and female reproductive organs have been observed in animals at doses of ≥ 10 mg/kg, which is approximately 4 times the exposure of the clinical dose. Luteinized nonovulatory follicles were seen in the ovaries of rats after 3 weekly doses. Findings in male reproductive organs, that were adverse and progressed following repeat dosing in rat, included marked degeneration/atrophy of seminiferous tubules that generally did not reverse following dosing cessation (SmPC, section 5.3). Based on findings in animals and the mechanism of action, belantamab mafodotin may impair fertility in females and males of reproductive potential (SmPC section 4.6). Therefore, women of childbearing potential who may desire offspring in the future should be counselled prior to therapy regarding the option of having eggs frozen before treatment. Men being treated with this medicine are advised to have sperm samples frozen and stored before treatment (SmPC section 4.6). Based  on  the  mechanism  of  action  of  the  cytotoxic  component  monomethyl  auristatin  F  (MMAF), belantamab mafodotin can cause embryo- fetal harm when administered to a pregnant woman. Human immunoglobulin  G  (IgG)  is  known  to  cross  the  placenta;  therefore,  belantamab  mafodotin  has  the potential to be transmitted from the mother to the developing fetus (SmPC section 4.6). BLENREP should not be used during pregnancy unless the benefit to the mother outweighs the potential risks to the fetus. If a pregnant woman needs to be treated, she should be clearly advised on the potential risk to the fetus (SmPC, section 4.6). It is not known whether belantamab mafodotin is excreted into human milk. Immunoglobulin G (IgG) is present in human milk in small amounts. Since belantamab mafodotin is a humanised IgG monoclonal antibody, and based on the mechanism of action, it may cause serious adverse reactions in breast-fed children.  Women  should  be  advised  to  discontinue  breast-feeding  prior  to  initiating  treatment  with BLENREP and for 3 months after the last dose (SmPC, section 4.6). The pregnancy status of child-bearing women should be verified prior to initiating therapy with BLENREP. Women of child-bearing potential should use effective contraception during treatment with BLENREP and for 4 months after the last dose (SmPC, section 4.6). Men with female partners of child-bearing potential should use effective contraception during treatment with BLENREP and for 6 months after the last dose (SmPC, section 4.6). The active substance is composed of a natural substance (monoclonal antibody) conjugated with tubulin polymerization inhibitor mcMMAF. PECSURFACEWATER of belantamab mafodotin is below the trigger limit of 0.01  µg/L  and  therefore  the  product  is  not  expected  to  adversely  affect  the  aquatic  or  terrestrial environments. 2.3.1. Conclusion on the non-clinical aspects Overall, the non-clinical documentation submitted was considered adequate. The relevant information has been included in the SmPC (sections 4.6, 5.1 and 5.3). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

GCP The Clinical trials were performed in accordance with good clinical practice (GCP) as claimed by the applicant. The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC. · Tabular overview of clinical studies Table 10  Clinical studies in the clinical development program supporting the MA 2.4.2. Pharmacokinetics The pharmacokinetics of belantamab mafodotin, total mAb (antibody with or without the cys-mcMMAF moiety), and cys-mcMMAF has been evaluated in two clinical studies DREAMM-1 and DREAMM-2 conducted in subjects with RRMM. In addition, a population PK analysis was performed in order to characterize the population PK of belantamab mafodotin in patients with RRMM and identify covariates of clinical interest. The PPK model was subsequently used for exposure-response analyses. Absorption Maximum concentration for belantamab mafodotin occurred at or shortly after the end of infusion while cys-mcMMAF concentrations peaked ~24 hours after dosing. Geometric mean belantamab mafodotin Cmax and AUC(0-tau) concentrations were 43 mcg/mL and 4,666 mcg.h/mL, respectively. Geometric mean  cys-mcMMAF  Cmax  and  AUC(0-168h)  concentrations  were  0.90  ng/mL  and  84  ng.h/mL, respectively (SmPC, section 5.2). Medicinal product no longer authorised

<!-- image -->

<!-- image -->

The dose of belantamab mafodotin was 2.5 mg/kg. Median tmax (range) values were 22.83 h (1.92-65.63 h) at Cycle 1 and 23.24 h (0.58-46.08 h) at Cycle 3 for cys-mcMMAF.

<div style=\"page-break-after: always\"></div>

## Distribution

The mean steady-state volume of distribution of belantamab mafodotin was 10.8 L (SmPC, section 5.2). Geometric mean value of distribution at steady state for belantamab mafodotin was 4.08 L at Cycle 1 in study BMA117159 (mean 2.9-5.2 L/different dose levels) and 8.0-9.0 L at Cycle 1 in study DREAMM-2.

Belantamab mafodotin binds to the sBCMA in plasma. The assay for quantifying belantamab mafodotin plasma concentrations measures both free and complexed belantamab mafodotin. In vitro , cysmcMMAF exhibited low protein binding in human plasma in a concentration-dependent manner. The unbound percentages in the three donors ranged from 49 to 62% at 0.5 ng/mL, from 69 to 71% at 5 ng/mL, and from 81 to 89% at 50 ng/mL. Elimination Belantamab is a large protein which is degraded to small peptides. The antibody-drug compound is not expected to be excreted. As belantamab mafodotin binds to the cell surface, it is internalised and the cytotoxic moiety cys-mcMMAF is released. Belantamab mafodotin was cleared slowly with total plasma clearance of 0.92 L/day and a terminal phase half-life of 12 days. Over time, clearance was reduced to 0.72 L/day with an elimination half-life of 14 days. Predose cys-mcMMAF concentrations at each dose were typically below the limit of quantification (0.05 ng/mL) (SmPC, section 5.2). In Part 1 of Study BMA117159, urine was collected for 24 h at each cycle, and aliquots were taken for the determination of cys-mcMMAF concentrations at Cycles 2, 4, 7, 10, 13, and 16. Combining all dose levels at Cycle 2, median cys-mcMMAF fraction excreted into the urine over 24 hours was 0.073% of the administered dose. The median value after Cycle 4 was 0.122 % (n=10; range 0.008 to 0.546%). Dose proportionality and time dependencies · Belantamab mafodotin Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 11 Summary of Belantamab Mafodotin PK Parameters on Cycle 1 (Study BMA117159)

<!-- image -->

<!-- image -->

Table 12 Summary of Belantamab Mafodotin PK Parameters at Cycle 1 (Study DREAMM-2) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Table 13 Summary of Key Belantamab Mafodotin PK Parameters at Cycle 3 (Study DREAMM2)

<!-- image -->

<!-- image -->

· Total mAb Table 14 Summary of Total mAb Pharmacokinetic Parameters on Cycle 1 (Study BMA117159) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 15 Summary of Total mAb Pharmacokinetic Parameters at Cycle 1 (Study DREAMM-2)

<!-- image -->

<!-- image -->

| product   |
|-----------|

Table 16 Summary of Key Total mAb Pharmacokinetic Parameters at Cycle 3 (Study DREAMM-2) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## · Time dependency

## Table 17 Summary of Accumulation Ratios Based on End-of-Infusion Plasma Concentrations (Study BMA117159)

<!-- image -->

Table 18 Summary of Accumulation Ratio Values (Study DREAMM-2) Special populations Impaired renal function No  specific  clinical  studies  were  conducted  to  assess  the  effects  of  intrinsic  factors  on  belantamab mafodotin, total mAb, or cys-mcMMAF pharmacokinetics; the inclusion/exclusion criteria for the clinical studies in subjects with RRMM included in the submission allowed the enrollment of subjects with mild or moderate renal impairment or with mild hepatic impairment (NCI-ODWG classification) (Patel, 2004). The effects of renal impairment on the exposure of belantamab were derived from the population PK model which included 47 patients with normal renal, 103 with mild, 60 with moderate, and 7 with severe renal impairment. Baseline calculated estimated glomerular filtration ratio (eGFR) was not found to be a significant factor based on population pharmacokinetic analysis accounting for interindividual variability in  belantamab mafodotin or cys-mcMMAF pharmacokinetics with baseline eGFR values as low as 14 mL/min/1.73 m 2  (there were eight subjects with data at baseline eGFR values &lt;30 mL/min/1.73 m 2 , seven with severe renal impairment and one with end stage renal disease). Medicinal product no longer authorised

Decrease in GFR from normal to low was seen in 18 % of the patients after dose 2.5 mg/kg and in 15 % of the patients after dose 3.4 mg/kg in study DREAMM-2.

<div style=\"page-break-after: always\"></div>

## Impaired hepatic function

No  specific  clinical  studies  were  conducted  to  assess  the  effects  of  intrinsic  factors  on  belantamab mafodotin, total mAb, or cys-mcMMAF pharmacokinetics; the inclusion/exclusion criteria for the clinical studies in subjects with RRMM included in the submission allowed the enrollment of subjects with mild or moderate renal impairment or with mild hepatic impairment (NCI-ODWG classification) (Patel, 2004).

The effects of hepatic impairment on the exposure of belantamab were derived from the population PK model which included 192 patients with normal hepatic function, and 24 with mild hepatic impairment. Mild hepatic impairment was not found to be a significant factor accounting for interindividual variability in belantamab mafodotin or cys-mcMMAF pharmacokinetics. Gender In population PK analysis, gender was found to be a statistically significant covariate for belantamab mafodotin central volume of distribution, but the impact of gender on predicted exposure parameters was &lt; 15%. Race Race was not found to have effect on pharmacokinetics of belantamab mafodotin in the population PK analyses. Weight Clearance  and  volume  of  distribution  of  belantamab  mafodotin  and  cys-mcMMAF  increased  with increasing body weight. Patients with baseline weight between 42.4 and 130 kg were investigated in the two clinical studies. Population PK model-predicted average exposure in the extreme body weights were compared against the exposure in a typical patient (body weight 75 kg). The predicted percent change from a typical patient for ADC Ctau was -20.1% for a 40 kg patient and -10.2% for a 55 kg patient for the lower extreme weight range and +9.97% for a 100 kg patient and +19.5% for a 130 kg patient for the upper extreme weight range. Elderly The age of the subjects included in the efficacy and safety studies ranged between 34 and 89 years. Age was not found to affect pharmacokinetics. Table 19 Patient age distribution by study Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic interaction studies

No in vitro or in vivo studies on pharmacokinetic drug interactions have been submitted (see discussion on clinical pharmacology).

<!-- image -->

BCMA expression in bone marrow aspirate samples was examined by two immunohistochemical (IHC) assays: a single-color BCMA assay with pathological examination, and a BCMA + CD138 dual-colour IHC assay.  The  dual-colour  assay  was  used  to  identify  myeloma  cells  by  CD138 staining  rather  than  by histology. The single-color BCMA assay showed that patients had moderate BCMA positivity in all bone marrow cells; however, essentially all bone marrow plasma cells examined expressed BCMA. Since there was near uniform expression of BCMA in plasma cells, no relationship was observed with response.

Pharmacokinetics using human biomaterials N/A 2.4.3. Pharmacodynamics Mechanism of action Belantamab mafodotin is a humanized immunoglobulin (Ig)G1 immuno-conjugate that binds specifically to B-cell maturation antigen (BCMA). Upon binding to the cell surface, belantamab mafodotin is rapidly internalized and active cytotoxic drug (cys-mcMMAF) is released inside the cell via proteolysis of the mAb component, resulting in cell killing through disruption of the microtubule network and leading to cell cycle arrest and apoptosis. Additionally, the antibody is afucosylated, which increases binding to FcγRIIIa receptors and enhances recruitment and activation of immune effector cells. Immune effector cells can kill tumour cells by antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis (ADCC and ADCP, respectively). Moreover, ADC-induced apoptosis by belantamab mafodotin was shown to be potentially immunogenic, as measured by cell surface externalization of calreticulin (CRT) and secretion of high mobility group box 1 (HMGB1) and ATP. Immunogenic cell death (ICD) induced by belantamab mafodotin resulted in activation of dendritic cells in vitro and may contribute to a T cell-mediated anti-tumour response. Primary and Secondary pharmacology Primary pharmacology Free soluble BCMA was explored as a potential marker of response. Target engagement by belantamab mafodotin was indirectly observed by assessing the binding of belantamab mafodotin to sBCMA, observed by reductions in the levels of free sBCMA and increases in the levels of bound sBCMA by the end of the infusion, with return to baseline levels by seven days after dosing. Study BMA117159 The populations examined included 73 participants from Total Part 1 and Part 2 with valid biomarker data was available; the Biomarker or Pharmacodynamic (PD) Population. In instances where values obtained were outside the limit of quantification and upper or lower limits of detection are known, results were imputed. Medicinal product no longer authorised

Examination of plasma cell BCMA staining intensity similarly revealed no striking relationship between BCMA expression and response to belantamab mafodotin. Likewise, in the BCMA + CD138 IHC assay,

<div style=\"page-break-after: always\"></div>

myeloma cells (CD138+) had high BCMA expression, with most participants having greater than 80% BCMA positivity in CD138+ cells, with no relationship to response. BCMA Intensity in CD138+ myeloma cells also did not show a relationship with response.

The  BCMA  receptor  was  known  to  be  cleaved  by  gamma-secretase,  leading  to  a  release  of  the extracellular domain of BCMA as sBCMA into the circulation. Since belantamab mafodotin binds sBCMA, the levels of free and belantamab mafodotin-bound sBCMA were measured. Baseline levels of sBCMA were found to be consistent with the MM data observed during the assay validation. The baseline sBCMA levels were compared with response in the dose escalation and expansion cohorts, and no relationships between baseline sBCMA levels and responses were observed. Examinations of the levels of free and belantamab mafodotin-bound sBCMA prior to and after infusion showed that belantamab mafodotin binds to sBCMA after infusion, as the levels of free sBCMA decrease with an apparent dose-dependent relationship, and the levels of bound sBCMA increase. Consistent, high levels of sBCMA (&gt;90%) engagement were seen in all dose groups ≥ 1.92 mg/kg. A rebound in free sBCMA concentrations and a corresponding decrease in drug-bound sBCMA were also noted between the EOI samples and the subsequent pre-infusion time points. Most patients with data beyond the second treatment cycle showed relatively consistent levels of free and drug-bound sBCMA concentrations, with drug-bound sBCMA concentrations consistently greater than their corresponding free sBCMA levels. Secondary pharmacology A concentration-QT interval analysis was conducted on data from two studies in 291 subjects with RRMM (Study BMA117159 and Study DREAMM-2) to assess the potential effect of belantamab mafodotin on cardiac repolarization and to evaluate any relationship between concentrations of belantamab mafodotin, total mAb, or cys-mcMMAF and QT interval. In total, the analysis dataset contained time-matched ECG and concentration data from 290 subjects, the majority (N=217) from Study DREAMM-2. Within Study DREAMM-2, 11% of subjects (16% of observations from this study) received a lyophilized configuration of belantamab mafodotin. All other Study DREAMM-2 subjects and all BMA117159 subjects received a frozen liquid solution configuration. Using the estimated slopes and intercepts (where applicable) from the linear regression analyses, the concentrations of belantamab mafodotin, total mAb, and cys-mcMMAF required to result in a 10 msec prolongation in QTc and QTcF were derived. For all three analytes, the derived concentrations required to cause a 10 msec prolongation in QTc were higher than those observed for either starting dose level in Study DREAMM-2. For both QTc and QTcF, for three analytes, both dose levels and both regression types, the upper 90% CI did not exceed 10 msec. There were no ΔQTc greater than 10 msec corresponding to assumed Cmax of belantamab mafodotin, total mAb, and cys-mcMMAF, based on regression with and without intercept. Consequently, there was a zero probability of the dose levels of belantamab mafodotin studied in Study DREAMM-2 (2.5 and 3.4 mg/kg) prolonging ΔQTc by more than 10 msec. There were no ΔQTcF greater than 10 msec corresponding to assumed Cmax of belantamab mafodotin and cysmcMMAF, based on regression with and without intercept. For maximal concentrations of total mAb, there was less than a 0.25% chance of prolonging ΔQTcF by more than 10 msec from the dose levels of belantamab mafodotin studied in Study DREAMM-2. Medicinal product no longer authorised

## Exposure-response analyses

The population PK models were used to generate individual post hoc exposure measures for ADC and cys-mcMMAF.  The  exposure  estimates  were  simulated  for  the  first  dose  using  the  actual  dose administered to each subject with their specific demographic and individual eta estimates.

<div style=\"page-break-after: always\"></div>

The ER analyses were focused on study DREAMM-2, in which doses 2.5 mg/kg and 3.4 mg/kg every three weeks (Q3W) were used. The figure below presents the best response category achieved for the 194 subjects who received the frozen liquid presentation by quartile of belantamab mafodotin trough concentration (Ctau).

<!-- image -->

<!-- image -->

In the ER analyses for safety, higher exposure to belantamab mafodotin and lower baseline sBCMA level were identified as predictors of any keratopathy event and grade 2+ keratopathy event in multivariate logistic  regression  analysis  for  study  DREAMM-2.  Belantamab  mafodotin  and  cys-mcMMAF  exposure measures were not found to predict blurred vision or dry eye events. In univariate logistic regression analysis for grade 3+ thrombocytopenia baseline platelet count was overall the strongest predictor and natural  log  of  cys-mcMMAF  Cmax  was  the  strongest  exposure  measure  predictor.  Both  entered  the multivariate model for probability of grade 3+ thrombocytopenia ( Table 21 ).

Figure 3 Best Response by Cycle 1 belantamab mafodotin Ctau (Study DREAMM-2, Frozen Liquid formulation) sCR = stringent complete response, CR = complete response, VGPR = very good partial response, PR = partial response, MR = minimal response, SD = stable disease, PD = progressive disease, NA =not applicable. In univariate logistic regression analyses the probability of clinical response seemed to increase with increasing belantamab mafodotin exposure and no clear relationship between plasma concentration of cys-mcMMAF and probability of response was observed. However, the strongest univariate predictor of response was baseline soluble BCMA (sBCMA) level. In multivariate analysis, only baseline sBCMA was found to predict probability of response ( Table 20 ). Table 20 Probability of Response Logistic Regression Analysis Final Model (Study DREAMM-2 - Frozen Liquid Presentation) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 21 Probability of Grade 3+ Thrombocytopenia Event - Regression Analysis Multivariate Results (Study DREAMM-2 - Frozen Liquid Presentation)

<!-- image -->

| Covariate      |   Beta (β) |   SE | 95% CI        | dOFV   | Delta   | Odds Ratio (95%  CI   |
|----------------|------------|------|---------------|--------|---------|-----------------------|
| Intercept (βo) |      -8.87 | 3.41 | (-15.9,-2.43) | NA     |         |                       |

<!-- image -->

Pharmacokinetic data for belantamab mafodotin are available from two clinical studies. Most subjects were treated with a frozen liquid formulation; only 24 subjects in study DREAMM-2 were treated with a lyophilized presentation at dose 3.4 mg/kg. The lyophilized presentation is intended for the market. Approximately 1 to 10% differences in average exposure (AUC and Cmax) were observed between the two formulations in noncompartmental analysis; between-subject variability was moderate to high.

The primary concentration-QTc analysis had time-matched electrocardiogram (ECG,12-lead, in triplicate) and concentration data in 217 subjects from study DREAMM-2. Figure 4 presents the linear regression analysis of cysmcMMAF concentration vs ΔQT (using correction factor 0.410 estimated using predose QT and RR values) and ΔQTcF (using the Fr edericia correction factor 0.33) for Study DREAMM-2 with both the slope and intercept parameters estimated. Fixing the intercept at 0 did not markedly change the estimated slope. Results were similar when belantamab mafodotin and total mAb concentrations were used as the exposure measure. Figure  4 Linear  Regression  of  cysmcMMAF  concentration  vs  ΔQT  and  ΔQTcF  for  Study DREAMM-2 2.4.4. Discussion on clinical pharmacology Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Population PK analysis was used to characterize the PK of the ADC, total mAb and cys-mcMMAF and identify covariates affecting the PK. Biomarkers associated with severe RRMM (high sBCMA and IgG and low albumin levels at baseline) predicted higher clearance of the ADC, which makes exposureresponse analyses for efficacy more challenging. The PK model for ADC might be over-parameterised and empirical study effect covariates were implemented in the models. A substantial proportion of observed cys-mcMMAF concentrations were below the lower limit of quantitation (BLQ); an updated model incorporating the BLQ data using the so-called M3 method was requested during the assessment which was considered adequate.

No formal studies have been conducted in patients with hepatic impairment.  Mild hepatic impairment (bilirubin greater than ULN to less than or equal to 1.5 × ULN or aspartate transaminase [AST] greater than ULN), was not associated with exposure to belantamab mafodotin in the population PK analysis, but increased exposure to cys-mcMMAF was observed. Although data are limited, it is acknowledged that observed safety profiles for patients with hepatic impairment were similar when compared with patients with normal hepatic function. Dose adjustment is not proposed in patients with mild hepatic

Data following subtherapeutic and supratherapeutic doses is not robust enough to draw conclusion on dose proportionality over the entire investigated dose range (0.03 mg/kg to 4.6 mg/kg). However, it can be concluded that belantamab mafodotin exhibits dose-proportional pharmacokinetics over the recommended dose range with a reduction in clearance over time (SmPC section 5.2). The estimated clearance and volume parameter values for belantamab mafodotin are in the expected range for an antibody-drug compound. Elimination rate of belantamab mafodotin decreases following repeated dosing, but dose adjustment due to this pharmacokinetic characteristic is not needed. There are sufficient safety data with proposed Q3W dosing. The observed duration of exposure to cysmcMMAF following IV administration of belantamab mafodotin in clinical studies was long compared with exposure following IV administration of cys-mcMMAF in cynomolgus monkeys. Assuming that the PK in monkey can be extrapolated to human, rate of release of cys-mcMMAF into circulation appears to be slower than rate of elimination. The protein moiety of the ADC, belantamab, is degraded to small peptides. Further characterisation on elimination of belantamab is not required. It is acknowledged that a mass balance study with radiolabelled cys-mcMMAF in rats was conducted demonstrating that approximately 83 % of the radioactive dose was excreted in faeces and 13 % in urine after an IV dose of 3H-cys-mcMMAF. In human only intact cys-mcMMAF was detected in pooled urine samples. The metabolism, elimination and excretion pathways of cys-mcMMAF in man remain partly unknown .  In vitro studies indicated maleimide exchange of mcMMAF into human serum albumin. Hypoalbuminemia is however unlikely to have clinical impact through maleimide exchange in patients with multiple myeloma. No formal studies have been conducted in patients with renal impairment. Renal function was not a significant covariate in population pharmacokinetic analyses that included patients with normal renal function and mild or moderate renal impairment (SmPC, section 5.2). No dose adjustment is required in patients with mild or moderate renal impairment (eGFR ≥ 30 mL/min). There are insufficient data in patients with severe renal impairment to support a dose recommendation (SmPC, section 4.2). No studies have been performed in patients with renal insufficiency, but a phase 1 open label study (209626) of belantamab mafodotin in relapsed/refractory MM patients with renal impairment has been planned to address this issue (see RMP). No formal studies have been conducted in elderly patients. Age was not a significant covariate in population pharmacokinetic analyses (SmPC, section 5.2). No dose adjustment is required for elderly patients (SmPC, section 4.2). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

impairment. A phase 1 open label study (209627) in patients with relapsed/refractory MM and hepatic impairment is planned to investigate the effect of moderate or severe hepatic impairment on the pharmacokinetics and safety and tolerability of belantamab mafodotin (see RMP).

Hepatic function was not a significant covariate in population pharmacokinetic analyses that included patients with normal hepatic function or mild hepatic impairment (SmPC section 5.2). No dosage adjustment is required in patients with mild hepatic impairment. There are insufficient data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment to support a dosage recommendation (SmPC section 4.2). The proposed dose 2.5 mg/kg is based on body weight. Body weight was a significant covariate in population pharmacokinetic analyses. Belantamab mafodotin Ctau was predicted to be +10% at a body weight of 100 kg (+20% for 130 kg) and -10% at a body weight of 55 kg (-20% for 40 kg) compared to the typical patient (75 kg) (SmPC section 5.2). BLENREP has not been studied in patients with body weight &lt; 40 kg or &gt; 130 kg (SmPC, section 4.2). The CHMP recommended the applicant to explore alternative dosing strategies for patients with body weight &gt; 130 kg to achieve similar exposure as in patients with body weight within 40-130 kg. Dose adjustment based on age, gender or race is not required. Based on the in vitro studies, in was concluded that interactions between belantamab mafodotin and other drugs are unlikely, so specific interactions studies were not performed. Combined non-clinical and clinical data indicated that release of cys-mcMMAF from the antibody-drug compound is probably the rate-limiting step that determines its concentration in plasma and inhibition of these transporters is not expected to clinically significantly increase the systemic exposure to cys-mcMMAF. Based on available in vitro and clinical data, there is a low risk of pharmacokinetic or pharmacodynamic drug interactions for belantamab mafodotin (SmPC section 4.4). The exposure parameter values used in the exposure-response analyses were the predicted exposure following the first dose (cycle 1), whereas the response parameters were efficacy and safety observed over multiple treatment cycles. It was not taken into account that a large proportion of patients had dose reduction and/or dose delay. For example, in study DREAMM-2, 29% and 42% of participants had at least 1 dose reduction, and 39% and 48% of participants had 1 or more dose delays among subjects randomized to 2.5 mg/kg and 3.4 mg/kg dose groups, respectively. Results of the ER analyses should therefore be interpreted very cautiously. The effects of baseline characteristics associated with disease severity (sBCMA, IgG, and albumin levels) on the pharmacokinetics of belantamab mafodotin and its time-varying kinetics (reduced clearance over time) also hinder making definite conclusions on relationships between exposure and efficacy. Overall, results of the ER analyses for efficacy did not indicate markedly better clinical response for doses higher than the one proposed. Lack of association between cys-mcMMAF exposure metrics and efficacy endpoints was presumed to be partly due to poor membrane permeability of free cys-mcMMAF. Medicinal product no longer authorised

Higher exposure to belantamab mafodotin was associated with all grade keratopathy and grade 2+ keratopathy events. Exposure to belantamab mafodotin or cys-mcMMAF did not seem to predict blurred vision or dry eye events. Higher exposure to cys-mcMMAF predicted grade 3+ thrombocytopenia events. Baseline platelet count was the most significant predictor of thrombocytopenia, however. No exposure parameters predicted grade 3+ neutropenia or infusionrelated reactions. Dose adjustment based on corneal adverse reactions and thrombocytopenia are included in section 4.2 of the SmPC.

Results of the concentration-QTc analysis do not indicate significant potential for prolongation of QTc interval. The analysis had data from patients treated with 3.4 mg/kg dose ( i.e. , 36% higher than the

<div style=\"page-break-after: always\"></div>

proposed dose). It is also acknowledged that in vitro , cys-mcMMAF had no detectable effect on hERG channels. Based on the available data, further investigation on the potential of belantamab mafodotin to prolong the QTc interval is not required.

<!-- image -->

<!-- image -->

BMA117159 Part 1 explored the administration of belantamab mafodotin to humans with RRMM at doses ranging from 0.03 to 4.6 mg/kg. Ocular events and thrombocytopenic events were the most frequent toxicities in Part 1 and these events were the most common reasons for dose modifications. Due to emerging corneal events in the expansion cohort at 3.40 mg/kg, an intermediate dose of 2.50 mg/kg was subsequently added to Part 1.

2.4.5. Conclusions on clinical pharmacology The PK and PD of belantamab mafodotin have been reasonably well investigated. 2.5. Clinical efficacy 2.5.1. Dose response study Study BMA117159 (DREAMM-1) This was an open-label, dose-escalation trial consisted of the following 2 parts: Part 1 dose escalation phase and Part 2 expansion phase for safety confirmation, and clinical activity testing. Subjects were scheduled to be administered belantamab mafodotin via 60 min IV infusion on either once every 3 weeks (21-day cycle) or once weekly schedule. Table 22 Design of Study belantamab mafodotin Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

No protocol-defined dose-limiting toxicities were observed in Part 1, even at the highest dose tested (4.60 mg/kg), and thus no MTD was established. However, 2 subjects in the 4.6 mg/kg cohort discontinued treatment due to AEs, indicating poor tolerability of this dose.

A dose of 3.40 mg/kg every 3 weeks was identified as the RP2D based on the totality of safety and tolerability data. While the next tested dose of 4.6mg/kg did not result in adverse events fulfilling dose limiting toxicity (DLT) definition, it was felt to be poorly tolerated. In addition, the estimated receptor saturation was at 90% for doses ≥ 1.92 mg/kg in Part 1. Moreover, clinical activity became apparent at 3.4 mg/kg dose where all 3/3 patients enrolled at this dose level achieved a response. Weekly dosing based on 28 days cycle was not pursued in this study. In summary there was 1 response out of 8 in the 2.5 mg/kg group and 3/3 responses in the 3.4 mg/kg group. No responses were observed across the lowest doses from 0.03 to 0.48 mg/kg. The main results of BMA117159 Part 2 (N=35) are as follows: · The ORR based on confirmed investigator-assessed response was 60% (95% CI:42.1, 76.1), including 54% Very Good Partial Response (VGPR) or better; · The median time-to-response was rapid at 1.2 months (95% CI: 0.7, 1.4); · The median duration of response was 14.3 months (95% CI: 10.6, NE); · Median PFS was 12.0 months (95% CI: 3.1, NE). Responses were observed in all analysed subgroups. The DLT was investigated in the Part 1 of the study. No dose-limiting toxicities were observed at any dose level, including the maximum administered dose (4.6 mg/kg). Thus, the maximum tolerated (MTD) was not established. However, different AEs leading to dose reduction started to occur at doses ≥ 0.96 mg/kg. There were several AEs related to ocular events, which are uncommon with other current MM treatments options (proteasome inhibitors, immunomodulating agents), leading to dose reductions, dose delays and even permanent discontinuation of study treatment without clear link to the dose (one limbal stem cell deficiency at 1.92 mg/kg dose, one grade 2 keratopathy at 2.5 mg/kg dose). While there seem to be trend with increasing haematological AEs with increasing dose, the trend with ocular events with increasing doses (1.92 to 4.6 mg/kg) is not so clear. In the part 2 of the study 35 subjects with RRMM received at least one 3.4 mg/kg dose. 43% (15/35) were previously treated with mAb, specifically, 14 subjects had daratumumab. The median dose intensity reached was 2.89 mg/kg/cycle. Majority of patients experienced dose reductions and dose delays. Similarly, to part 1, many AEs leading to dose intensity less than targeted 3.4 mg/kg/cycle were related to ocular events. The ORR for part 2 was 60% with 54% of patients achieving VGPR or better. 2.5.2. Main study Study 205678 (DREAMM-2) Medicinal product no longer authorised

## Methods

This was a Phase II, open label, randomized, two-arm study to investigate the efficacy and safety of two doses of the belantamab mafodotin in participants with MM who had 3 or more prior lines of

<div style=\"page-break-after: always\"></div>

treatment, are refractory to a proteasome inhibitor and an immunomodulatory agent and have failed an anti-CD38 antibody.

The study included an additional independent cohort of approximately 25 additional participants who received a lyophilized presentation of belantamab mafodotin at 3.4 mg/kg. An ocular sub-study was also included to evaluate the effectiveness of steroid eye drops in up to 30 participants.

7. All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.03, must be ≤ Grade 1 at the time of enrolment except for alopecia and Grade 2 peripheral neuropathy.

Study Participants The key inclusion criteria were the following: 1. Male or female, 18 years or older (at the time consent was obtained) 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 3. Histologically or cytologically confirmed diagnosis of MM as defined according to International Myeloma Working Group (IMWG), (Rajkumar, 2015) criteria, AND a) Had undergone stem cell transplant or was considered transplant ineligible, AND b) Had failed at least 3 prior lines of anti-myeloma treatments, including an anti-CD38 antibody (e.g., daratumumab)  alone  or  in  combination,  and  was  refractory  to  an  immunomodulatory  agent  (i.e., lenalidomide  or  pomalidomide),  and  to  a  proteasome  inhibitor  (e.g.,  bortezomib,  ixazomib  or carfilzomib).  The  number  of  prior  lines  of  therapy  was  determined  according  to  the  guidelines  in Rajkumar, 2014. Refractory myeloma is defined as disease that is nonresponsive while on primary or salvage therapy or progresses within 60 days of last therapy. Nonresponsive disease was defined as either failure to achieve at least minimal response or development of disease progression (PD) while on therapy (Rajkumar, 2011b) 4. Has measurable disease with at least one of the following: · Serum Mprotein ≥0.5 g/dL (≥5 g/L), · Urine Mprotein ≥200 mg/24h, · Serum Free Light Chain (FLC) assay: Involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum free light chain ratio (&lt;0.26 or &gt;1.65). 5.  Participants  with  a  history  of  autologous  stem  cell  transplant  are  eligible  for  study  participation provided the following eligibility criteria are met: · transplant was &gt;100 days prior to study enrolment, · no active infection(s), · participant meets the remainder of the eligibility criteria outlined in this protocol. 6. Adequate organ system functions. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

The key exclusion criteria were the following:

1. Systemic anti-myeloma therapy within &lt;14 days, or plasmapheresis within 7 days prior to the first dose of study drug.

2. Symptomatic  amyloidosis,  active  polyneuropathy,  organomegaly,  endocrinopathy,  myeloma protein,  and  skin  changes  (POEMS)  syndrome,  active  plasma  cell  leukemia  at  the  time  of screening. 3. Prior allogeneic stem cell transplant. 4. Current corneal epithelial disease except mild punctate keratopathy. 5. Use of an investigational drug within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a mAb within 30 days of receiving the first dose of study drugs. Prior BCMA targeted therapy. 6. Evidence of active mucosal or internal bleeding. 7. Any major surgery within the last four weeks. 8. Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). 9. Any  serious  and/or  unstable  pre-existing  medical,  psychiatric  disorder  or  other  conditions (including lab abnormalities) that could interfere with participant ' s safety, obtaining informed consent or compliance to the study procedures. 10. Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites,  encephalopathy,  coagulopathy,  hypoalbuminemia,  esophageal  or  gastric  varices, persistent  jaundice,  or  cirrhosis.  Note:  Stable  chronic  liver  disease  (including  Gilbert ' s syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria. 11. Malignancies other than disease under study are excluded, except for any other malignancy from which the participant has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy. 12. Evidence of cardiovascular risk including any of the following: a. QTcF interval ≥ 470 msecs (the QT interval values must be corrected for heart rate by Fredericia's formula [QTcF]), b. Evidence  of  current  clinically  significant  uncontrolled  arrhythmias,  including  clinically significant ECG abnormalities such as 2nd degree (Type II) or 3rd degree atrioventricular (AV) block, c. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening, d. Class III or IV heart failure as defined by the New York Heart Association functional classification system [NYHA, 1994], Medicinal product no longer authorised

- e. Uncontrolled hypertension.
13. Known  immediate  or  delayed  hypersensitivity  reaction  or  idiosyncrasy  to  drugs  chemically related to GSK2857916, or any of the components of the study treatment.

<div style=\"page-break-after: always\"></div>

14. Pregnant or lactating female.
15. Active infection requiring antibiotic, antiviral, or antifungal treatment.
16. Known HIV infection.

17. Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb at screening or within 3 months prior to first dose of study treatment. 18. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment. Treatments Belantamab mafodotin was administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an IV infusion on day 1 of each cycle; each cycle was 21 days. The lyophilized cohort (3.4 mg/kg) was initiated when enrolment had completed in the 2 arms receiving frozen solution and the lyophilized presentation became available. Patients were treated until disease progression, until unacceptable toxicity, or until confirmed CR. Objectives Primary Objective · To evaluate the clinical efficacy of two doses of belantamab mafodotin in participants with RRMM. Secondary Objectives Key Secondary: · To further evaluate the clinical measures of efficacy of belantamab mafodotin in participants with RRMM. · To evaluate the safety of belantamab mafodotin in participants with RRMM. · To evaluate the pharmacokinetic profile of belantamab mafodotin. Other Secondary: · To assess ADAs against belantamab mafodotin. · Participant self-reported symptomatic adverse effects by evaluation of tolerability of belantamab mafodotin. · To evaluate disease and treatment related symptoms and impact on function and health-related quality-of-life. · To assess the safety, efficacy, immunogenicity, and pharmacokinetics of belantamab mafodotin in a lyophilized presentation (n=25). Ocular sub-study: Medicinal product no longer authorised

- To evaluate the effect of topical corticosteroids on corneal findings in up to 30 participants who will receive monocular topical corticosteroids for the first 4 cycles.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

## Primary Efficacy Endpoint

<!-- image -->

The primary efficacy endpoint of the study was overall response rate (ORR), defined as sCR+CR+VGPR+PR, according to 2016 International Myeloma Working Group (IMWG) Response Criteria (Table 29) and as assessed by Independent Review Committee (IRC) based on intention to treat (ITT) population. Key Secondary Efficacy Endpoints Duration of Response (DoR) was defined as the time from first documented evidence of PR or better until the earliest date of disease progression (PD) per IMWG, or death due to PD among participants who achieve a response (i.e., confirmed PR or better). Responders without disease progression will be censored at the censoring time point for time to progression (TTP). Time to response (TTR) was defined as the time between the date of first dose and the first documented evidence of response (PR or better), among subjects who achieve a response (i.e., confirmed PR or better). Progression free survival (PFS) was defined as the time from first dose until the earliest date of PD per IMWG, or death due to any cause. Overall Survival (OS) was defined as the time from first dose until death due to any cause. Other Secondary Efficacy Endpoints Exploratory minimal residual disease (MRD) negative rate is defined as the proportion of subjects who are negative for MRD at any time point after first dose as determined by the protocol defined testing procedure. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 23 International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma (2016)

<!-- image -->

| longer authorised   |
|---------------------|
| no                  |
| product             |

<div style=\"page-break-after: always\"></div>

## Sample size

<!-- image -->

The following assumptions were made in the estimation of the required sample size: Normal approximation of binomial proportion; a response rate of ≥ 33% in the BCMA arm and ≤ 15% for the historical control; a 1.25%, 1-sided risk of erroneously claiming superiority of the BCMA arm, in the presence of no true underlying improvement; a ~90% chance of rejecting the null hypothesis when the alternative hypothesis is true. An interim analysis was conducted after approximately 38% of information was available (i.e., approximately after 25 participants out of the originally planned 65 participants per arm were evaluable for interim analysis), with a futility rule based on a gamma spending function. The operating characteristics were refined using simulation to account for both within arm futility rule and the comparative futility rule. Based on the simulation results with the planned sample size of 65 participants, there was 86.90% power to reject the null hypothesis within each arm with a 1-sided type I error of 1.23%. Due to over-enrolment (addressed in Protocol amendment 3), it was estimated that approximately 200 participants (approximately 100 per arm) would be randomized to the frozen liquid solution. At the primary analysis, the null hypothesis would be rejected if the lower bound of 2-sided 97.5% exact CI exceeded the historical control rate of 15%. With no change to the planned IA (i.e., approximately after 25 participants/arm were evaluable for IA, and same futility boundary), simulation results showed that there was 92.38% power to reject the null hypothesis within each arm with a 1-sided type I error of 0.97% for 100 participants per arm. Randomisation Eligible participants in the main study (frozen liquid) were assigned in a 1:1 ratio to receive treatment with either 3.4 mg/kg IV Q3W or 2.5 mg/kg IV Q3W belantamab mafodotin in accordance with the randomization schedule. The following information for stratification was entered into the system to obtain the treatment assignment: · Number of prior lines of therapy ( ≤ 4 vs &gt;4) · Cytogenetic risk categories (high risk defined as t(4;14), t(14;16), and 17p13del vs non-high risk all others); The lyophilized cohort (3.4 mg/kg) was initiated when enrolment had completed in the 2 arms receiving frozen solution and the lyophilized presentation became available. Blinding (masking) This was an open-label study. Medicinal product no longer authorised

## Statistical methods

Interim analyses were introduced with the first protocol amendment. For each arm (2.5 mg/kg or 3.4 mg/kg), a single futility interim analysis was planned for the primary endpoint ORR after

<div style=\"page-break-after: always\"></div>

approximately 25 participants out of originally planned 65 participants per arm were evaluable. A userdefined gamma spending function (γ=4.2) was planned to be used as a beta-spending function to determine the nonbinding futility boundary. With this β -spending function, the stopping boundary in IA was identified as 0.16 on the proportion scale (4 responders out of 25 participants), which is close to the historical control of 0.15. The spending function and associated boundary were chosen to ensure good operating characteristics, specifically, the type 1 error and power.

<!-- image -->

Trial was designed to provide evidence with respect to ORR to either support the null hypothesis, H0: ORR ≤15%, or reject H0 in favour of the alternative hypothesis, H1: ORR &gt;15%. The hypothesis testing was performed within each dose separately. No hypothesis testing for comparing ORR between the two doses was performed. To control the overall type I error at 5%, alpha was split between two dose cohorts and a dose cohort would be considered statistically superior to the historical control of 15% if the lower bound of 97.5% confidence interval (CI) for ORR is greater than 15%. The historical control comparator of 15% was selected based on the previously reported response rates of 10% to 18% in patients at 4th relapse [i.e., having relapsed after 3 prior lines of therapy]. The following key analysis population were defined: · The enrolled population included all participants who passed screening and entered the study. · The ITT population included all participants who were randomly assigned to frozen liquid treatment, whether or not treatment was administered. · The lyophilized population (Lyo) included all randomized participants who received at least 1 dose of lyophilized study treatment. · The full analysis population included all randomized participants included in either the ITT or Lyo population. · The efficacy population consisted of the first 130 ITT participants. · The evaluable population included all participants who had at least 2 doses of frozen liquid study treatment and completed at least 1 disease assessment after the second dose, progressed, died, or discontinued treatment due to other reasons. · The safety population included all randomized participants who received at least 1 dose of frozen liquid study treatment and the full safety population included all participants who received at least 1 dose of study treatment (frozen liquid or lyophilized). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

## Conduct of the study

Figure 5 Study Participant flow (Study DREAMM-2) Recruitment Patients with RRMM were recruited from 58 centres in 8 countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom and the United States). Study initiation date: first subject was screened on 18 June 2018 and last 2 January 2019. Medicinal product no longer authorised

Summary of main protocol amendments

There were 3 amendments to the study protocol. The main changes are described below:

<div style=\"page-break-after: always\"></div>

- Amendment 1 (2 April 2018):

The protocol was amended to address regulatory agency advice. The original single-arm design with 1 dose level (3.4 mg/kg GSK2857916 Q3W) was amended to an open-label, randomized, 2-arm study with 2  dose  levels  by  including  the  2.5  mg/kg  Q3W  dose.  In  addition,  a  new  exploratory  cohort  of  25 participants, who will receive a lyophilized configuration of GSK2857916, has been added to gain clinical experience with the lyophilized configuration. To accommodate these main changes, the overall sample size and related analytical methods have been changed.

· Amendment 2 (4 September 2018): The protocol was amended to address feedback from regulatory agencies, EC/IRB, and investigators. The updates include the addition of exclusion criteria defining the use of high dose steroids, clarification of specific timeframe from last treatment required for systemic anti-myeloma therapy and increase of QTcF criteria. Additional PK sampling timepoints were added to capture the Cmax of the free cytotoxic drug (cys-mcMMAF) and to better define the kinetics of cys-mcMMAF and the elimination phase of ADC and  cys-mcMMAF.  Soluble  BCMA  collection  timepoints  were  also  added  to  capture  the  effect  of GSK2857916 administration on soluble BCMA concentrations over time as a marker of pharmacodynamic effect.  The  dose  modifications  guidelines  for  GSK2857916  related  Corneal  Events  clarify  dose adjustments for GSK Scale Grade 2 events. · Amendment 3 (17 December 2018): The protocol was to address over-enrollment in the frozen liquid solution portion of the study. Due to the over-enrollment, the primary analysis was to be based on all randomized participants (anticipated ~200) enrolled into the frozen liquid solution arms. In addition, a sensitivity analysis based on the first 130 participants was performed to account for the original design. Protocol Deviations There  were  inclusion  or  exclusion  criteria  deviations  for  6%  and  5%  of  participants  who  were inadvertently enrolled in the study. · 5  participants  were  HBcAb-positive  and  were  recommended  to  have  prophylactic  antiviral therapy after stopping study treatment and to be followed for HBV increases or reactivation. · 2 participants had organ system deviations: 1 participant had a spot urine of &lt;500 mg/g at screening but was &gt;500 mg/g at Cycle 1 Day, and the other participant did not have spot urine or absolute neutrophil count assessments performed at Screening. An absolute neutrophil count was done at Cycle 1 Day 1 prior to dosing. · 1 participant had measurable disease based on local laboratory, but this result was not confirmed by the central laboratory results. · 1 participant was enrolled with moderate punctate keratopathy. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Baseline data

## Table 24 Demographic Characteristics (ITT Population, Study DREAMM-2)

|    |        | authorised   |
|----|--------|--------------|
|    | longer |              |
| no |        |              |

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 25 Baseline Disease Characteristics (ITT Population Study DREAMM-2)

<!-- image -->

Prior anti-cancer medications are presented in Table 26 . Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 26 Prior Anti-Cancer Medications by Drug Class of Agents (ITT Population, Study DREAMM-2) (cut-off date of 20 September 2019)

| Drug Class                                                           | Number (%) of Participants Belantamab Mafodotin Q3W       | Number (%) of Participants Belantamab Mafodotin Q3W              |
|----------------------------------------------------------------------|-----------------------------------------------------------|------------------------------------------------------------------|
|                                                                      | 9-Month FU (20Sep19) 2.5 mg/kg                            | 3.4 mg/kg                                                        |
| Steroids                                                             | (N=97)                                                    | (N=99)                                                           |
| Immunomodulator Lenalidomide                                         | 97 (100) 97 (100)                                         | 99 (100) 99 (100) 99 (100) 84 (85)                               |
| Pomalidomide Thalidomide Proteasome Inhibitor Bortezomib Carfilzomib | 97 (100) 89 (92) 29 (30) 97 (100) 95 (98) 74 (76) 22 (23) | 39 (39) 99 (100) 97 (98) 64 (65) 23 (23) authorised              |
| Chemotherapy                                                         | 92 (95) no                                                | 99 (100) 96 (97) 13 (13) 5 (5) 2 (2) 1 (1) 1 (1) 0 1 (1) 95 (96) |
| Stem cell transplant                                                 | 73 (75)                                                   | 9 (9)                                                            |
|                                                                      | 11 (11)                                                   |                                                                  |
| Ixazomib Monoclonal Antibody Daratumumab                             | 97 (100) 15 (15)                                          |                                                                  |
| Elotuzumab                                                           | 97 (100)                                                  |                                                                  |
|                                                                      | longer                                                    |                                                                  |
| Durvalumab                                                           | 4 (4)                                                     |                                                                  |
| Isatuximab                                                           | 3 (3)                                                     |                                                                  |
| Pembrolizumab Investigational                                        | 2 (2) 1 (1)                                               |                                                                  |
| antineoplastic Blinatumomab                                          | 1 (1)                                                     |                                                                  |
| MOR03087                                                             | 0                                                         |                                                                  |
|                                                                      |                                                           | 86 (87)                                                          |
| HDAC inhibitor                                                       |                                                           |                                                                  |
| Other                                                                | 32 (33)                                                   |                                                                  |
|                                                                      |                                                           | 31                                                               |
|                                                                      |                                                           | (31)                                                             |

<!-- image -->

Note: Multiple categories per participant was possible, therefore the total may add up to more than 100%. The refractoriness status of the patients to prior anti-cancer therapies are presented in Table 27 . Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 27 Participants Refractory to Prior Anti-Cancer Therapy (ITT Population, Study DREAMM-2) (cut-off date of 20 September 2019)

| Drug Class                                                                                                                                                                                      | Number (%) of Participants Belantamab Mafodotin Q3W 9-Month FU (20Sep19)               | Number (%) of Participants Belantamab Mafodotin Q3W 9-Month FU (20Sep19)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------|
|                                                                                                                                                                                                 | 2.5 mg/kg (N=97)                                                                       | 3.4 mg/kg (N=99)                                                           |
| Immunomodulator Lenalidomide Pomalidomide Thalidomide                                                                                                                                           | 97 (100) 87 (90) 86 (89) 13 (13) 97 (100)                                              | 99 (100) 90 (91) 79 (80) 18 (18) 99 (100) authorised                       |
| Proteasome Inhibitor Bortezomib Carfilzomib Ixazomib Monoclonal Antibody Daratumumab Elotuzumab Durvalumab Isatuximab Pembrolizumab Investigational antineoplastic agents Blinatumomab MOR03087 | 76 (78) 63 (65) 21 (22) 97 (100) 97 (100) 13 (13) 4 (4) 3 (3) 2 (2) 1 (1) 1 (1) longer | 74 (75) 57 (58) 21 (21) 99 (100) 95 (96)                                   |
| Steroids Chemotherapy                                                                                                                                                                           | 0                                                                                      | 10 (10) 4 (4) 2 (2) 1 (1) 1 (1) 0 1 (1)                                    |
|                                                                                                                                                                                                 | 95 (98) 66 (68)                                                                        | 92 (93)                                                                    |
|                                                                                                                                                                                                 | no                                                                                     |                                                                            |
|                                                                                                                                                                                                 |                                                                                        | 70 (71)                                                                    |
| Stem cell transplant                                                                                                                                                                            | 11 (11)                                                                                | 25 (25)                                                                    |
|                                                                                                                                                                                                 | 27 (28)                                                                                |                                                                            |
| Other                                                                                                                                                                                           |                                                                                        | 13 (13)                                                                    |
|                                                                                                                                                                                                 | 11                                                                                     | (8)                                                                        |
| HDAC                                                                                                                                                                                            | (11)                                                                                   |                                                                            |
| inhibitor                                                                                                                                                                                       |                                                                                        | 8                                                                          |

<!-- image -->

Note: Multiple categories per participant was possible, therefore the total may add up to more than 100%. Numbers analysed Table 28 Analysis Populations (Study DREAMM-2) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

- Primary endpoint - Overall Response Rate (ORR)

## Table 29 Best confirmed response based on independent review committee and investigator assessments (ITT Population, Study DREAMM-2) (cut-off date 21 June 2019)

|                                                                          | Belantamab Mafodotin Q3W   | Belantamab Mafodotin Q3W    | Belantamab Mafodotin Q3W    | Belantamab Mafodotin Q3W    |
|--------------------------------------------------------------------------|----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                                                          | 2.5 mg/kg (N=97)           | 2.5 mg/kg (N=97)            | 3.4 mg/kg (N=99) authorised | 3.4 mg/kg (N=99) authorised |
|                                                                          | IRC                        | INV                         | IRC                         | INV                         |
| Best Response, n (%)                                                     |                            |                             |                             |                             |
| Stringent complete response (sCR)                                        | 2 (2)                      | 2 (2)                       | 3 (3)                       | 1 (1) 2 (2)                 |
| Complete response (CR)                                                   | 1 (1)                      | 6 (6)                       | 0                           |                             |
| Very good partial response (VGPR)                                        | 15 (15)                    | 12 (12)                     | 17 (17)                     | 18 (18)                     |
| Partial response (PR)                                                    | 12 (12)                    | 9 (9)                       | 14 (14)                     | 10 (10)                     |
| Minimal response (MR)                                                    | 3 (3)                      | 4 (4)                       | 5 (5)                       | 6 (6)                       |
| Stable disease (SD)                                                      | 30 (31)                    | 30 (31)                     | 23 (23)                     | 25 (25)                     |
| Progressive disease (PD)                                                 | 27 (28)                    | 28 (29)                     | 26 (26)                     | 27 (27)                     |
| Not evaluable (NE) a                                                     | 7 (7)                      | 6 (6)                       | 11 (11)                     | 10 (10)                     |
| Overall Response Rate, n (%) sCR+CR+VGPR+PR 97.5% confidence interval    | 30 (31) (20.8, 42.6)       | 29 (30) (19.9, 41.5) longer | 34 (34) (23.9, 46.0)        | 31 (31) (21.2,42.8)         |
| Clinical Benefit Rate, n (%) sCR+CR+VGPR+PR+MR 97.5% confidence interval | 33 (34) (23.5, 45.8)       | 33 (34) (23.5, 45.8)        | 39 (39) (28.5, 51.1)        | 37 (37) (26.6,49.1)         |

|                                                                     | 2.5 mg/kg (N = 97)      | 3.4 mg/kg (N=99)         |
|---------------------------------------------------------------------|-------------------------|--------------------------|
| Overall response rate (ORR), %(97.5% CI)                            | 32% (22%, 44%)          | 35% (25%, 47%)           |
| Stringent complete response (sCR), n (%)                            | 2 (2%)                  | 2 ( 2 %)                 |
| Complete response (CR), n (%)                                       | 5 ( 5 %)                | 3 (3%)                   |
| Very good partial response (VGPR), n (%)                            | 11 (1 1 %)              | 1 8 (1 8 %)              |
| Partial response (PR), n (%)                                        | 1 3 (1 3 %)             | 12 (12%)                 |
| Median duration of response in months (95% CI)                      | 11 [4.2 to Not reached] | 6.2 [4.8 to Not reached] |
| Probability of Maintaining Response at 12 Months (95% CI) Medicinal | 0.50 (0.29, 0.68)       | 0.42 (0.25, 0.59)        |
| Median time to response in months (95% CI)                          | 1.5 (1.0, 2.1)          | 1.4 (0.9, 2.1)           |
| Median time to best response in months (95% CI)                     | 2.2 (1.5, 3.6)          | 3.5 (2.8, 4.3)           |

IRC: Independent Review Committee; INV: Investigator a. NE could be due to response not confirmed or inadequate baseline assessment/no post-baseline assessment. As of the 9 -month FU data (cut-off date of 31 January 2020), the ORR was 32% in the 2.5 mg/kg dose cohort (31/97; 97.5% CI: 21.7, 43.6%). There was a further deepening of response, with 58% of responders achieving VGPR or better, including 2 sCRs and 5 CRs. The median time to best response was consistent with the primary analysis at 2.2 months (95% CI: 1.5, 3.6). Table 30 Best confirmed response (ITT Population, Study DREAMM-2) (cut-off date of 31 January 2020) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## · Secondary efficacy endpoint- Duration of response

## Table 31 DOR Based on IRC assessment (ITT Population, Study DREAMM-2) (cut-off date 31 January 2020)

|        | authorised   |
|--------|--------------|
| longer |              |

<!-- image -->

<!-- image -->

Figure 6 K-M Analysis of IRC-assessed DoR (Study DREAMM-2, 2.5 mg/kg Cohort) (cut-off date of 31 January 2020) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

A worst-case sensitivity analysis was conducted based on the assumption that all participants who were censored with follow-up ongoing would progress immediately at the next visit. In this sensitivity analysis the median DoR was 10.3 months (95% CI: 4.2, 12.5) in the 2.5 mg/kg cohort. The estimated probability of having a DoR of ≥ 12 months was 50% in the 2.5 mg/kg cohort and 42% in the 3.4 mg/kg cohort. Among the 31 responders in the 2.5 mg/kg cohort, 11 participants still maintained response with follow-up ongoing, out of whom 6 participants had a DoR of more than 12 months.

| longer   |
|----------|
| no       |

<!-- image -->

· Secondary efficacy endpoint- Time to Response The time to response was short and was similar for both cohorts (median: 1.4 months, 95% CI: 1.0, 1.6; median: 1.4 months, 95% CI: 0.9, 2.1). · Secondary efficacy endpoint-Progression-Free Survival Table 32 PFS Based on IRC Assessment (ITT Population, Study DREAMM-2) (cut-off date of 31 January 2020) Furthermore, when adjusting for potential prognostic factors, the HR estimate for the 2 randomized dose cohorts became 0.96 (95% CI: 0.69, 1.35). Table 33 Cox Regression Analysis of Progression-Free Survival per IRC (Study DREAMM-2, cut -off date of 31 January 2020) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                                              | 13-Month FU (31Jan20)   | 13-Month FU (31Jan20)   |
|--------------------------------------------------------------|-------------------------|-------------------------|
|                                                              | HR (95% CI)             | p-value                 |
| Without adjustment for covariates 3.4 mg/kg versus 2.5 mg/kg | 0.933 (0.668, 1.303)    | 0.684                   |
| With adjustment for covariates 3.4 mg/kg versus 2.5 mg/kg    | 0.964 (0.687, 1.354)    | 0.835                   |
| ISS Staging at Screening: I to II versus III                 | 0.572 (0.405, 0.809)    | 0.002                   |
| Number of prior lines of therapy: 3 to 8 versus ≥9           | 0.664 (0.434, 1.016)    | 0.059                   |

<!-- image -->

ECOG: Eastern Cooperative Oncology Group; ISS: International Staging System; IRC: Independent Review Committee; PFS: progressionfree survival. Note: For each covariate, a hazard ratio &lt;1 indicates a lower hazard to experience the event in the first subgroup compared with the second subgroup. Covariates were selected using backward variable selection with exit criteria of alpha=0.10. The dose group (2.5 mg/kg frozen vs. 3.4 mg/kg frozen) was forced in the model. Other covariates include age group ('&lt; 65' vs. '&gt;=65'), cytogenetic risk ('Other' vs. 'High'), ISS staging at screening ('I/II' vs. 'III'), type of Myeloma ('Non-IgG' vs. 'IGG'), number of prior lines of therapy ('3-8' vs.'&gt;=9'), ECOG performance status ('0-1' vs.'&gt;=2'), and penta-refractory ('No' vs. 'Yes'). Note: A subject is considered as high risk if the subject has any of the following cytogenetics: t(4;14), t(14;16), and 17p13del. Pentarefractory is defined as refractory to: Bortezomib AND Carfilzomib AND Lenalidomide AND Pomalidomide AND Daratumumab. · Secondary efficacy endpoint- Overall Survival The OS was not mature at the time of the primary analysis. As of the data cut-off (21 June 2019), the 6-month overall survival rate was 72% and 75% in the 2.5 mg/kg and 3.4 mg/kg cohorts, respectively. As of the 13-month FU data (cut-off date of 31 January 2020), OS at 6 months was estimated as 72% in the 2.5 mg/kg cohort. OS at 12 months has been estimated based on the updated data as 57% and the median OS estimate was 13.7 months in the 2.5 mg/kg cohort. Figure 7 K-M Analysis of OS (Study DREAMM-2, ITT Population) (cut-off date of 31 January 2020) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

- Secondary efficacy endpoint- Minimal residual disease

Table 34 MRD negativity rate by best response based on IRC assessment (DREAMM-2, ITT Population)

<!-- image -->

| authorised   |
|--------------|

<!-- image -->

Ancillary analyses The ORR results in demographic and disease-based subgroups based on IRC assessment for the 2.5 mg/kg and the 3.4 mg/kg are presented in Figure 8 and Figure 9. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 8 ORR in Demographic and Disease-Based Subgroups Based on IRC Assessment (DREAMM-2 13-Month FU, ITT Population, 2.5 mg/kg Cohort)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 9 ORR in Demographic and Disease-Based Subgroups Based on IRC Assessment (DREAMM-2 13-Month FU, ITT Population, 3.4 mg/kg Cohort)

<!-- image -->

<div style=\"page-break-after: always\"></div>

| authorised   |
|--------------|

<!-- image -->

Table 35 IRC-Assessed Best Response with Confirmation (DREAMM-2, 13-Month FU (cut-off date of 31 January 2020, Full Analysis Population)

<!-- image -->

The other efficacy parameters for the 3.4 mg/kg Lyo cohort were similar to the 3.4 mg/kg frozen liquid-cohort (data not shown). Summary of main study The following table summarises the efficacy results from the main study supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections). Table 36 Summary of Efficacy for Study 205678 (DREAMM-2) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                          | Duration of Post-treatment Follow-up phase:                                                                                                                                                    | Duration of Post-treatment Follow-up phase:                                                                                                                                                    | For participants who discontinued study treatment for a reason other than PD, PFS follow-up occurred every 21 days (±7 days). Disease evaluations continued until confirmed PD, death, start of a new anti-cancer treatment, withdrawal of consent, or end of the study, whichever occurred first. For participants who discontinued due to PD, follow-up occurred authorised                                                                                                                                                                                                                                                                                                                              | For participants who discontinued study treatment for a reason other than PD, PFS follow-up occurred every 21 days (±7 days). Disease evaluations continued until confirmed PD, death, start of a new anti-cancer treatment, withdrawal of consent, or end of the study, whichever occurred first. For participants who discontinued due to PD, follow-up occurred authorised                                                                                                                                                                                                                                                                                                                              | For participants who discontinued study treatment for a reason other than PD, PFS follow-up occurred every 21 days (±7 days). Disease evaluations continued until confirmed PD, death, start of a new anti-cancer treatment, withdrawal of consent, or end of the study, whichever occurred first. For participants who discontinued due to PD, follow-up occurred authorised                                                                                                                                                                                                                                                                                                                              |
|----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis                                               | Study DREAMM-2 was designed to provide evidence with respect to ORR to either support the null hypothesis: H 0 : ORR ≤15% or reject H 0 in favour of the alternative hypothesis: H : ORR >15%. | Study DREAMM-2 was designed to provide evidence with respect to ORR to either support the null hypothesis: H 0 : ORR ≤15% or reject H 0 in favour of the alternative hypothesis: H : ORR >15%. | Study DREAMM-2 was designed to provide evidence with respect to ORR to either support the null hypothesis: H 0 : ORR ≤15% or reject H 0 in favour of the alternative hypothesis: H : ORR >15%.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Study DREAMM-2 was designed to provide evidence with respect to ORR to either support the null hypothesis: H 0 : ORR ≤15% or reject H 0 in favour of the alternative hypothesis: H : ORR >15%.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Study DREAMM-2 was designed to provide evidence with respect to ORR to either support the null hypothesis: H 0 : ORR ≤15% or reject H 0 in favour of the alternative hypothesis: H : ORR >15%.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Treatments groups                                        | 2.5 mg/kg                                                                                                                                                                                      | 2.5 mg/kg                                                                                                                                                                                      | 2.5 mg/kg belantamab mafodotin (frozen), n (number randomised/ITT) = 97                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.5 mg/kg belantamab mafodotin (frozen), n (number randomised/ITT) = 97                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.5 mg/kg belantamab mafodotin (frozen), n (number randomised/ITT) = 97                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Treatments groups                                        | 3.4 mg/kg                                                                                                                                                                                      | 3.4 mg/kg                                                                                                                                                                                      | 3.4 mg/kg belantamab mafodotin (frozen), n (number randomised/ITT) = 99                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3.4 mg/kg belantamab mafodotin (frozen), n (number randomised/ITT) = 99                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3.4 mg/kg belantamab mafodotin (frozen), n (number randomised/ITT) = 99                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Treatments groups                                        | 3.4 mg/kg Lyo                                                                                                                                                                                  | 3.4 mg/kg Lyo                                                                                                                                                                                  | 3.4 mg/kg belantamab mafodotin (lyophilised), n (number randomised) = 25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3.4 mg/kg belantamab mafodotin (lyophilised), n (number randomised) = 25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3.4 mg/kg belantamab mafodotin (lyophilised), n (number randomised) = 25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Endpoints and definitions                                | Primary endpoint                                                                                                                                                                               | Overall response rate (ORR)                                                                                                                                                                    | The percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response [VGPR], complete response [CR] and stringent CR), according to the 2016 IMWG Response Criteria by Independent Review                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | The percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response [VGPR], complete response [CR] and stringent CR), according to the 2016 IMWG Response Criteria by Independent Review                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | The percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response [VGPR], complete response [CR] and stringent CR), according to the 2016 IMWG Response Criteria by Independent Review                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Endpoints and definitions                                | Secondary Endpoints                                                                                                                                                                            | ORR by investigator assessment Duration of response (DoR) Time to response (TTR) Progression- free survival (PFS) Time to progression (TTP) Overall survival (OS) product                      | The percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and stringent CR), according to the 2016 IMWG Response Criteria by investigator assessment (IA). The time from first documented evidence of PR or better until the earliest date of documented PD per IMWG, or death due to PD. The time between the date of randomisation and the first documented evidence of response (PR or better). The time from randomisation until the earliest date of documented PD per IMWG, or death due to any cause. The time from randomisation until the earliest date of documented PD per IMWG, or death due to PD. The time from randomisation until death due to any cause. no longer | The percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and stringent CR), according to the 2016 IMWG Response Criteria by investigator assessment (IA). The time from first documented evidence of PR or better until the earliest date of documented PD per IMWG, or death due to PD. The time between the date of randomisation and the first documented evidence of response (PR or better). The time from randomisation until the earliest date of documented PD per IMWG, or death due to any cause. The time from randomisation until the earliest date of documented PD per IMWG, or death due to PD. The time from randomisation until death due to any cause. no longer | The percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and stringent CR), according to the 2016 IMWG Response Criteria by investigator assessment (IA). The time from first documented evidence of PR or better until the earliest date of documented PD per IMWG, or death due to PD. The time between the date of randomisation and the first documented evidence of response (PR or better). The time from randomisation until the earliest date of documented PD per IMWG, or death due to any cause. The time from randomisation until the earliest date of documented PD per IMWG, or death due to PD. The time from randomisation until death due to any cause. no longer |
| Database lock                                            | 31 January 2020                                                                                                                                                                                | 31 January 2020                                                                                                                                                                                | 31 January 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 31 January 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 31 January 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Results and Analysis                                     | Results and Analysis                                                                                                                                                                           | Results and Analysis                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Analysis description                                     | Primary Analysis - Overall Response Rate (ORR) by Independent Review Committee (IRC)                                                                                                           | Primary Analysis - Overall Response Rate (ORR) by Independent Review Committee (IRC)                                                                                                           | Primary Analysis - Overall Response Rate (ORR) by Independent Review Committee (IRC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Primary Analysis - Overall Response Rate (ORR) by Independent Review Committee (IRC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Primary Analysis - Overall Response Rate (ORR) by Independent Review Committee (IRC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Analysis population and time point description Medicinal | Full Analysis Population, which included all randomised participants, whether or not treatment was administered.                                                                               | Full Analysis Population, which included all randomised participants, whether or not treatment was administered.                                                                               | Full Analysis Population, which included all randomised participants, whether or not treatment was administered.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Full Analysis Population, which included all randomised participants, whether or not treatment was administered.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Full Analysis Population, which included all randomised participants, whether or not treatment was administered.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate                      | Treatment group                                                                                                                                                                                | Treatment group                                                                                                                                                                                | 2.5 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3.4 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3.4 mg/kg Lyo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| variability                                              | Number of subjects                                                                                                                                                                             | Number of subjects                                                                                                                                                                             | 97                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 99                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                          | ORR by IRC, n (%)                                                                                                                                                                              | ORR by IRC, n (%)                                                                                                                                                                              | 31 (32)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 35 (35)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13 (52)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                          | 97.5% CI Not applicable (NA)                                                                                                                                                                   | 97.5% CI Not applicable (NA)                                                                                                                                                                   | (21.7, 43.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (24.8, 47.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (28.9, 74.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Notes                                                    |                                                                                                                                                                                                |                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Analysis description                                                            | Secondary Analysis - Overall Response Rate (ORR) by Investigator                                                               | Secondary Analysis - Overall Response Rate (ORR) by Investigator                                                               | Secondary Analysis - Overall Response Rate (ORR) by Investigator                                                               | Secondary Analysis - Overall Response Rate (ORR) by Investigator                                                               |
|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point                                              | Assessment Full Analysis Population                                                                                            | Assessment Full Analysis Population                                                                                            | Assessment Full Analysis Population                                                                                            | Assessment Full Analysis Population                                                                                            |
| description Descriptive statistics and estimate                                 | Treatment group                                                                                                                | 2.5 mg/kg                                                                                                                      | 3.4 mg/kg                                                                                                                      | 3.4 mg/kg Lyo                                                                                                                  |
| variability                                                                     | Number of subjects                                                                                                             | 97                                                                                                                             | 99                                                                                                                             | 25                                                                                                                             |
|                                                                                 | ORR by IA, n (%)                                                                                                               | 32 (33) (22.6, 44.7)                                                                                                           | 32 (32) (22.1, 43.9)                                                                                                           | 13 (52) (28.9, 74.5)                                                                                                           |
| Analysis description                                                            | 97.5% CI Secondary Analysis - Duration of Response (DoR) by IRC                                                                | 97.5% CI Secondary Analysis - Duration of Response (DoR) by IRC                                                                | 97.5% CI Secondary Analysis - Duration of Response (DoR) by IRC                                                                | 97.5% CI Secondary Analysis - Duration of Response (DoR) by IRC                                                                |
| Analysis population and time point description                                  | Full Analysis Population authorised                                                                                            | Full Analysis Population authorised                                                                                            | Full Analysis Population authorised                                                                                            | Full Analysis Population authorised                                                                                            |
| Descriptive statistics and estimate variability                                 | Treatment group                                                                                                                | 2.5 mg/kg                                                                                                                      | 3.4 mg/kg                                                                                                                      | 3.4 mg/kg Lyo                                                                                                                  |
|                                                                                 | Number of subjects                                                                                                             | 31                                                                                                                             | 35                                                                                                                             | 13                                                                                                                             |
|                                                                                 | Median DoR (months)                                                                                                            | 11.0                                                                                                                           | 6.2                                                                                                                            | 9.0                                                                                                                            |
| description Analysis                                                            | 95% CI (4.2, -) Secondary Analysis - Time to Response (TTR)                                                                    |                                                                                                                                | (4.8, -)                                                                                                                       | (2.8, -)                                                                                                                       |
| Analysis                                                                        | by IRC                                                                                                                         | by IRC                                                                                                                         | by IRC                                                                                                                         | by IRC                                                                                                                         |
| population and time point description                                           | Full Analysis Population longer                                                                                                | Full Analysis Population longer                                                                                                | Full Analysis Population longer                                                                                                | Full Analysis Population longer                                                                                                |
| Descriptive statistics and estimate variability                                 | Treatment group                                                                                                                | 2.5 mg/kg                                                                                                                      | 3.4 mg/kg                                                                                                                      | 3.4 mg/kg Lyo                                                                                                                  |
|                                                                                 | Number of subjects Median TTR (months)                                                                                         | 31                                                                                                                             | 35                                                                                                                             | 13                                                                                                                             |
| Analysis description                                                            | 95% CI Secondary Analysis - Progression Free Survival (PFS)                                                                    | 1.5 (1.0, 2.1)                                                                                                                 | 1.4 (0.9, 2.1)                                                                                                                 | 0.9 (0.8, 2.3)                                                                                                                 |
| Analysis population and time point                                              | by IRC no                                                                                                                      | by IRC no                                                                                                                      | by IRC no                                                                                                                      | by IRC no                                                                                                                      |
| description                                                                     | Full Analysis Population                                                                                                       | Full Analysis Population                                                                                                       | Full Analysis Population                                                                                                       | Full Analysis Population                                                                                                       |
| Descriptive statistics and estimate                                             | Treatment group                                                                                                                | 2.5 mg/kg                                                                                                                      | 3.4 mg/kg                                                                                                                      | 3.4 mg/kg Lyo                                                                                                                  |
| variability                                                                     | Number of subjects                                                                                                             | 97                                                                                                                             | 99                                                                                                                             | 25                                                                                                                             |
|                                                                                 | Median PFS (months)                                                                                                            | 2.8                                                                                                                            | 3.9                                                                                                                            | 5.7                                                                                                                            |
| Analysis description                                                            | 95% CI (1.6, 3.6) (2.0, 5.8) (2.2, 9.7) Secondary Analysis - Time to Progression (TTP) by IRC Full Analysis Population product | 95% CI (1.6, 3.6) (2.0, 5.8) (2.2, 9.7) Secondary Analysis - Time to Progression (TTP) by IRC Full Analysis Population product | 95% CI (1.6, 3.6) (2.0, 5.8) (2.2, 9.7) Secondary Analysis - Time to Progression (TTP) by IRC Full Analysis Population product | 95% CI (1.6, 3.6) (2.0, 5.8) (2.2, 9.7) Secondary Analysis - Time to Progression (TTP) by IRC Full Analysis Population product |
| Analysis population and time point description Descriptive statistics           | Treatment group                                                                                                                | 2.5 mg/kg                                                                                                                      | 3.4 mg/kg                                                                                                                      | 3.4 mg/kg Lyo                                                                                                                  |
| and estimate variability                                                        | Number of subjects                                                                                                             | 97                                                                                                                             | 99                                                                                                                             | 25                                                                                                                             |
|                                                                                 | Median TTP (months) 95% CI                                                                                                     | 2.9 (2.0, 3.6)                                                                                                                 | 4.9 (2.3, 6.2)                                                                                                                 | 5.7 (2.2, -)                                                                                                                   |
| Analysis description                                                            | Secondary Analysis - Overall Survival (OS)                                                                                     | Secondary Analysis - Overall Survival (OS)                                                                                     | Secondary Analysis - Overall Survival (OS)                                                                                     | Secondary Analysis - Overall Survival (OS)                                                                                     |
| Analysis population and time point description Descriptive statistics Medicinal | Full Analysis Population Treatment group                                                                                       | 2.5 mg/kg                                                                                                                      | 3.4 mg/kg                                                                                                                      | 3.4 mg/kg Lyo                                                                                                                  |
| and estimate variability                                                        | Number of subjects                                                                                                             | 97                                                                                                                             | 99                                                                                                                             | 25                                                                                                                             |
|                                                                                 | Median OS (months)                                                                                                             | 13.7                                                                                                                           | 13.8                                                                                                                           | NR                                                                                                                             |
|                                                                                 | CI                                                                                                                             | (9.9,                                                                                                                          | -)                                                                                                                             | -)                                                                                                                             |
|                                                                                 | 95%                                                                                                                            |                                                                                                                                | (10.0,                                                                                                                         |                                                                                                                                |
|                                                                                 |                                                                                                                                | -)                                                                                                                             |                                                                                                                                | (8.7,                                                                                                                          |

<div style=\"page-break-after: always\"></div>

## Analysis performed across trials (pooled analyses and meta-analysis)

<!-- image -->

<!-- image -->

<!-- image -->

N/A Clinical studies in special populations Table 37 Number of elderly participants in DREAMM-1 and DREAMM-2 Supportive study Study BMA117159 (DREAMM-1) Belantamab mafodotin was initially evaluated in a first time in human study in participants with RRMM (DREAMM-1; BMA117159), who were refractory to a PI and an immunomodulatory agent. The objectives of DREAMM-1 were safety, tolerability, and clinical activity. Participants were treated on Q3W schedule as a 1-hour IV infusion. Part 1 of DREAMM-1 was a dose escalation phase testing doses from 0.03 to 4.60 mg/kg (n=38). The 3.4 mg/kg dose was chosen as the RP2D due to receptor saturation, promising clinical activity at the 3.4 and 4.6 mg/kg doses, and lower tolerability of the 4.6 mg/kg dose. In Part 2, participants (n=35) received the 3.4mg/kg dose for up to 16 cycles. The primary analysis was performed based on a data cut-off date of 31 August 2018, with 1 participant still ongoing. In Part 1 (dose escalation) the ORR in the 2.5mg/kg subgroup (n=8) was 13% (95% CI: 0.3, 52.7) and in the 3.4-mg/kg subgroup (n=3) the ORR was 100% (95% CI: 29.2, 100.0). However, no responses were noted in the 4 participants in the 2.5-mg/kg subgroup who had also received prior daratumumab treatment in addition to a PI and an immunomodulatory agent. In Part 2 (dose expansion, 3.4 mg/kg; n=35), the ORR was 60% (95% CI: 42.1, 76.1), with 54% of participants achieving a VGPR or better and median DoR was 14.3 months (95% CI: 10.6, -). In the subpopulation of participants who had received prior daratumumab (n=13), ORR was 38% with all responders achieving a VGPR or better and median DoR was 6.7 months (95% CI: 5.3, -) (see section 2.5.1.  Dose response study). 2.5.3. Discussion on clinical efficacy Medicinal product no longer authorised

## Design and conduct of clinical studies

The justification for the selected two doses (2.5 mg/kg or 3.4 mg/kg) of belantamab mafodotin was based on the results of the dose-finding study BMA117159 (DREAMM-1). The DLTs were investigated in the Part 1 of the study and no dose-limiting toxicities were observed at any dose level, including the

<div style=\"page-break-after: always\"></div>

maximum administered dose (4.6 mg/kg). Thus, the MTD was not established. The 2.5 mg/kg dose was acceptable by the CHMP to be the recommended dose.

The efficacy data of belantamab mafodotin was based mainly on a single phase 2 study 205678 (DREAMM-2). In principle, the study design was fit for its purpose, i.e. , to demonstrate efficacy in this heavily pre-treated MM patient population. MM patients relapsed or refractory to a proteasome inhibitor and immunomodulatory agent and in whom treatment with an anti-CD38 antibody had failed, have a dismal prognosis. The target population on the pivotal phase II study represents a MM patient population with multi-refractory disease and most the patients were previously treated with more than 5 previous lines of therapy. Currently there are limited options for these last line MM patients. Due to over-enrolment, 196 RRMM patients were recruited in this study; 97 in the 2.5 mg/kg dose cohort and 99 in the 3.4 mg/kg dose cohort. In general, the chosen inclusion and exclusion criteria are appropriate. Patients with prior allogeneic stem cell transplant were excluded mainly due the difficulties to separate possible corneal (eye) side-effects of belantamab mafodotin and clinical manifestations of GVHD, including keratoconjunctivitis sicca. Before the initiation of the study and in response to the feedback from regulatory agencies, the study was amended from an original single-arm design with 1 dose level (3.4 mg/kg) to an open-label, randomized, 2-arm study with 2 dose levels,  including the 2.5 mg/kg Q3W dose (Amendment 1) and the addition of a lyophilised cohort.  Due to over-enrolment in DREAMM-2,the overall sample size was increased from 65 subjects to ~100 subjects per arm.  As a result, the minimum observed ORR required for claiming efficacy changed from 26% (i.e. 17 responders for a sample size of 65 per arm) to 24% (i.e. 24 responders for sample size of 100 per arm). The phase 2 study was conducted without an active control arm which is a limitation.  Because there is no standard treatment for these patients, the missing control arm may be considered acceptable. To use historical data as a justification for the proposed ORR has also well-known limitations. The ORR rate of 15% (statistical design) of the study (amendment 1) was selected based on the previously reported response rate of 15% in participants at fourth relapse based on historical control data and was also discussed extensively with the applicant in Protocol Assistance (EMEA/H/SA/3559/2/2018/PA/PR/III) . The target ORR rate (≥ 24%) was not rejected, but in order to demonstrate a positive benefit/risk for belantamab mafodotin in the context of a CMA, it was expected that ORR rates markedly greater than 15% are observed from historical data. Furthermore, it was concluded that when using ORR as a primary endpoint, the treatment effect on ORR will have to be substantial to allow confidence in the clinical benefit. It was concluded that if the ORR proves to be according to expectations (33%) and if the secondary objectives and safety data of this study demonstrate an adequate risk/benefit profile, these analyses could provide a clinically meaningful outcome. Efficacy data and additional analyses Medicinal product no longer authorised

The originally proposed wording of the indication ''BLENREP is indicated as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received three prior lines of therapy including an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent''  allows treatment of patients after three prior treatments, relapsed or refractory to an immunomodulatory agent, PI and anti-CD38 antibody. Only 5 patients in the pivotal study fulfilled these minimum criteria, and the majority of the patients were heavily pre-treated, with two proteasome inhibitors and two immunomodulatory agents. In addition, most of the patients were refractory to bortezomib, carfilzomib, lenalidomide and pomalidomide and, by definition, all patients in the pivotal study were refractory to an immunomodulatory agent and a proteasome inhibitor and an

<div style=\"page-break-after: always\"></div>

anti-CD38 antibody. Although the patients included in this pivotal trial had minimum requirement of having failed at least 3 prior lines of anti-myeloma treatments, including an anti-CD38 antibody (e.g., daratumumab) alone or in combination, and being refractory to an immunomodulatory agent (i.e., lenalidomide or pomalidomide), to a proteasome inhibitor (e.g., bortezomib or carfilzomib) and to an anti-CD38 mAb (triple-class refractory), the vast majority of the patients were heavily pretreated. To better reflect the patient population, both in terms of prior lines of treatment received, and refractoriness to prior therapies, the indication was revised as follows:

The study included an additional independent cohort of 24 participants who received a lyophilized presentation of belantamab mafodotin at 3.4 mg/kg. So far, no patients have been treated with the proposed (SmPC) dose of 2.5 mg/kg with the commercial lyophilized formulation. Some differences in terms of patient characteristics were reported between patients treated with the 3.4 mg/kg frozen and the 3.4 mg/kg lyophilized presentations. Patients included in the lyophilized cohort were less pretreated and a lower percentage of them had high cytogenetic risk compared with those treated with the frozen formulation. In addition, response rate to most recent prior anticancer therapy was higher in the lyophilized cohort (52% vs. 30%). These differences in important prognosis factors along with the

BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 antibody, and who have demonstrated disease progression on the last therapy. The study met its primary endpoint for ORR as assessed by IRC in both the 2.5 mg/kg Q3W frozen cohort and 3.4 mg/kg Q3W frozen cohort. The ORR observed in this study by IRC was 31% (97.5%CI: 20.8, 42.6) in the 2.5 mg/kg cohort and 34% (97.5%CI: 23.9, 46.0) in the 3.4 mg/kg cohort (comparable to the 30% ORR observed in the pomalidomide study, study MM-003  which compared the efficacy of pomalidomide plus low-dose dexamethasone with high-dose dexamethasone in patients with refractory MM who had failed therapy with both bortezomib and lenalidomide, administered either alone or in combination). In the updated results with 13-month follow-up, the dose of 2.5 mg/kg Q3W has demonstrated ORR of 32% with mDOR of 11 months. There was a further deepening of response, with 58% of responders achieving VGPR or better, including 2 sCRs and 5 CRs. When interpreting these results, it should be kept in mind that these MM patients were heavily pre-treated with limited therapeutic options available. Thus, the updated data with longer FU confirmed that the responses are durable. With regard to OS, based on the 13-month FU the median OS estimate was 13.7 months in the 2.5 mg/kg cohort. When compared indirectly to the expected survival in this patient population, the probability of an OS ≥ 12 months of 57%is acknowledged, taking into consideration of the immaturity of the OS data. In the updated PFS results with 13-month follow-up, the median PFS estimate in the 2.5 mg/kg was 2.8 months compared to 3.9 in the 3.4 mg/kg cohort. The median PFS point estimate seems to be better in the 3.4 mg/kg dose cohort. The results of a sensitivity analysis with cytogenetics stratification (Yes, No and Other) were in-line with the primary results. MRD data was missing from 14 participants. However, among these, eight of these participants have relapsed and one died before MRD assessment. It would have been preferable to have MRD-data available from all participant with CR or VGPR. However, whether these participants would have reached MRD-data negativity or not, relapse seem to be unavoidable for these participants. In addition, seven out of 20 MRD-tested participants had achieved MRD negativity as of the 9-month follow-up. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

small sample size of the lyophilized cohort may explain the higher ORR reported in these patients (48% by IRC; 97.5% CI: 25.5%,71.1%) as compared to patients receiving the frozen formulation.

The exposure was decreased by ~10% when 3.4 mg/kg lyophilised formulation was administered compared to 3.4 mg/kg frozen formulation, which could suggest a lower exposure for 2.5 mg/kg Lyophilised than the 2.5 mg/kg frozen formulation. However, no significant differences were observed for Cmax and other exposure metrics, showing that the effect is not systematic, and it may likely be influenced by an imbalance in the distribution of patients receiving each formulation (lyophilised and frozen) (see discussion on clinical pharmacology). The covariate analysis did not identify a formulation effect as a significant covariate relationship. According to model predictions and efficacy/safety data, those differences are considered of minor relevance. Besides, from a quality point of view, both formulations are considered comparable (see section 2.2 Quality aspects). Additional efficacy data needed in the context of a conditional MA Based on the observed efficacy, a clinical benefit for belantamab mafodotin can be considered established, but a confirmation from a phase III comparative study is needed in order to better quantify the magnitude of the effect. In view of the established clinical benefit, and the fact that this application falls within scope and fulfils the remaining conditional marketing authorisation requirements, the CHMP agreed that the conditional marketing authorisation requested by the applicant could be granted. DREAMM-3, a phase III study of single agent belantamab mafodotin versus pomalidomide plus lowdose dexamethasone in participants with relapsed/refractory multiple myeloma is ongoing (SOB, Annex II.E) and a considerable proportion of patients would be in later treatment lines in line with DREAMM-2. Single arm study settings also impair the causality assessment of several key unfavourable effects leading to remaining uncertainties. These could be addressed by the proposed randomised study with pomalidomide/low-dose dexamethasone as comparator since it would allow comparisons of both efficacy and safety, and the proposed number of patients (n=320) would allow a more comprehensive analysis of both favourable and unfavourable effects. DREAMM-3 will be conducted in 184 sites and 19 countries worldwide. In addition, the CHMP considered that the MAH should submit the final results of the pivotal study DREAMM-2 study investigating the efficacy of belantamab mafodotin in patients with RRMM who have failed prior treatment with an anti-CD38 antibody which will also provide comprehensive data suitable to confirm the positive benefit-risk balance of BLENREP (SOB, Annex II.E). 2.5.4. Conclusions on the clinical efficacy Medicinal product no longer authorised

Data from the pivotal study DREAMM-2 showed a clinically significant response rate to belantamab mafodotin as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 mAb, and who have demonstrated disease progression on the last therapy. These results are further supported by durable responses. The achieved ORR is considered clinically meaningful in this heavily pre-treated MM patient population. However, efficacy results from direct comparison with available regimens are needed in order to better quantify the magnitude of the effect. In addition, the CHMP considered that the MAH should submit the final results of the pivotal study DREAMM-2 study which, together with the results from the comparative phase III DREAMM-3 study, will provide comprehensive data suitable to confirm the positive benefit-risk balance of BLENREP in the recommended indication.

<div style=\"page-break-after: always\"></div>

The CHMP considers the following measures necessary to address the missing efficacy data in the context of a conditional MA:

<!-- image -->

· In order to confirm the efficacy and safety of BLENREP in relapsed/refractory multiple myeloma adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy, the MAH should submit the results of the DREAMM-2 (205678) study investigating the efficacy of belantamab mafodotin in patients with multiple myeloma who had 3 or more prior lines of treatment, are refractory to a proteasome inhibitor and an immunomodulatory agent and have failed an anti-CD38 antibody. The final results of the study should be submitted by April 2021. · In order to confirm the efficacy and safety of BLENREP in multiple myeloma adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 mAb, and who have demonstrated disease progression on the last therapy, the MAH should submit the results of the DREAMM-3 (207495) study comparing the efficacy of belantamab mafodotin vs. pomalidomide plus low dose dexamethasone (pom/dex) in patients with relapsed/refractory multiple myeloma. The final report of the study should be submitted by July 2024. 2.6. Clinical safety Patient exposure The safety database is based on two clinical studies, first in human trial (FIHT) study DREAMM-1 and phase 2 study DREAMM-2. Two hundred and ninety-one (291) patients have been exposed to belantamab mafodotin (single agent), and 103 patients have been treated with the proposed registration dose. Safety assessment relies on pivotal study DREAMM-2, as the expansion cohort in the FIHT study DREAMM-1 was treated with a dose higher than the proposed registration dose (3.4 mg/kg vs. 2.5 mg/kg), and the enrolled patient population is not completely in line with the proposed indication. Thus, the primary safety assessment (21 June 2019) is mainly based on 103 patients (DREAMM-1 and DREAMM-2) with a median time on treatment of 9.1 weeks, and a median follow-up time of 6.37 months. At the time of the 13-month safety update (31 January 2020), median time on treatment was 9.3 weeks and the median time on study was 12.35 months. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 38 Exposure to Belantamab Mafodotin (DREAMM-2 Safety Population)

<!-- image -->

| authorised   |
|--------------|

<!-- image -->

A named patient compassionate use program has treated 174 patients as of 27 February 2020. Physicians were not obligated to report adverse events. but asked to report SAEs and AEs and SAEs. This has been reported as supportive information. In the pooled (DREAMM-2 and DREAMM-1) 2.5 mg/kg cohort, 22 (21%) of the 103 patients were ongoing and  receiving  study  treatment  at  data  cut-off  (21  June  2019).  The  most  common  reason  for discontinuation was progressive disease (65 patients, 63%). Eight patients (8%) discontinued due to AEs. Overall, the discontinuation rates were very similar in 2.5 mg/kg pooled group and 3.4 mg/kg pooled  groups,  with  the  exception  of  lower  proportion  of  patients  discontinuing  due  to  progressive disease in the 3.4 mg/kg pooled (Patients receiving 3.4 mg/kg in DREAMM-1 and DREAMM-2, N=137). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 39 Treatment Status and Reasons for Discontinuation of Study Treatment (DREAMM-2 Safety Population)

<!-- image -->

| authorised   |
|--------------|

|           | no      |
|-----------|---------|
|           | product |
| Medicinal |         |

Table 40 Dose Reductions of Belantamab Mafodotin (DREAMM-2 Safety Population) Medicinal product no longer authorised

Note:Participantsmaybecounted multipletimesin thesamereason'rowif theparticipanthad multiplereductionsfor the same reason.

a. Notevaluablemeanstheparticipantdidnotreceive anystudytreatmentinanysucceedingtimeperiod afterthe first dose.

<div style=\"page-break-after: always\"></div>

Table 41 Dose Delays of Belantamab Mafodotin (DREAMM-2 ITT Population) (cut-off date of 21 June 2019 and 20 September 2019)

|                                         | Belantamab Mafodotin Q3W   | Belantamab Mafodotin Q3W   | Belantamab Mafodotin Q3W    | Belantamab Mafodotin Q3W   |
|-----------------------------------------|----------------------------|----------------------------|-----------------------------|----------------------------|
|                                         | Primary Analysis (21Jun19) | Primary Analysis (21Jun19) | Updated Data (20Sep19)      | Updated Data (20Sep19)     |
|                                         | 2.5 mg/kg (N=95)           | 3.4 mg/kg (N=99)           | 2.5 mg/kg (N=95) authorised | 3.4 mg/kg (N=99)           |
| Participants with Any Dose Delay, n (%) | 37 (39)                    | 48 (48)                    | 39 (41)                     | 48 (48)                    |
| Total Number of Dose Delays             | 55                         | 82                         | 74                          | 105                        |
| Dose Delays, n (%)                      |                            |                            |                             |                            |
| 0                                       | 47 (49)                    | 36 (36)                    | 45 (47)                     | 36 (36)                    |
| 1                                       | 21 (22)                    | 27 (27)                    | 18 (19)                     | 24 (24)                    |
| 2                                       | 14 (15)                    | 12 (12)                    | 11 (12)                     | 8 (8)                      |
| >=3                                     | 2 (2)                      | 9 (9)                      | 10 (11)                     | 16 (16)                    |
| Not Evaluable a                         | 11 (12)                    | 15 (15)                    | 11 (12)                     | 15 (15)                    |
| Delay Duration (days), n (%)            |                            |                            |                             |                            |
| 1-21                                    | 20 (36)                    | 38 (46)                    | 27 (36)                     | 49 (47)                    |
| 22-42                                   | 10 (18)                    | 18 (22)                    | 11 (15)                     | 22 (21)                    |
| >42                                     | 25 (45)                    | 26 (32)                    | 36 (49)                     | 34 (32)                    |
| Reasons for Delay, n (%)                |                            |                            |                             |                            |
| Adverse Event                           | 53 (96)                    | 78 (95)                    | 68 (92)                     | 97 (92)                    |
| Scheduling Conflict                     | 1 (2)                      | 2 (2)                      | 4 (5)                       | 4 (4)                      |
| Other                                   | 1 (2)                      | 2 (2)                      | 2 (3)                       | 4 (4)                      |
| Participants with Dose Delays by        |                            | longer                     |                             |                            |
| Planned Time, n/N (%)                   | no                         |                            |                             |                            |
| Cycle 2 Day 1                           | 9/84 (11)                  | 17/84 (20)                 | 9/84 (11)                   | 17/84 (20)                 |
| Cycle 3 Day 1                           | 14/54 (26)                 | 20/61 (33)                 | 15/55 (27)                  | 20/61 (33)                 |
| Cycle 4 Day 1                           | 13/39 (33)                 | 13/43 (30)                 | 14/40 (35)                  | 14/44 (32)                 |
| Cycle 5 Day 1                           | 11/26 (42)                 | 13/33 (39)                 | 11/26 (42)                  | 18/38 (47)                 |
| Cycle 6 Day 1                           | 3/14 (21)                  | 6/26 (23)                  | 9/20 (45)                   | 8/34 (24)                  |
| Cycle 7 Day 1                           | 1/10 (10)                  | 9/20 (45)                  | 4/15 (27)                   | 13/27 (48)                 |
| Cycle 8 Day 1                           | 3/5 (60) product           | 3/11 (27)                  | 6/11 (55)                   | 8/19 (42)                  |
| Cycle 9 Day 1                           | 1/3 (33)                   | 1/7 (14)                   | 2/ 8 (25)                   | 4/13 (31)                  |
| Cycle 10 Day 1                          | 0/2                        | 0/2                        | 2/ 6 (33)                   | 2/ 8 (25)                  |
| Cycle 11 Day 1                          | 0/1                        | 0                          | 2/ 4 (50)                   | 0/3                        |
| Cycle 12 Day 1                          |                            |                            | 0/3                         | 0/2                        |
| Cycle 13 Day 1                          |                            |                            | 0/2                         | 0/2                        |
| Cycle 14 Day 1                          |                            |                            | 0/2                         | 1/1 (100)                  |
| Cycle 15 Day 1                          |                            |                            | 0/1                         | 0                          |

Source: Table 1.0290 a. Not evaluable means the participant did not receive any study treatment in any succeeding time period after the first dose. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Adverse events

An overview of the AEs observed in the safety population is given in Table 42

Table 42 Adverse Event Overview (DREAMM-2 Safety Population)

| authorised   | authorised   | authorised   | authorised   | authorised   | authorised   |
|--------------|--------------|--------------|--------------|--------------|--------------|
|              | longer       |              |              |              |              |

<!-- image -->

| Medicinal   |
|-------------|

Treatment-related AEs In the 2.5 mg/kg pooled data, a treatment-related AE was reported for 91 (88%) participants. Table 43 TreatmentRelated AEs by PT Reported for ≥10% of Participants in Any Cohort (DREAMM-2 Safety Population) Medicinal product no longer authorised

## Adverse reactions

Adverse reactions described in this section were reported from 95 patients who received BLENREP 2.5 mg/kg in study DREAMM2. The most frequent adverse reactions (≥30%) were keratopathy (71%) and thrombocytopenia (38%). The most commonly reported serious adverse reactions were pneumonia

<div style=\"page-break-after: always\"></div>

(7%), pyrexia (7%) and IRRs (3%). Permanent discontinuation due to an adverse reaction occurred in 9% of patients who received BLENREP with 3% related to ocular adverse reactions.

<!-- image -->

| System Organ Class                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Adverse reactions a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Frequency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Incidence (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Incidence (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| System Organ Class                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Adverse reactions a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Frequency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Any Grade                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Grade 3-4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Infections and infestations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Pneumonia b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Very common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Infections and infestations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Upper respiratory tract infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Blood and lymphatic system disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Thrombocytopenia c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Very common authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Blood and lymphatic system disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Anaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Very common authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Blood and lymphatic system disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Lymphopenia d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Very common authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Blood and lymphatic system disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Leukopenia e                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Very common authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Blood and lymphatic system disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Neutropenia f                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Very common authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Eye disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Keratopathy g                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Very common longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 71                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 31                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Eye disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Blurred vision events h                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Very common longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Eye disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Dry eye events i                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Very common longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Eye disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Photophobia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Eye disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Eye irritation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Eye disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Ulcerative keratitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Uncommon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Eye disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Infective keratitis no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Uncommon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Gastrointestinal disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Nausea                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Very common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Gastrointestinal disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Diarrhoea                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Gastrointestinal disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| General disorders and administration site conditions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pyrexia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Very common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| General disorders and administration site conditions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Fatigue                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Very common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Investigations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Increased aspartate aminotransferase product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Very common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Investigations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Increased gamma glutamyltransferase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Very common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Investigations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Increased creatine phosphokinase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Injury, poisoning and procedural complications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Infusion-related reactions j                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Very common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| a Adverse reactions coded using MedDRA and graded for severity based CTCAE v4.03. b Includes pneumonia, and herpes simplex pneumonia c Includes thrombocytopenia and decreased platelet count. d Includes lymphopenia and decreased lymphocyte count. e Includes leukopenia and decreased leukocyte count. f Includes neutropenia and decreased neutrophil count. g Based on eye examination, characterised as corneal epithelium changes with or without symptoms. h Includes diplopia, vision blurred, visual acuity reduced and visual impairment. i Includes dry eye, ocular discomfort, and eye pruritus. Medicinal | a Adverse reactions coded using MedDRA and graded for severity based CTCAE v4.03. b Includes pneumonia, and herpes simplex pneumonia c Includes thrombocytopenia and decreased platelet count. d Includes lymphopenia and decreased lymphocyte count. e Includes leukopenia and decreased leukocyte count. f Includes neutropenia and decreased neutrophil count. g Based on eye examination, characterised as corneal epithelium changes with or without symptoms. h Includes diplopia, vision blurred, visual acuity reduced and visual impairment. i Includes dry eye, ocular discomfort, and eye pruritus. Medicinal | a Adverse reactions coded using MedDRA and graded for severity based CTCAE v4.03. b Includes pneumonia, and herpes simplex pneumonia c Includes thrombocytopenia and decreased platelet count. d Includes lymphopenia and decreased lymphocyte count. e Includes leukopenia and decreased leukocyte count. f Includes neutropenia and decreased neutrophil count. g Based on eye examination, characterised as corneal epithelium changes with or without symptoms. h Includes diplopia, vision blurred, visual acuity reduced and visual impairment. i Includes dry eye, ocular discomfort, and eye pruritus. Medicinal | a Adverse reactions coded using MedDRA and graded for severity based CTCAE v4.03. b Includes pneumonia, and herpes simplex pneumonia c Includes thrombocytopenia and decreased platelet count. d Includes lymphopenia and decreased lymphocyte count. e Includes leukopenia and decreased leukocyte count. f Includes neutropenia and decreased neutrophil count. g Based on eye examination, characterised as corneal epithelium changes with or without symptoms. h Includes diplopia, vision blurred, visual acuity reduced and visual impairment. i Includes dry eye, ocular discomfort, and eye pruritus. Medicinal | a Adverse reactions coded using MedDRA and graded for severity based CTCAE v4.03. b Includes pneumonia, and herpes simplex pneumonia c Includes thrombocytopenia and decreased platelet count. d Includes lymphopenia and decreased lymphocyte count. e Includes leukopenia and decreased leukocyte count. f Includes neutropenia and decreased neutrophil count. g Based on eye examination, characterised as corneal epithelium changes with or without symptoms. h Includes diplopia, vision blurred, visual acuity reduced and visual impairment. i Includes dry eye, ocular discomfort, and eye pruritus. Medicinal |

<div style=\"page-break-after: always\"></div>

## Adverse events of interest

· Corneal adverse reactions Events in this category include 45 MedDRA AE PTs that the applicant considered to be related to keratopathy. This includes the 'microcyst-like epithelial keratopathy (MEK)' term that investigators were instructed to use to report ocular examination findings, which was mapped to the MedDRA PT keratopathy. Corneal adverse reactions were assessed in Study DREAMM-2 from the safety population (n = 218) which included patients treated with 2.5 mg/kg (n=95). Eye disorder events occurred in 74% patients and the most common adverse reactions were keratopathy or microcyst-like epithelial changes in corneal epithelium [identified on eye exam, with or without symptoms] (71%), blurred vision (25%), and dry eye (15%). Decreased vision (Snellen score Visual Acuity worse than 20/50) in the better eye was reported in 18% and severe vision loss (20/200 or worse) in the better seeing eye was reported in 1% of patients treated with belantamab mafodotin (SmPC, section 4.8). The median time to onset of Grade 2 or above corneal findings (best corrected visual acuity or keratopathy on eye examination) was 36 days (range: 19 to 143 days). The median time to resolution of these corneal findings was 91 days (range: 21 to 201 days). Corneal findings (keratopathy) led to dose delays in 47% of patients, and dose reductions in 27% of patients. Three percent of patients discontinued treatment due to ocular events (SmPC, section 4.8). Table 45 Characteristics of keratopathy events (CTCAE) (DREAMM-2 Safety Population) Medicinal product no longer authorised

3. Participants could have more than 1 Action Taken and be represented more than once. b. One paricipant was withdrawn due to keratopalhy, this has been correcled in the eCRF and is reflecled in the updated data.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 46 Keratopathy events (CTCAE) by PT (DREAMM-2 Safety Population)

<!-- image -->

|                | Number(%) of Participants BelantamabMafodotinQ3W   | Number(%) of Participants BelantamabMafodotinQ3W   | Number(%) of Participants BelantamabMafodotinQ3W   | Number(%) of Participants BelantamabMafodotinQ3W   | Number(%) of Participants BelantamabMafodotinQ3W   | Number(%) of Participants BelantamabMafodotinQ3W   |
|----------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Preferred Term | Primary Analysis                                   | 9-Month FU                                         | 13-MonthFU                                         | 13-MonthFU                                         |                                                    |                                                    |

<!-- image -->

Table 47 Characteristics of blurred vision events (CTCAE) (DREAMM-2 Safety Population) Medicinal product no longer authorised a. Participants could have more than 1 Action Taken and be represented more than once.

<div style=\"page-break-after: always\"></div>

Table 48 Blurred vision events (CTCAE) by PT (DREAMM-2 Safety Population)

<!-- image -->

| Number(%6)ofParticipants BelantamabMafodotinQ3w   | Number(%6)ofParticipants BelantamabMafodotinQ3w   | Number(%6)ofParticipants BelantamabMafodotinQ3w   | Number(%6)ofParticipants BelantamabMafodotinQ3w   | Number(%6)ofParticipants BelantamabMafodotinQ3w   | Number(%6)ofParticipants BelantamabMafodotinQ3w   |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Primary Analysis                                  | 9-MonthFU                                         | 13-MonthFU                                        | 13-MonthFU                                        |                                                   |                                                   |

<!-- image -->

Table 49 Characteristics of dry eye events (CTCAE) (DREAMM-2 Safety Population) Medicinal product no longer authorised

|           |         | longer   |
|-----------|---------|----------|
|           | no      |          |
|           | product |          |
| Medicinal |         |          |

a. Participants could have more than 1 Action Taken and be represented more than once.

<div style=\"page-break-after: always\"></div>

Table 50 Dry eye events (CTCAE) by PT (DREAMM-2 Safety Population)

<!-- image -->

| Number(%) of Participants BclantamabMafodotinQ3W   | Number(%) of Participants BclantamabMafodotinQ3W   | Number(%) of Participants BclantamabMafodotinQ3W   | Number(%) of Participants BclantamabMafodotinQ3W   | Number(%) of Participants BclantamabMafodotinQ3W   | Number(%) of Participants BclantamabMafodotinQ3W   |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|

<!-- image -->

<!-- image -->

· Infusion-related reactions In clinical studies, the incidence of infusion-related reactions (IRR) with belantamab mafodotin 2.5 mg/kg was 21%, and most (90%) occurred during the first infusion. Most IRRs were reported as Grade 1 (6%) and Grade 2 (12%) while 3% experienced Grade 3 IRRs. Serious IRRs were reported by 4% of patients and included symptoms of pyrexia and lethargy. Median time to onset and the median duration of the first occurrence of an IRR was 1 day. One patient (1%) discontinued treatment due to IRRs, experiencing Grade 3 IRRs at first and second infusion. No Grade 4 or 5 IRRs were reported (SmPC, section 4.8). Although not protocol-mandated, pre-medications for IRR prophylaxis were administered to 33 (32%) participants in the 2.5 mg/kg pooled data, most commonly analgesics (26%), antihistamines (22%) and steroids (16%). Table 51 Infusion-Related Reactions by PT, grade and cycle (DREAMM-1/DREAMM-2 Safety Population) Primary Analysis Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 52 Characteristics of infusion-related reactions (DREAMM-1/DREAMM-2 Safety Population)

<!-- image -->

|        | authorised   |
|--------|--------------|
| longer |              |

<!-- image -->

As of the 13-month FU data cut-off for DREAMM-2, there were no additional IRR events reported in comparison to the 9-month FU. · Thrombocytopenia Thrombocytopenic events, (thrombocytopenia and platelet count decreased) occurred in 38% of patients treated with belantamab mafodotin 2.5 mg/kg. Grade 2 thrombocytopenic events occurred in 3% of patients, Grade 3 in 9%, and Grade 4 in 13%. Grade 3 bleeding events occurred in 2% of patients and no Grade 4 or 5 events were reported (SmPC, section 4.8). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 53 Characteristics of thrombocytopenic events (DREAMM-2 Safety Population)

<!-- image -->

<!-- image -->

Table 54 Thrombocytopenic events by preferred term (DREAMM-2 Safety Population) a. Designated by the site as a thrombocytopenic AESI for Participant 6002; Platelets were 52 Gi/L at the event and were always &gt;50 Gi/L during the study. b. Note: The total number of participants who had a thrombocytopenic event decreased by two in the 3.4 mg/kg cohort in the updated data. This was due to the deletion of 3 events of platelet count decreased that were confirmed as not clinically significant by the investigator (therefore not considered an AE), and due to the addition of 1 new event of cerebral haemorrhage. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## · Infections

Upper respiratory tract infections were commonly reported across the belantamab mafodotin clinical programme and were mostly mild to moderate (Grade 1 to 3), occurring in 9% in patients treated with belantamab mafodotin 2.5 mg/kg. There were no SAEs of upper respiratory tract infections reported. Pneumonia was the most frequent infection reported in 11% of patients treated with belantamab mafodotin 2.5 mg/kg. Pneumonia was also the most frequent SAE, reported in 7% of patients. Infections with a fatal outcome were primarily due to pneumonia (1%).

|           | no      |
|-----------|---------|
|           | product |
| Medicinal |         |

Serious adverse event/deaths/other significant events · Serious adverse events In the 2.5 mg/kg pooled data, an SAE was reported for 42 (41%) participants. A treatment-related SAE was reported for 12 (12%) participants. The most commonly reported treatment-related SAE PT was IRR, reported for 4 (4%) participants, followed by pyrexia and sepsis, each reported for 2 (2%) participants. Table 55 SAEs by PT Reported for ≥ 2 participants in any cohort (DREAMM-2 Safety Population) Medicinal product no longer authorised

## · Deaths

## Table 56 Summary of deaths (DREAMM-2 Safety Population)

<div style=\"page-break-after: always\"></div>

| Number(%) of Participants BelantamabMafodotinQ3W   | Number(%) of Participants BelantamabMafodotinQ3W   | Number(%) of Participants BelantamabMafodotinQ3W   | Number(%) of Participants BelantamabMafodotinQ3W   |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Primary Analysis (21Jun19)                         | Primary Analysis (21Jun19)                         | 9-Month FU (20Sep19)                               | 9-Month FU (20Sep19)                               |
| 2.5 mg/kg (S6=N)                                   | 3.4mg/kg (66=N)                                    | 2.5mg/kg (N=95)                                    | 3.4 mg/kg (66=N)                                   |

Laboratory findings Renal parameters Renal failure is a common complication of MM. In preclinical studies, degeneration of the kidney and glomerulopathy associated with proteinuria were observed. In the 2.5 mg/kg group, 26% of patients had an increase from baseline in serum creatinine. One patient experienced a grade 4 increase and developed an acute kidney failure, not considered to be related to the study treatment. 18% of patients had a decrease from normal to low GFR. In approximately half of these patients, the decrease in eGFR was associated with disease progression. Four patients had a post-baseline albumin creatinine ratio of &gt;2000  and  required  treatment  interruption  as  per  protocol.  One  of  the  patients  discontinued  the treatment permanently due to this AE. Proteinuria was reported in 4% of patients in 2.5 mg/kg group, 3/4 cases being grade 1 events. Haematology assessments Decreased  cellularity  of  the  bone  marrow  and  adaptive  effects  of  the  hematopoietic  system  were observed in the preclinical studies. In the 2.5 mg/kg pooled data, the most frequent increases to any AE grade were in platelets decreased (63% of patients), lymphocytes (lymphocyte count decreased) (50%), leukocytes (white blood cell decreased) (36%), and haemoglobin (anaemia) (32%). Increases to grade 3  occurred  in  17%  of  patients  for  haemoglobin  (anaemia),  and  lymphocytes  (lymphocyte  count decreased), reported for 19% of patients. Platelets decreased was reported as a grade 4 event for 12 (12%) patients. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 57 Worst Case Haematology Grade Changes from Baseline Grade (cut-off date of 31 January 2020)

| Test Category                                                                                                    | Number (%) of Participants Belantamab Mafodotin Q3W 13-Month FU (31Jan20)   | Number (%) of Participants Belantamab Mafodotin Q3W 13-Month FU (31Jan20)   |
|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
|                                                                                                                  | 2.5 mg/kg (N=95)                                                            | 3.4 mg/kg Frozen (N=99)                                                     |
| Haemoglobin (Haemoglobin increased) (g/L), n Any Grade Increase                                                  | 95 2 (2)                                                                    | 97 0                                                                        |
| Haemoglobin (Anaemia) (g/L), n Any Grade Increase Increase to Grade 3                                            | 95 33 (35) 19 (20)                                                          | 97 44 (45) 30 (31) authorised                                               |
| Lymphocytes (Lymphocyte count increased) (10 9 /L), n Any Grade Increase                                         | 95 1 (1)                                                                    | 97 1 (1)                                                                    |
| Lymphocytes (Lymphocyte count decreased) (10 9 /L), n Any Grade Increase Increase to Grade 3 Increase to Grade 4 | 95 48 (51) 16 (17) 5 (5) longer                                             | 97 46 (47) 24 (25) 5 (5)                                                    |
| Neutrophils decreased (10 9 /L), n Any Grade Increase Increase to Grade 3 Increase to Grade 4                    | 95 30 (32) 4 (4) 6 (6)                                                      | 97 47 (48) 10 (10) 3 (3)                                                    |
| Platelets decreased (10 9 /L), n Any Grade Increase Increase to Grade 3 Increase to Grade 4                      | 95 62 (65) 8 (8) 13 (14) no                                                 | 97 74 (76) 11 (11) 25 (26)                                                  |
| Leukocytes (Leukocytosis) (10 9 /L), n Any Grade Increase                                                        | 95 0                                                                        | 97 0 97                                                                     |
| Leukocytes (White blood cell decreased) (10 9 /L), n Any Grade Increase Increase to Grade 3 Increase to Grade 4  | 95 37 (39) 5 (5) 3 (3)                                                      | 44 (45) 8 (8) 3 (3)                                                         |

Note: Subjects with missing baseline grade are assumed to have baseline of Grade 0. All increases are an increase in grade from baseline. Liver-related assessments In preclinical  studies, hepatocellular necrosis and increased liver enzymes were observed. Increased alanine  aminotransferase  (22%),  aspartate  aminotransferase  (58%),  alkaline  phosphatase  (26%), bilirubin (5%) and gamma glutamyl transferase (26%) were observed, all showing some degree of dose proportionality (higher frequency of increased values in 3.4 mg/kg group). However, increases to grade 3/4 were infrequent, with the exception of gamma glutamyl transferase (increase to grade 3 in 6% of patients). ALT was increased more than 3 x Upper Limit of Normal (ULN) in only one patient in 2.5 mg/kg group (&lt;1%). No patient in either DREAMM-1 or DREAMM-2 met the Hy's law criteria. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 58 Hepatobiliary Laboratory Abnormalities (Primary Analysis)

<!-- image -->

|        | authorised   |
|--------|--------------|
| longer |              |

Safety in special populations No significant differences were observed in safety profile based on baseline renal impairment status. However, majority of the patients were categorized to have a mild renal impairment (n=48) and only two  patients  had  severe  renal  impairment  in  the  2.5  mg/kg  group.  In  population  pharmacokinetic analyses, baseline renal function was not found to be a significant factor accounting for interindividual variability. No safety data has been presented based on hepatic insufficiency. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 59 AEs by age groups and by MedDRA terms (9-month data cut)

<!-- image -->

In study DREAMM-1, all patients tested negative for ADAs both at baseline and in all assessments after treatment. In study DREAMM-2, 5/211 patients tested positive for anti-belantamab mafodotin ADAs, with one patient testing positive for NAbs at baseline. Only one of these patients tested positive after treatment. A total of 2 patients tested positive for ADAs at a single time point after treatment with one patient testing positive for NAbs. Thus, 1/274 patients with post-baseline ADA results had treatmentemergent ADAs. All antibody titers were close to sensitivity limit of the assay.

Immunological events In silico modelling Using an in silico approach, the potential immunogenicity risk for belantamab mafodotin was calculated using T-cell epitopes predicted with the TEpredict software. Belantamab mafodotin scored in same range as other therapeutic mAbs that have low incidence of clinical immunogenicity. Immunogenicity assessment Serum samples for immunogenicity assessment were collected on day 1 of cycles 1, 2, 3, 6, 9, 12 and 16, on day 15 of cycle 1 and at the end of study in study DREAMM-1, and on day 1 of cycles 1, 2, 3, 6, 9, 12, and on every 6 cycles thereafter until end of treatment in study DREAMM-2. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No specific clinical studies assessing the effects of other drugs or extrinsic factors on belantamab mafodotin, total mAb, or cys-mcMMAF pharmacokinetics were submitted (see discussion on clinical safety).

<!-- image -->

| longer   | longer   | longer   | longer   | longer   | longer   |
|----------|----------|----------|----------|----------|----------|
|          | no       |          |          |          |          |
| product  |          |          |          |          |          |

## Post marketing experience

Discontinuation due to adverse events In 2.5 mg/kg group, 9% of patients discontinued treatment due to an AE. The most commonly reported AE that led to permanent discontinuation of study treatment was keratopathy, reported for 3 (3%) participants. Table 60 Adverse Events Leading to Permanent Discontinuation of Study Treatment by PT (DREAMM-2 Safety Population) AE: adverse event; PT: preferred term. a. One participant was reported in the primary analysis as having an AE of keratopathy that led to withdrawal, that was later confirmed as not having led to withdrawal and is reflected in the updated data. No other reason for discontinuation was reported for more than one patient. Medicinal product no longer authorised

N/A

<div style=\"page-break-after: always\"></div>

## 2.6.1. Discussion on clinical safety

Single arm study settings impair the causality assessment of several key unfavourable effects. Adverse effects of disease under study, previous treatments and adverse events predicted based on mechanism of action and structure of belantamab mafodotin are overlapping, and only rough estimates for frequencies of these events can be made in this heterogeneous patient population. Dose-dependency of these adverse effects is not evident for rare AEs, and absence of dose-dependency may in some cases be due to small differences between exposure levels achieved between the two dose levels studied. This issue will be addressed in the randomized confirmatory study DREAMM-3 which will evaluate the safety and tolerability of belantamab mafodotin vs pom/dex in participants with RRMM (see Annex II and RMP).

The number of patients treated with belantamab mafodotin in studies DREAMM-1 and DREAMM-2 is limited. A total of 103 patients have been exposed to the proposed registration dose of 2.5 mg/kg as a single agent, majority of them in the pivotal study DREAMM-2. In the 13-month follow-up, the median number of treatment cycles was 3 (range 1-15), and median time on treatment 9.3 weeks. Treatment was discontinued due to disease progression in majority of cases and thus, loss of benefit, rather than tolerability, mainly determined the duration of exposure. The median time on study was 12.35 months, and therefore for majority of the patients, follow-up covering the expected time on treatment is available. Moreover, the most common toxicities (keratopathy and other ocular AEs, thrombocytopenia) have mainly been reported within this period, and no major differences were reported between the primary analysis (data cut-off 21 June 2019) and 13-month follow-up (data cutoff 31 January 2020) despite significantly longer follow-up time. The pivotal study is ongoing, and 10 patients (11%) in the 2.5 mg/kg cohort were receiving study treatment at the time of the latest data cut-off. The final study report from DREAMM-2 will provide further information on the AEs (see Annex II and RMP). The frozen formulation of belantamab mafodotin has been used in majority of patients so far. The lyophilized formulation, intended for commercial use, has been tested in a separate cohort of 25 patients treated with 3.4 mg/kg dose in DREAMM-2. The incidence of SAEs was numerically higher in the lyophilised cohort compared with the frozen dose cohort (63% vs 47%). However, the difference does not seem to be driven by any particular adverse event. The various numerical differences observed in side-by side comparison of the two formulations are likely attributed to the small number of participants in the lyophilized cohort and different baseline disease characteristics. The final study report of DREAMM-2 will provide further information on the AEs (see Annex II and RMP). Two different dose levels were compared in the pivotal study DREAMM-2. Dose dependency both in terms of frequency and severity or majority of the AEs were observed. Selection of the registration dose was largely based on better tolerability of the 2.5 mg/kg dose as compared to 3.4 mg/kg. Incidence of thrombocytopenia, particularly those associated with bleeding events, neutropenia, infections and increased incidence and severity of corneal events were considered to favour selection of the lower dose level of 2.5 mg/kg. Moreover, more deaths were reported in the 3.4 mg/kg group. Although these AEs are agreed to be serious, the number of each of these events in this small singlearm study is very low, and causality difficult to determine due to overlapping toxicities related to the disease under study and previous treatments. However, the small differences in individual AEs are consistent between the dose groups, and the overall safety profile of the lower dose level is more favourable. Medicinal product no longer authorised

Although there is more clinical experience with 3.4 mg/kg dosing (n=161) and the commercial formulation has only been tested with 3.4 mg/kg dosing, from safety perspective selection of the lower dose level of 2.5 mg/kg is supported. The safety differences observed in clinical studies may become more exaggerated in clinical use due to likely less vigorous patient follow-up and dose modifications in

<div style=\"page-break-after: always\"></div>

clinical practice. Due to small differences in median exposure between the dose levels, safety data from the higher dose level 3.4 mg/kg is considered relevant for assessment of the overall safety profile of belantamab mafodotin.

Numerous dose reductions and delays were applied; keratopathy events were the most common reason for dose modifications in both dose groups. Discontinuation of study treatment was rare, only 9% of patients in the pooled 2.5 mg/kg cohort permanently discontinued treatment due to an AE. The most common reason for discontinuation was corneal events. Cautious criteria for dose modifications likely prevented progression of adverse events to a point when discontinuation was necessary. The follow-up and dose modification criteria are considered adequate to ensure that dose modifications are guided in a similar fashion in clinical use (SmPC, section 4.2). Moreover, higher exposure resulting from different dose modification criteria is unlikely to pose unexpected safety concerns, as safety data from higher exposure level achieved in 3.4 mg/kg dose group (2.95 mg/kg/3 weeks) is available. Adverse events were reported in nearly all the patients (98%), and 83% of patients reported a grade 3 or 4 AE. The most frequent adverse reactions ( ≥ 30%) (any grade) were keratopathy (71%) and thrombocytopenia (38%) (SmPC, section 4.8). Common eye-related AEs included vision blurred (25%), dry eye (15%) and photophobia (4%). Other common adverse events in the 2.5 mg/kg pooled data were anaemia (27%) and nausea (25%). For AEs possibly related to disease under study or previous medications (thrombocytopenia, anaemia, neutropenia) assessment of causality is complicated. Worsening of these events during treatment can also be caused by disease progression. However, a clear dose dependency has been shown for these events indicating that study treatment contributes to these AEs. Events like keratopathy were closely monitored during the study, and thus likely assigned as treatment related. For some AEs like pyrexia and infections, evaluation of causality seemed to vary between apparently similar cases. Overall, in this heavily pre-treated population, distinction between disease symptoms and AEs is, in general, very challenging in this open label, uncontrolled study. Keratopathy (31%), thrombocytopenia (22%) and anaemia (21%) were the most common grade 3 or 4 AEs reported in 2.5 mg/kg pooled data. Serious adverse events were reported in 42% of the patients in the pooled 2.5mg/kg cohort. The most commonly reported serious adverse reactions were pneumonia (7%), pyrexia (7%) and Infusionrelated reactions (IRRs) (3%) (SmPC, section 4.8). There is no clear difference in number of individual SAEs between the dose levels. In the 2.5 mg/kg group, 32 patients died during the study. The primary cause of death was disease under study for 25% of patients. In the 13-month follow-up data, 7 new deaths were reported, all considered to be due to disease under study. One patient had a fatal SAE (sepsis) that was considered to be related to the study treatment. Several of the fatal events reported during the clinical studies included adverse events of special interest for belantamab mafodotin. Due to lack of control/comparator group, last line disease setting and varying previous treatment regimens, the likelihood of specific disease-related complications is difficult to estimate. Additional follow up data provided did not suggest that the events were causally related, or particularly that belantamab mafodotin may have contributed to events. Medicinal product no longer authorised

Limited data are available on progression of asymptomatic keratopathy findings during treatment. Based on data from 28 patients who continued treatment despite corneal findings, the AEs did lead to symptoms and dose modifications later, but the outcome was not altered due to the delay.

Corneal adverse reactions have been reported with the use of BLENREP. The most commonly reported adverse reactions were keratopathy or microcyst-like epithelial changes in corneal epithelium (as seen on eye examination) with or without changes in visual acuity, blurred vision, and dry eye. Patients with

<div style=\"page-break-after: always\"></div>

a history of dry eye were more prone to develop changes in the corneal epithelium. Changes in visual acuity may be associated with difficulty in driving or operating machinery (SmPC, section 4.4).

Ophthalmic examinations, including assessment of visual acuity and slit lamp examination, should be performed at baseline, before the subsequent 3 treatment cycles and during treatment as clinically indicated. Patients should be advised to administer preservative-free artificial tears at least 4 times a day during treatment. Patients should avoid using contact lenses until the end of treatment (SmPC, section 4.4).

Patients experiencing keratopathy with or without changes in visual acuity may require a dose modification (delay and/or reduction) or treatment discontinuation based on severity of findings (SmPC, section 4.4). Cases of corneal ulcer (ulcerative and infective keratitis) have been reported. These should be managed promptly and as clinically indicated by an eye care professional. Treatment with BLENREP should be interrupted until the corneal ulcer has healed (SmPC, section 4.4). Corneal adverse reactions may include findings upon eye examination and/or changes in visual acuity. The treating physician should review the patient's ophthalmic examination report before dosing and should determine the dose of BLENREP based on the highest category from the report in the most severely affected eye as both eyes may not be affected to the same degree. During the ophthalmic examination, the eye care professional should assess the following: · The corneal examination finding(s) and the decline in best corrected visual acuity (BCVA). · If there is a decline in BCVA, the relationship of corneal examination findings to BLENREP should be determined. · The highest category grading for these examination findings and BCVA should be reported to the treating physician (SmPC, section 4.2). An ocular sub-study was performed to further characterize the keratopathy events, and to explore the possibility to use topical corticosteroid administration to prevent the eye-related adverse events. The sample size was small (17 patients in the 2.5 mg/kg group, and 13 patients in the 3.4 mg/kg group). Topical corticosteroid did not appear to prevent keratopathy or any other ocular symptoms. This is in contrast with published results (Eaton JS et al, 2015, Donaghy H. 2016, Matulonis UA et al, 2019) from other MMAF-conjugated ADCs. Corneal epithelial cells do not express BCMA, and as with other ADCs, the toxicity has been shown to be caused by macropinocytosis of the ADC into the cells and intracellular release of cys-mcMMAF. However, as there does not appear to be inflammatory component to the ocular toxicity, and it was confirmed that systemic corticosteroids were not a significant confounding factor in the sub-study, no additional studies are deemed necessary. As corticosteroids are themselves associated with potential adverse events, the available information does not support prophylactic use of topical corticosteroids to prevent belantamab mafodotin-induced keratopathy. Keratopathy (or MEC) in the corneal epithelium (as seen on eye examination) with or without changes in visual acuity, blurred vision, or dry eye has been classified as an important identified risk in the RMP. The corneal events and visual changes can be managed in clinical practice through appropriate monitoring, as well as dose modifications, and additional risk minimisation measures have been implemented in order to mitigate the possible risks of keratopathy. The additional risk minimisation activity will help oncologists, eye care professionals and patients to understand the corneal risks associated with belantamab mafodotin, so that corneal examination findings, and/or visual changes can be promptly identified and managed according to the product labelling (see Annex II and RMP). Medicinal product no longer authorised

Thrombocytopenic events (thrombocytopenia and platelet count decreased) were frequently reported.

<div style=\"page-break-after: always\"></div>

Thrombocytopenia may lead to serious bleeding events, including gastrointestinal and intracranial bleeding. Complete blood counts should be obtained at baseline and monitored during treatment, as clinically indicated. Patients experiencing Grade 3 or 4 thrombocytopenia or those on concomitant anticoagulant treatments may require more frequent monitoring and should be managed with a dose delay or dose reduction. Supportive therapy (e.g. platelet transfusions) should be provided according to standard medical practice (SmPC, section 4.4).

Infusion-related reactions have been reported with belantamab mafodotin. Most IRRs were Grade 1-2 and resolved within the same day. If a grade 2 or higher infusion- related reaction occurs during administration, the infusion rate should be reduced or the infusion should be stopped, depending on the severity of the symptoms. It is recommended to institute appropriate medical treatment and restart infusion at a slower rate, if the patient's condition is stable. If Grade 2 or higher IRR occurs, premedication for subsequent infusions should be administered (SmPC, section 4.4). IRRs were more common in patients who received pre-medication (38%) as compared to the patients who did not (16%). However, this difference may be biased as the patients who were pre-treated were likely identified as high-risk patients. Although not identified as AESIs, infections are considered to be relevant AEs for safety of belantamab mafodotin. Infections were the most frequent treatment-related SAEs. The frequency and severity, and particularly clinical consequences of neutropenia, appeared to be dose dependent. The targeted therapeutic effect of belantamab mafodotin is depletion of B cells, and thus increased risk of infections is plausible. In a patient population prone to infections, consequences of these effects may be more pronounced. Events within SOC infections and infestations were reported for 43% of patients in 2.5 mg/kg pooled data, and 56% of patients in 3.4 mg/kg group. In analysis of additional information on infection events, no clear pattern regarding types or timing of the infections, or patient sub-groups, apart from higher incidence in older patients. The PI has been updated to reflect the most recent AE data from the 13-month update. Increased risk of infections due to immunosuppression and/or neutropenia has been classified as an important potential risk in the RMP. The immunogenicity potential of belantamab mafodotin appears to be low. Two out of the 274 exposed patients with post-baseline results tested positive for ADAs, and treatment-emergent ADAs were only observed in one patient. All antibody titers were low, near the sensitivity of the assays used. Very limited data is thus available on effect of ADAs, and due to lack of post-baseline PK data from the only NAb positive patient, the effect of NAbs could not be determined. The immunogenicity potential of belantamab mafodotin is considered to be low; however, additional data from on-going studies will be provided for a more comprehensive analysis of immunogenicity and its clinical role (see RMP). BLENREP has a moderate influence on the ability to drive or use machines. Patients should be advised to use caution when driving or operating machines as BLENREP may affect their vision (SmPC, section 4.7). There has been no experience of overdosage in clinical studies. There is no known specific antidote for belantamab mafodotin overdose. In the event of an overdose, the patient should be monitored for any signs or symptoms of adverse effects and appropriate supportive treatment should be instituted immediately (SmPC, section 4.9). In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded (SmPC, section 4.4). Medicinal product no longer authorised

This medicinal product contains less than 1 mmol sodium (23 mg) per 100 mg dose, that is to say essentially 'sodium-free' (SmPC, section 4.4).

From the safety database all the adverse reactions reported in clinical trials have been included in the SmPC.

<div style=\"page-break-after: always\"></div>

## Additional safety data needed in the context of a conditional MA

The various numerical differences observed in side-by side comparison of the two formulations are likely attributed to the small number of participants in the lyophilized cohort and different baseline disease characteristics. Final study report of DREAMM-2 will provide further information on resolution of the AEs (see Annex II and RMP).

· In order to confirm the efficacy and safety of BLENREP in multiple myeloma adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 mAb, and who have demonstrated disease progression on the last therapy, the MAH should submit the results of the DREAMM-3 (207495) study comparing the efficacy of belantamab mafodotin vs. pomalidomide plus low dose dexamethasone (pom/dex) in patients with relapsed/refractory multiple myeloma. The final report of the study should be submitted by July 2024.

Single arm study setting impairs the causality assessment of several key unfavourable effects. Adverse effects of disease under study, previous treatments and adverse events predicted based on mechanism of action and structure of belantamab mafodotin are overlapping, and only rough estimates for frequencies of these events can be made in this heterogeneous patient population. This issue will be addressed in the randomized confirmatory study DREAMM-3 which will evaluate the safety and tolerability of belantamab mafodotin vs pom/dex in participants with RRMM (see Annex II and RMP). 2.6.2. Conclusions on the clinical safety Overall, the toxicity profile is considered to be acceptable in the target patient population. Ocular toxicities and their clinical management are currently considered to be the most important safety concern. Haematological toxicities are also significant, both due to overlapping toxicity profile with previous treatments and disease under study, and due to possibly serious clinical consequences (infections and bleeds). However, the follow-up and dose modification recommendations are considered sufficient to manage the observed toxicity profile in clinical practice. Relevant safety information and recommendations are presented in the SmPC. Additional studies are expected to provide further information regarding effects of belantamab mafodotin on keratopathy, nephrotoxicity and increased risk of infections (due to immunosuppression and/or neutropenia) and also in patients with severe renal impairment and hepatic impairment (see RMP). The safety has been considered sufficiently characterised in the context of a conditional MA. Additional data from confirmatory studies will be provided in support of the overall safety profile of belantamab mafodotin. The CHMP considers the following measures necessary to address the missing safety data in the context of a conditional MA: · In order to confirm the efficacy and safety of BLENREP in relapsed/refractory multiple myeloma adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 mAb, and who have demonstrated disease progression on the last therapy, the MAH should submit the results of the DREAMM-2 (205678) study investigating the efficacy of belantamab mafodotin in patients with multiple myeloma who had 3 or more prior lines of treatment, are refractory to a proteasome inhibitor and an immunomodulatory agent and have failed an anti-CD38 antibody. The final results of the study should be submitted by April 2021. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.7. Risk Management Plan

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                         |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • Keratopathy (or MEC) in the corneal epithelium (as seen on eye examination) with or without changes in visual acuity, blurred vision, or dry eye |
| Important potential risks    | • Nephrotoxicity • Increased risk of infections due to immunosuppression and/or neutropenia                                                        |
| Missing information          | • Safety in patients with severe renal impairment • Safety in patients with hepatic impairment                                                     |

| Study Status                                                                                                                                                                                                                   | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Safety concerns addressed                                                                                                                                                                                                                                                                                                                                                                                                                         | Milestones                                                                                                                                                                                           | Due dates                                                                                                                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                     | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                                                                                                                                                                                                                        | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                           |
| None                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                      |                                                                                                                                                                                                      |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances longer                           | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances longer                                                                                                                                                                                                                                              | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances longer | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances longer |
| 205678 (DREAMM-2): Open-label, randomized study of two doses of belantamab mafodotin in participants with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-CD38 antibody (DREAMM-2) - Ongoing | Primary: To evaluate the clinical efficacy of 2 doses of belantamab mafodotin in participants with relapsed/refractory multiple myeloma Secondary: To further evaluate the clinical measures of efficacy of belantamab mafodotin in participants with RRMM To evaluate the safety of belantamab mafodotin in participants with RRMM To evaluate the pharmacokinetic profile of belantamab mafodotin To assess anti-drug antibodies (ADAs) against belantamab mafodotin Participant self-reported symptomatic adverse effects by evaluation of tolerability of belantamab mafodotin To evaluate disease and treatment related symptoms and impact on function and health-related quality-of life Medicinal product no | Standard clinical and laboratory tests Collection of AEs and SAEs AEs of special interest Ocular findings on ophthalmic exam Further characterization of important identified and potential risks: • Keratopathy (or MEC) in the corneal epithelium (as seen on eye examination) with or without changes in visual acuity, blurred vision, or dry eye • Nephrotoxicity • Increased risk of infections due to immunosuppression and/or neutropenia | Final study report Final study report submission                                                                                                                                                     | Jan 2021 Apr 2021                                                                                                                                                                                    |
| 207495 (DREAMM-3): Phase III Study of Single Agent                                                                                                                                                                             | Primary: To compare the efficacy with belantamab mafodotin vs pomalidomide plus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Incidence of AEs and changes in laboratory parameters                                                                                                                                                                                                                                                                                                                                                                                             | Projected Primary                                                                                                                                                                                    | Aug 2021                                                                                                                                                                                             |

Pharmacovigilance plan Table 61 On-going and planned additional pharmacovigilance activities Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Study                                                                                                                                    | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Safety concerns addressed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Milestones                                                                    | Due dates        |
|------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------|
| Status                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                               |                  |
| Belantamab Mafodotin versus Pomalidomide plus Low-dose Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma - Planned | low dose dexamethasone (pom/dex) in participants with relapsed/refractory multiple myeloma Key Secondary: To compare the overall survival with belantamab mafodotin vs pom/dex in participants with RRMM Secondary: To compare other markers of efficacy of belantamab mafodotin vs pom/dex in participants with RRMM To evaluate the safety and tolerability of belantamab mafodotin vs pom/dex in participants with RRMM To evaluate the pharmacokinetic profile of belantamab mafodotin To assess anti-drug antibodies (ADAs) against belantamab mafodotin To evaluate the tolerability of belantamab mafodotin vs pom/dex based on self-reported symptomatic adverse effects To evaluate and compare changes in symptoms and health-related quality of life (HRQOL)of belantamab mafodotin to pom/dex To assess Minimal Residual Disease (MRD) in participants who achieve ≥VGPR or better for belantamab mafodotin vs product no | Ocular findings on ophthalmic exam Symptomatic adverse effects as measured by the PRO-CTCAE and OSDI Changes in safety assessments, including vital signs and ECGs Further characterization of important identified and potential risks: • Keratopathy (or MEC) in the corneal epithelium (as seen on eye examination) with or without changes in visual acuity, blurred vision, or dry eye • Nephrotoxicity • Increased risk of infections due to immunosuppression and/or neutropenia longer authorised | endpoint analysis Study report submission Overall survival and Final analysis | 2Q 2022 Jul 2024 |
| Category 3- Required additional pharmacovigilance                                                                                        | pom/dex                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                               |                  |
| 209626: A Phase 1 open label study of GSK2857916 in relapsed/refractory multiple myeloma patients with renal impairment Medicinal        | Primary: To describe the effects of renal impairment on the pharmacokinetics of belantamab mafodotin in participants with RRMM and with severe renal impairment, ESRD (not on dialysis) or ESRD (on dialysis) compared to participants with normal renal function Secondary: To evaluate safety and tolerability using parameters, including adverse events, vital signs, ECGs, and clinical laboratory assessments in participants with RRMM who have normal or impaired renal functions                                                                                                                                                                                                                                                                                                                                                                                                                                             | Safety of belantamab mafodotin in patients with severe renal impairment Plasma belantamab mafodotin, total mAb, and cys-mcMMAF pharmacokinetic parameters;dialysate PK parameters, as data permit Change from baseline in vital signs (blood pressure and heart rate), monitoring and incidence of adverse events, toxicity                                                                                                                                                                               | Final study report                                                            | 1Q2025           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study Status                                                                                                                  | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                   | Safety concerns addressed                                                                                                                                                                                                                                                                                                                                                      | Milestones         | Due dates   |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------|
|                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                         | grading of clinical laboratory tests, ECG findings, and physical                                                                                                                                                                                                                                                                                                               |                    |             |
| 209627: A Phase 1 open label study of GSK2857916 in patients with relapsed/refractory multiple myeloma and hepatic impairment | Primary: To evaluate the effects of hepatic impairment on the PK of belantamab mafodotin in RRMM participant with impaired hepatic function as compared to RRMM participants with normal hepatic function Secondary: To evaluate the safety, and tolerability parameters, including AEs, vital signs, ECGs, and clinical laboratory assessments in participants with RRMM who have normal or impaired hepatic functions | examinations Safety of belantamab mafodotin in patients with hepatic impairment Plasma belantamab mafodotin, total mAb and cys-mcMMAF pharmacokinetic parameters Change from baseline in vital signs (blood pressure and heart rate), monitoring and incidence of AEs, toxicity grading of clinical laboratory tests, ECG findings and physical examinations longer authorised | Final study report | 2Q2028      |

<!-- image -->

<!-- image -->

| Safety concern                                                                                                                                             | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Identified Risks                                                                                                                                           | Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Keratopathy (or MEC) in the corneal epithelium (as seen on eye examination) with or without changes in visual acuity, blurred vision, or dry eye Medicinal | Routine risk minimisation measures : SmPC Sections: 4.2, 4.4, 4.8 PL Sections: 2, 4 Recommended treatment modifications are provided in SmPC section 4.2. Instruction regarding symptom evaluation, treatment modifications and interventions are provided in SmPC section 4.4. Prescription only medicine Use restricted to physicians experienced in the use of anticancer medicinal products Additional risk minimisation measures : Healthcare professionals (haematologists/oncologists/eye care professionals) educational materials: • The Summary of Product Characteristics product | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : Targeted follow-up questionnaire Additionalpharmacovigilance activities : 205678 (DREAMM-2): Open-label, randomized study of two doses of belantamab mafodotin in participants with relapsed/refractory multiple myeloma who have failed prior treatment with an anti- CD38 antibody (DREAMM-2) - Ongoing 207495 (DREAMM-3): Phase III Study of Single Agent Belantamab Mafodotin versus Pomalidomide plus Low-dose Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3) |

<!-- image -->

Risk minimisation measures Table 62 Summary table of pharmacovigilance activities and risk minimisation activities by safety concern Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Safety in patients with severe renal impairment

Routine risk minimisation measures :

Prescription only medicine Use restricted to physicians experienced in the use of anticancer medicinal products

Routine pharmacovigilance activities beyond adverse reactions reporting and  signal detection :

None

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Additional risk minimisation measures : None Additional pharmacovigilance activities : 209626: A Phase 1 open label study of GSK2857916 in relapsed/refractory multiple myeloma patients with renal impairment Safety in patients with hepatic impairment Routine risk minimisation measures : Prescription only medicine Use restricted to physicians experienced in the use of anticancer medicinal products Additional risk minimisation measures : None Routine pharmacovigilance activities beyond adverse reactions reporting and  signal detection : None Additional pharmacovigilance activities : 209627: A Phase 1 open label study of GSK2857916 in patients with relapsed/refractory multiple myeloma and hepatic impairment Conclusion The CHMP and PRAC considered that the RMP version 0.4 is acceptable. 2.8. Pharmacovigilance Pharmacovigilance system The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC. Periodic Safety Update Reports submission requirements The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points. 2.9. New Active Substance Medicinal product no longer authorised

The applicant declared that belantamab mafodotin has not been previously authorised in a medicinal product in the European Union.

The CHMP, based on the available data, considers belantamab mafodotin to be a new active substance as it is not a constituent of a medicinal product previously authorised within the Union.

<!-- image -->

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.10. Product information

2.10.1. User consultation The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. 2.10.2. Additional monitoring Pursuant to Article 23(1) of Regulation No (EU) 726/2004, BLENREP (belantamab mafodotin) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU. Therefore, the summary of product characteristics and the package leaflet include a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle. 3. Benefit-Risk Balance 3.1. Therapeutic Context BLENREP, as monotherapy, is for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. 3.1.1. Disease or condition Multiple myeloma is a rare and incurable disease of the plasma cells which typically affects adults who are more than 60 years of age (median age is at diagnosis is ~ 70 years). It is the second most common haematological malignancy (after non-Hodgkin's lymphoma [NHL], representing 1% of all cancers and 2% of all cancer deaths. Progress has been made over the last 15 years in the treatment of multiple myeloma, such that survival of patients with newly diagnosed multiple myeloma has increased from approximately 3 years from the years 1985 to 1998 (Kyle 2003) to 6 to 10 years (Moreau 2015). 3.1.2. Available therapies and unmet medical need Medicinal product no longer authorised

<!-- image -->

Current treatment of MM includes glucocorticoids (dexamethasone, prednisolone, methylprednisolone), chemotherapy, primarily alkylating agents, including high dose chemotherapy followed by autologous stem cell transplantation (ASCT), PIs ( such as bortezomib, carfilzomib and ixazomib), mAbs (such as daratumumab, isatuximab and elotuzumab) and the histone deacetylase inhibitor panobinostat. There is a clear unmet medical need for new therapies because the treatment options are very limited, and their median OS is around 3-5 months.

<!-- image -->

<div style=\"page-break-after: always\"></div>

With the approval of daratumumab and its wide use in combinations in earlier lines of MM treatment, a new population of patients is created who have become refractory to all available agents (including daratumumab). This population can be referred to as triple-class refractory MM and it encompasses those patients with disease refractory to at least 1 PI, 1 immunomodulatory agent, and 1 anti-CD38 mAb (such as daratumumab).

<!-- image -->

Therefore, the discovery of therapies with new mechanisms of action to overcome drug resistance, also including patients pre-treated with daratumumab, remains as an unmet medical need. 3.1.3. Main clinical studies The clinical package of belantamab mafodotin was primarily supported by data from a phase II, openlabel, 2-arm, randomized, multicentre study to evaluate the efficacy and safety of belantamab mafodotin monotherapy at a dose of 2.5 mg/kg or 3.4 mg/kg IV, Q3W, in participants with RRMM who had 3 or more prior lines of treatment, were refractory to a proteasome inhibitor and an immunomodulatory agent, and for whom treatment with an anti-CD38 antibody had failed (study 205678 [DREAMM-2]). 3.2. Favourable effects · The ORR per IRC based on IMWG criteria was 32% (97.5%CI: 21.7, 43.6) in the 2.5 mg/kg dose cohort (13 months follow up). There was a further deepening of response, with 58% of responders achieving VGPR or better, including 2 sCRs and 5 CRs. · The mDOR was 11 months. · The point estimate of median PFS for 2.5 mg/kg and 3.4 mg/kg was 2.8 months versus 3.9 months with the Hazard ratio (HR) estimate of 3.4 mg/kg versus 2.5 mg/kg being 0.92. · The mOS was 13.7 months in the 2.5 mg/kg cohort. · In addition, to gain clinical experience with the lyophilized presentation, 25 participants were enrolled in a separate cohort (the 3.4-mg/kg Lyophilized cohort). The ORR by IRC assessment for the Lyophilized cohort (n=25) was 52% (97.5% CI: [28.9, 74.5]). 3.3. Uncertainties and limitations about favourable effects One limitation of the study is the single-arm design, since the phase 2 study was conducted without an active control arm. Although the observed durable response in highly pre-treated patients whose disease is refractory to three classes of agents is considered a clinically meaningful benefit there is a need to further quantify the efficacy of belantamab mafodotin in the approved indication in a comparative trial (Annex II.E). Unfavourable effects Medicinal product no longer authorised

Adverse events were reported in 98% of patients, and 80% of the patients reported a grade 3 or 4 AE in the pooled 2.5 mg/kg cohort.

Adverse events in SOC eye disorders were reported in 71% of patients. The most commonly reported PT was keratopathy (66%), and 25% of patients reported a grade 3 or 4 keratopathy AE. Blurred

<div style=\"page-break-after: always\"></div>

vision was reported in 18% of patients, dry eye in 12%, and photophobia in 4% of patients. Patients also reported clinically significant deterioration of visual function both by NEI VFQ-25 and OSDI indices. The first incidence of a corneal event usually occurred within the first 4 treatment cycles. The 13month safety update revealed that the median duration of a keratopathy, blurred vision and dry eye events were longer than reported in the primary analysis. Majority of the events resolved during the treatment period, and in 11% of patients the event resolved after treatment discontinuation. Eyerelated AEs were the most common reason for dose reductions and delays. Three percent of patients permanently discontinued belantamab mafodotin treatment due to corneal AE. Eye disorders were closely monitored and actively managed during the clinical studies mainly by dose modifications, and majority of the events resolved, and dosing was resumed.

Cytopenia's have been carefully characterized by regular blood counts, but the causality of these events is particularly difficult to evaluate. Consistent dose-dependency supports treatment-related effects in thrombocyte, red blood cell and neutrophil counts. Ongoing clinical studies and study DREAMM-3 will provide additional data to evaluate the clinical significance of these events (see Annex II and RMP).

Thrombocytopenic events were more common in 3.4 mg/kg group: 58% of patients experienced a thrombocytopenic event, 34% of patients experienced a grade 3/4 event, and 5% of patients experienced a thrombocytopenic event and concomitant bleeding event. The probability of grade ≥ 3 thrombocytopenia was positively related to cys-mcMMAF maximum plasma concentration. Twenty-six (25%) participants experienced an AE of anaemia, a Grade 3 event was reported for 19 (18%) participants and 1 (&lt;1%) participant had an SAE of anaemia. Infections were reported for 43% of patients in the 2.5 mg/kg pooled data. The most common SAE PTs were pneumonia, reported for 21 (7%) patients, followed by pyrexia (5% patients) and lung infection reported for 3% of patients. Two of the fatal SAEs in the 2.5 mg/kg group were infection-related (sepsis and lung infection). 3.5. Uncertainties and limitations about unfavourable effects Single arm study setting impairs the causality assessment of several key unfavourable effects. Adverse effects of disease under study, previous treatments and adverse events predicted based on mechanism of action (MoA) and structure of belantamab mafodotin are overlapping, and only rough estimates for frequencies of these events can be made in this heterogeneous patient population. Dose-dependency of these adverse effects is not evident for rare AEs, and absence of dose-dependency may in some cases be due to small differences between exposure levels achieved between the two dose levels studied. This issue will be addressed in the randomized confirmatory study DREAMM-3 (see Annex II and RMP). The number of patients treated with belantamab mafodotin in studies DREAMM-1 and DREAMM-2 is limited, and no patient has been treated with the commercial formulation on the applied dose level. At the time of data cut-off, 11% of the patients were still on study treatment. Final study report of DREAMM-2 will provide further information on the AEs (see Annex II and RMP). Corneal events were the most significant factor in tolerability of belantamab mafodotin. The applicability of the proposed follow-up measures, and the toxicity profile observed in clinical practice remains to be tested in the post-marketing setting. Data from the on-going studies and confirmatory study DREAMM-3 will provide additional data on the current recommendations and prevention measures (see Annex II and RMP). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 63 Effects Table for BLENREP, as monotherapy for the treatment of adult patients multiple myeloma, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an antiCD38 mAb, and who have demonstrated disease progression on the last therapy''. (data cutoff 31 January 2020)

<!-- image -->

| Effect                | Short Description                                                                                                                                               | Treatment            | Result               | Uncertainties/ Strength of evidence                                                       | Refer ence           |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|-------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects    | Favourable Effects                                                                                                                                              | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                        | Favourable Effects   |
| ORR (%)               | Percentage of participants with a confirmed partial response (PR) or better ( i.e. , PR, VGPR, CR and sCR, according to the 2016 IMWG Response Criteria by IRC. | 2.5 mg/kg Q3W = 97   | 32%                  | No control arm other than another dose cohort Median follow up of 12.35 months authorised |                      |
| DOR, (median, months) | Time from first documented evidence of PR or better until the earliest date of documented PD per IMWG, or death due to PD                                       | 2.5 mg/kg Q3W = 97   | 11 months longer     | 95% CI: 4.2, NR                                                                           |                      |
| OS                    | The time from randomisation until death due to any cause                                                                                                        | 2.5mg/kg Q3W = 97 no | 13.7 months          | (9.9, -)                                                                                  |                      |
| Unfavourable Effects  | Unfavourable Effects                                                                                                                                            | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                      | Unfavourable Effects |
| Keratopathy           | - All grades - Grade 3-4                                                                                                                                        | %                    | 71 31                |                                                                                           |                      |
| Thrombocytopenia      | - All grades - Grade 3-4 product                                                                                                                                | %                    | 38 22                |                                                                                           |                      |
| Lymphopenia           | - All grades - Grade 3-4                                                                                                                                        | %                    | 20 17                |                                                                                           |                      |
| Anaemia               | - All grades - Grade 3-4                                                                                                                                        | %                    | 27 21                |                                                                                           |                      |

3.7.

Abbreviations: CI: confidence interval, CR: complete response, DOR: duration of response, IMWG: International Myeloma Working Group,  IRC: independent review committee,  NR: not reached, ORR: overall response rate, PD: progression of disease, PR: partial response, Q3W:every three weeks, sCR: stringent complete response, VGPR: very good partial response, Medicinal product no longer authorised

Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The use of the belantamab mafodotin as a single-agent therapy provides a clinically meaningful antitumour activity. The ORR (32% in the 2.5 mg/kg cohort) is comparable or better with previous last line

<div style=\"page-break-after: always\"></div>

therapies such as pomalidomide or daratumumab. This antitumor activity is durable as the mDoR was 11 months (95% CI: 4.2, NR). This benefit in this very last line of treatment is considered clinically relevant, providing a new alternative with a new MoA in the current therapeutic landscape of MM. Although the observed durable response is considered a clinical benefit, there is a need to further quantify the efficacy of BLENREP in the approved indication in a comparative trial (see Annex II).

''BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy''.

Adverse effects of belantamab mafodotin were mostly reversible. Treatment is tolerated when adverse effects are closely monitored and actively managed, mainly by dose modifications. Overall, the safety profile of belantamab mafodotin monotherapy appears sufficiently characterised. Additional data from future studies are expected to be provided in support of the overall safety (see Annex II). 3.7.2. Balance of benefits and risks Given the poor prognosis of patients heavily pre-treated, relapsed, who had received at least three prior therapies (median 7) and were refractory to at least one proteasome inhibitor (PI), at least one immunomodulatory agent , and an anti-CD38 mAb the treatment effect of belantamab mafodotin is considered clinically relevant and has been demonstrated in the single pivotal study that was submitted. Treatment is tolerated when adverse effects are closely monitored and actively managed, mainly by dose modifications. Therefore, the benefit-risk balance for belantamab mafodotin in the proposed indication is considered positive. 3.7.3. Additional considerations on the benefit-risk balance Justification for the wording of the indication The originally proposed wording of the indication ''BLENREP is indicated as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received three prior lines of therapy including an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent''  allows treatment of patients after three prior treatments, relapsed or refractory to an immunomodulatory agent, PI and anti-CD38 mAb. Only 5 patients in the pivotal study fulfilled these minimum criteria, and the majority of the patients were heavily pre-treated, with two proteasome inhibitors and two immunomodulatory agents. In addition, most of the patients were refractory to bortezomib, carfilzomib, lenalidomide and pomalidomide and, by definition, all patients in the pivotal study were refractory to an immunomodulatory agent and a proteasome inhibitor and an anti-CD38 antibody. Although the patients included in this pivotal trial had minimum requirement of having failed at least 3 prior lines of anti-myeloma treatments, including an anti-CD38 antibody (e.g., daratumumab) alone or in combination, and being refractory to an immunomodulatory agent  (i.e., lenalidomide or pomalidomide), to a proteasome inhibitor (e.g., bortezomib or carfilzomib) and to an anti-CD38 mAb (triple-class refractory), the vast majority of the patients were heavily pretreated. To better reflect the patient population, both in terms of prior lines of treatment received, and refractoriness to prior therapies, the indication was revised as follows: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Conditional marketing authorisation

As comprehensive data on the product are not available, a CMA was requested by the applicant in the initial submission.

The product falls within the scope of Article 14-a of Regulation (EC) No 726/2004 concerning conditional marketing authorisations, as it aims at the treatment of a life-threatening disease. In addition, the product is designated as an orphan medicinal product. Furthermore, the CHMP considers that the product fulfils the requirements for a conditional marketing authorisation: 1. The benefit-risk balance is positive, as discussed above. 2. It is likely that the applicant will be able to provide comprehensive data Efficacy has been established on the basis of durable ORR. Although the durable response is considered a clinically meaningful benefit, there is a need to further quantify the efficacy of BLENREP in the approved indication in a comparative trial. DREAMM-3, a phase III study of single agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in participants with relapsed/refractory multiple myeloma is planned and a considerable proportion of patients would be in later treatment lines in line with DREAMM-2. Single arm study setting also impairs the causality assessment of several key unfavourable effects leading to remaining uncertainties. These could be addressed by the proposed randomised study with pomalidomide/low-dose dexamethasone as comparator since it would allow comparisons of both efficacy and safety, and the proposed number of patients (n=320) would allow a more comprehensive analysis of both favourable and unfavourable effects. DREAMM-3 will be conducted in 184 sites and 19 countries worldwide. The Applicant has submitted applications for ethics committee and regulatory agency approval in all participating countries and has received 17 and 16 approvals respectively. Based on the above, the CHMP considered that DREAMM-3 is likely to provide comprehensive data suitable to confirm the positive benefit-risk balance of BLENREP. In addition, the CHMP considered that the MAH should submit the final results of the pivotal study DREAMM-2 study investigating the efficacy of belantamab mafodotin in patients with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-CD38 antibody which will also provide comprehensive data suitable to confirm the positive benefit-risk balance of BLENREP. In addition, the final study report of DREAMM-2 will provide further information on resolution of the AEs. 3. Unmet medical needs will be fulfilled Unmet medical needs will be addressed, as RRMM is a condition where there are a number of authorised treatment options but no curative treatments. Recently approved products for RRMM include lenalidomide, pomalidomide, bortezomib, carfilzomib, ixazomib, panobinostat, daratumumab, isatuximab, and elotuzumab. Medicinal product no longer authorised

For patients that have received at least 4 prior therapies and who are refractory to at least one immunomodulatory drug, one proteasome inhibitor, and one anti-CD-38 antibody, and whose disease has progressed on the last therapy, as detailed in the claimed indication for BLENREP, the treatment options become very limited.

Additional treatment options are needed in RRMM aiming to achieve control and remission of the disease for as long as possible given that almost all patients eventually relapse and become resistant to available treatments, where the remission duration generally decreases with each subsequent

<div style=\"page-break-after: always\"></div>

treatment regimen, and where the toxicity of different regimens is significant and quite different between products. In this context, medicinal products with a positive benefit-risk balance and new mechanism of action can provide a major therapeutic advantage to patients if they offer possible alternative or additional treatment options based on a different safety profile, or based on therapeutic efficacy when other products are not expected to be effective.

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of BLENREP is favourable in the following indication:

BLENREP has a mechanism of action that is different from that of authorised treatments and has shown to be associated with a 32% objective response rate and a median duration of response of 11 months in this group of highly pre-treated patients whose disease is refractory to three classes of agents. BLENREP has a distinct toxicity profile including significant toxicities like corneal toxicity and haematological toxicity. Adverse effects of belantamab mafodotin are mostly reversible. Treatment is tolerated when adverse effects are closely monitored and actively managed, mainly by dose modifications.  Therefore, BLENREP can be considered a major therapeutic advantage in the proposed target population for whom there are very limited and often no other treatment options available, in particular when available options are unlikely to be efficacious, or when it is the preferred option in view of its efficacy and safety profiles. In conclusion, BLENREP fulfils an unmet medical need as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 mAb, and who have demonstrated disease progression on the last therapy. 4. The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. In view of the limited treatments options for the highly pre-treated patients whose disease is refractory to three classes of agents and the new mechanism of action, the immediate availability of BLENREP on the market outweighs the risk inherent in the fact that additional data are still required. Conclusions The overall B/R of BLENREP is positive. 4. Recommendations Similarity with authorised orphan medicinal products The CHMP by consensus is of the opinion that BLENREP is not similar to Darzalex, Farydak, Imnovid, Kyprolis, and Ninlaro within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. Outcome Medicinal product no longer authorised

BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome

<div style=\"page-break-after: always\"></div>

inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

The CHMP therefore recommends the granting of the conditional marketing authorisation subject to the following conditions:

Conditions or restrictions regarding supply and use Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). Other conditions and requirements of the marketing authorisation Periodic Safety Update Reports The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation. Conditions or restrictions with regard to the safe and effective use of the medicinal product Risk Management Plan (RMP) The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. An updated RMP should be submitted: · At the request of the European Medicines Agency; · Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. Additional risk minimisation measures The educational programme is aimed at helping haematologists/oncologists, eye care professionals and patients understand the corneal risks associated with belantamab mafodotin, so that corneal examination findings, and/or visual changes can be promptly identified and managed according to the product labelling. Medicinal product no longer authorised

Prior to the launch of BLENREP (belantamab mafodotin) in each Member State the MAH must agree about the content and format of the educational materials, including communication media, distribution modalities, and any other aspects of the programme with the National Competent Authority.

<div style=\"page-break-after: always\"></div>

The MAH shall ensure that in each Member State where BLENREP (belantamab mafodotin) is marketed, all healthcare professionals and patients/carers who are expected to prescribe, dispense and receive BLENREP (belantamab mafodotin) have access to/are provided with the following educational materials to be disseminated through professional bodies consisting of the following:

· Educational materials for Healthcare professionals (HCPs) (includes haematologists/oncologists/eye care professionals): o Corneal adverse reaction guides o Eye care screening sheet · Educational materials for the patient o Corneal adverse reaction guides o Patient and pharmacy eye drop wallet cards. · Summary of the Product Characteristics (SmPC) and Package Leaflet (PL) Key elements to be included The healthcare professional's corneal adverse reaction guides The HCPs corneal adverse reaction guides will contain the following key information: Relevant information of the safety concern keratopathy or microcyst-like epithelial changes in the corneal epithelium: · Advise patients that corneal adverse reactions may occur during treatment. · Patients with a history of dry eyes are more prone to develop changes in the corneal epithelium. Details on how to minimise the safety concern addressed by the additional risk minimisation measures through appropriate monitoring: · Ophthalmic examinations, including assessment of visual acuity and slit lamp examination, should be performed at baseline, before the subsequent 3 treatment cycles, and as clinically indicated whilst on treatment. · Patients experiencing keratopathy with or without changes in visual acuity may require a dose modification (delay and/or reduction) or treatment discontinuation based on severity of findings. · Emphasise the need to consult the SmPC. Key messages to convey during patient counselling: · Patients should be advised to administer preservative-free artificial tears at least 4 times a day during treatment. · Patients should avoid using contact lenses until the end of treatment. Medicinal product no longer authorised

- Patients should consult their haematologist/oncologist if corneal adverse reactions occur.
- Patients who report corneal symptoms should be referred to an eye care professional.
- Patients should be advised to use caution when driving or operating machinery.

<div style=\"page-break-after: always\"></div>

## Healthcare professionals' training material

•

Consult the PL.

A description of the sign and symptoms of the risk of keratopathy:

Anatomy and physiology of the eye: · Images of the eye are provided and reviewed. · Keratopathy is characterised based on exam findings and patient reported outcomes. Description of eye exams: · Use of slit lamp exams provide detailed information on the anatomical structures in the eye. They can help detect a range of conditions, including keratopathy or microcyst-like epithelial changes in the corneal epithelium (as seen on eye examination). · Description of visual acuity provides a measure of the visual system's ability to discern fine distinctions in the visual environment. · Best corrected visual acuity (BCVA) refers to the visual acuity achieved with correction (such as glasses), as measured on the standard Snellen Visual Acuity Chart, monocularly and binocularly. · Summary of visual acuity scores (20/20 vs &lt;20/20) and how a score less than 20/20 can be corrected and managed by the patients. Eye care screening sheet: · Includes important information related to corneal adverse reactions associated with belantamab mafodotin, adverse event management, and instructions to facilitate communication between prescribers and eye care professionals for patients. Patient corneal adverse reaction guides The patient corneal adverse reaction guides will contain the following key information: · Corneal adverse reactions may occur during treatment. Patients with a history of dry eyes are more prone to develop changes in the corneal epithelium. · Ophthalmic examinations, including assessment of visual acuity and slit lamp examination, should be performed at baseline, before the subsequent 3 treatment cycles, and as clinically indicated whilst on treatment. · Patients experiencing keratopathy with or without changes in visual acuity may require a dose modification (delay and/or reduction) or treatment discontinuation based on severity of findings. · Tell your haematologist/oncologist about any history of vision or eye problems. Medicinal product no longer authorised

- If you experience changes with your vision whilst on belantamab mafodotin, contact your haematologist/oncologist. Symptoms include the following:

<div style=\"page-break-after: always\"></div>

- o redness, dryness, itching, burning sensation, or sandy or gritty sensation in their eyes;
- o sensitivity to light;

o blurred vision; o pain in their eyes; o excessive watering of their eyes. · If you experience changes in your vision or eyes after initiating treatment (changes have improved, persisted, or worsened since your last appointment), contact your haematologist/oncologist. · Your HCP will ask you to use eye drops called preservative-free artificial tears during treatment. Administer them as instructed. Patient eye drop wallet card: · Patient wallet card indicates the patient is on treatment with belantamab mafodotin and contains contact information for the haematologist/oncologist and the eye care professional. · Present to HCPs during follow up visits. Pharmacy eye drop wallet card: · Patients to present the pharmacy wallet card to the pharmacist to find eye drops called preservative-free artificial tears for use, as directed. Specific Obligation to complete post-authorisation measures for the conditional marketing authorisation This being a conditional marketing authorisation and pursuant to Article 14-a of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures: Medicinal product no longer authorised

<!-- image -->

| Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Due date   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| In order to confirm the efficacy and safety of BLENREP in relapsed/refractory multiple myeloma adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy, the MAH should submit the results of the DREAMM-2 (205678) study investigating the efficacy of belantamab mafodotin in patients with multiple myeloma who had 3 or more prior lines of treatment, are refractory to a proteasome inhibitor and an immunomodulatory agent and have failed an anti-CD38 antibody Medicinal | April 2021 |
| In order to confirm the efficacy and safety of BLENREP in multiple myeloma adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy, the MAH should submit the results of the DREAMM-3 (207495) study comparing the efficacy of belantamab mafodotin vs. pomalidomide plus low dose dexamethasone (pom/dex) in patients with relapsed/refractory multiple myeloma.                                                                                                                | July 2024  |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## REFERENCES

Anderson KC, Kyle RS, Rajkumar SV, et al. Clinically relevant end points and new drug approvals for myeloma, Leukemia, 2008;22: 231-9.

Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibodydrug conjugates. MAbs. 2016;8(4):659-71. Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials. J Ocul Pharmacol Ther. 2015;31(10):589-604. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144: 1941-53. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 Patients With Newly Diagnosed Multiple Myeloma Mayo Clin Proc. 2003 Jan;78(1):21-33. doi: 10.4065/78.1.21. Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, et al. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the AntibodyDrug Conjugate Mirvetuximab Soravtansine. Clinical Cancer Research. 2019;25(6):1727-36. Mikhael J.Clin Lymphoma Myeloma Leuk. Treatment Options for Triple-class Refractory Multiple Myeloma. 2020 Jan;20(1):1-7. doi: 10.1016/j.clml.2019.09.621. Epub 2019 Oct 9. Philippe Moreau , Michel Attal , Thierry Facon. Frontline Therapy of Multiple Myeloma.Blood 2015 May 14;125(20):3076-84. doi: 10.1182/blood-2014-09-568915. Epub 2015 Apr 2. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33(26):2863-9. Patel H, Egorin MJ, Remick SC, Mulkerin D, Takimoto CHM, Doroshow JH, Potter D, Ivy SP, Murgo AJ, Ramanathan RK. Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HP): Implications for chemotherapy dosing. J. Clin. Oncol. 2004; 22(14\\_suppl):6051. Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126:921-922. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014;15: e538-e548. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011b;86:57-65. Medicinal product no longer authorised

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37-44.